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Abstract 
A total of 136 chronically infected Canadian acne patients from Ottawa-Gatineau and 
Northeastern Ontario regions accounting for 75% of subjects (12-50 years old, with 90th 
percentile at the age of 30) who had suffered acne vulgaris (with various acne related scarring) 
for a median duration of 4 years, were sources for isolation of Propionibacterium acnes, the 
etiologic agent for acne vulgaris. Eighty-four percent of patients were subjected to various 
treatment regimens with topical and systemic agents including in combination with 1-3 different 
types of antibiotics (mean duration of 7 months). A diverse collection of 224 clinical P. acnes 
isolates from Canadian and Swedish subjects were characterized for their sensitivities to 
infection by a Canadian collection of 67 diverse phages belonging to siphoviridae; and multiple 
minimal cocktails consisting of 2-3  phages were formulated to be effective on global P. acnes 
isolates. Propionibacterium acnes isolates were characterized by multiplex PCR to belong to 
phylotypes IA, IB and II, which also showed resistance against commonly used antibiotics for 
treating acne vulgaris (overall resistance rate of 9.5%), were sensitive to phages regardless of 
their type and antibiotic resistance patterns, providing ground for phages as novel alternative 
therapeutics for future in vivo trials. The phage collection was diverse by virtue of their BamHI 
restriction patterns and full genome sequences and harboured a major tail protein (MTP) that 
appeared to be important in contributing to their host ranges. Three dimensional structural 
modeling of the N-domain of P. acnes MTPs implicated previously unreported involvement of 
the α1-β4 loop (C5 loop) within N-domain amino acid sequence in contributing to the expanded 
host range of a mutant phage to infect a naturally phage resistant P. acnes clinical isolate. Given 
the potential of phages for rapid mutational diversification surpassing that of their bacterial hosts 
and the fact that phages are generally regarded as safe (GRAS), rapid and cost-effective 
iii 
 
 
 
derivation of mutant phages with expanded host ranges provide a strong framework for 
improving phage cocktails for use in future personalized medicine.  
Keywords 
Bacteriophage, Phage, Siphoviridae,  Coryneform, P. acnes, Acne vulgaris, Antibiotic resistance, 
Phage Therapy, phylotype, Clinical isolate, Genome, Multiplex PCR, Host-range, 3D modeling, 
Major Tail protein, Receptor. 
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 Introduction 1
1.1 Propionibacterium acnes 
1.1.1 General Microbiology 
Propionibacterium acnes is a non-motile, asporogenous, Gram-positive, aerotolerant 
anaerobe. Described as a pleomorphic rod (Patrick & McDowell, 2012), its morphology 
is dependent on strain, age and culturing conditions; all of which seemingly confer 
variable colony morphology on agar media (Marples & McGinley, 1974). Anaerobic 
cultures typically exhibit coryneform morphology, representative of its earlier taxonomic 
nomenclature  as “Corynebacterium parvum” (Cummins & Johnson, 1974) and 
“Corynebacterium acnes” (Bergey et al., 1923). Cells range from 0.2 to 1.5µm wide by 1 
to 5µm in length, however, isolates of phylotype III group exhibit filamentous 
morphology and have been observed to grow up to 21.8µm in length (McDowell et al., 
2008). On the surface of agar media, colonies may appear raised, convex or pulvinate, 
and range from 1 to 4mm in diameter. As colonies become larger with age, they tend to 
transition from pale to deep shades of yellow, beige or pink. Appearance of the colonies 
is dependent on the type of media.  
Culturing in complex media is a necessity for this chemoorganotrophic microorganism, 
and renders it fastidious; its nutritional requirements may only be met by media rich in 
organic compounds such as sugars and polyhydroxy alcohols. Propionic acid production 
via fermentation of organic substrates, coupled with its aversion to aerobic conditions, 
was the basis by which Douglas and Gunter (Douglas & Gunter, 1946) argued to amend 
its original genus designation from “Corynebacterium” to “Propionibacterium”. 
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A prominent member of the healthy human skin microbiome (Funke et al., 1997; Grice & 
Segre, 2011), P. acnes thrives near-exclusively in the anoxic environment of the 
pilosebaceous unit, located just under the surface of the skin (Barnard et al., 2016a; Bek-
Thomsen et al., 2008; Grice & Segre, 2011; Leeming et al., 1984). The pilosebaceous 
unit provides a unique niche for P. acnes, where competition is scarce and nutrient 
resources are abundant.  
Colonization of this lipophilic commensal tends to be concentrated over areas of the head 
and trunk that are rich in sebaceous glands (Roth & James, 1988). Cell-to-cell adherence 
is promoted by metabolizing components of the sebum secreted by the glands, such as 
triacylglycerols (Gribbon et al., 1993; Marples et al., 1971). Liberation of free fatty acids 
combined with the secretion of acidic metabolic products—acetic and propionic acid—
imposes a decrease in the pH level of the stratum corneum, enhancing its suitability for 
occupation by normal flora and preventing pathogen colonization (Elias, 2007; Korting et 
al., 1990; Ushijima et al., 1984). A dominant and often exclusive occupant of the 
pilosebaceous unit, P. acnes is believed to aid in the protection against colonization of 
other pathogenic microbes (Bek-Thomsen et al., 2008; Gallo & Nakatsuji, 2011; Shu et 
al., 2013).    
Despite its presence as a predominant skin commensal, P. acnes is also known to 
colonize other areas of the body including the gastrointestinal tract and the genitourinary 
tract (Delgado et al., 2011, 2013; McDowell & Patrick, 2011; Montalban Arques et al., 
2016; Yang et al., 2013). The events that lead to colonization of P. acnes play a major 
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role in its ability to illicit robust immune responses. The substantial implications of 
colonization in relation to pathogenicity are discussed. 
1.1.2  Isolation and characterization 
Recovery of P. acnes from patient specimens is largely dependent on the length of 
incubation time and atmospheric composition. Length of incubation time to recover 
isolates depends on the species, size and age of the inoculum. P. acnes isolates are 
typically recovered after one to fourteen days of incubation (Funke et al., 1997). Isolation 
and cultivation require anaerobic to microaerophilic environments, however, anaerobic 
conditions seem to be especially favourable for the purpose of primary isolation (Funke 
et al., 1997). Published reports of P. acnes isolation, from a variety of infection sources, 
are rapidly accumulating as a result of extending incubation periods, optimizing specimen 
processing (i.e. sonicating to disrupt biofilm) and culture conditions (Abdulmassih et al., 
2016; Bayston et al., 2007; Bossard et al., 2016; Butler-Wu et al., 2011; Frangiamore et 
al., 2015; Kvich et al., 2016; Schäfer et al., 2008). 
Complex, non-selective media is employed for primary isolation and enrichment of P. 
acnes as no selective medium capable of exclusive isolation of the microbe is readily 
available. P. acnes is the primary microbial etiologic agent of acne vulgaris, however it is 
not the only agent involved in this polymicrobial condition (Brook, 1991; Leeming et al., 
1984; Marples & McGinley, 1974). There have also been reports of polymicrobial, deep-
seated infections involving P. acnes (Bémer et al., 2016). Therefore, multistep 
approaches beginning with culturing techniques, followed by visual inspection, 
biochemical testing and molecular methods to screen for and characterize clinical isolates 
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are employed as a reliable methodology for preparing pure clinical cultures of P. acnes 
(Bémer et al., 2016; Cazanave et al., 2013; Shah et al., 2015).  
Phylogenetic analysis of clinical P. acnes isolates has revealed significant associations 
between phylotype, virulence factors and pathologies such as acne vulgaris and deep 
tissue infections, among others (Barnard et al., 2016b; Davidsson et al., 2016; Johnson et 
al., 2016; Kwon & Suh, 2016; Lomholt et al., 2017; Lomholt & Kilian, 2010; McDowell 
et al., 2012; Paugam et al., 2017; Petersen et al., 2017; Yu et al., 2016). Development of 
methods for phylogenetic characterization of P. acnes isolates has revealed three main 
phylogenetic lineages—type I, II and III—encompassing various clades, clusters and 
strain types. Sequence analysis of housekeeping gene recA, putative hemolysin gene tly 
and CAMP factor genes led to the designation of the three major lineages and two major 
clades within the type I lineage—IA and IB (McDowell et al., 2005, 2008; Valanne et al., 
2005). More recently, multilocus sequence typing (MLST) schemes have been used to 
further divide the lineages into clusters IA1, IA2, IB, IC, II and III (Kilian et al., 2012; 
Lomholt & Kilian, 2010; McDowell et al., 2011, 2012). Other approaches, such as 
ribotyping and multiplex PCR-based approaches, yield results that align with the 
established phylogenetic groupings and are more rapid than sequence-based techniques 
(Barnard et al., 2015; Davidsson et al., 2016; Fitz-Gibbon et al., 2013; Shannon et al., 
2006a).  
1.1.3 Clinical significance 
Once acknowledged exclusively as a commensal, general perception of the relationship 
between P. acnes and its human host has evolved based on recognition of its capacity to 
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act as an opportunistic pathogen. Genome sequencing has exposed a plethora of encoded 
putative virulence factors, many of which likely contribute to its ability to damage host 
tissue and illicit robust inflammatory immune responses (Brüggemann et al., 2004). 
Genome characterization combined with clinical manifestations as a result of 
colonization, have revealed the microbe’s pathogenic potential, suggesting an alternative 
role for P. acnes as an opportunistic pathogen (Brüggemann et al., 2004; Brüggemann, 
2005). Accredited mainly as the primary microbial agent involved in the pathogenesis of 
acne vulgaris, P. acnes is gaining notoriety for its implication in deep-seated infections 
and various systemic inflammatory disorders (Perry & Lambert, 2011). 
1.1.3.1 Acne vulgaris 
Current consensus within the literature suggests that the pathogenesis of acne vulgaris is 
no longer solely dependent on abnormal desquamation and sebum overproduction (Das & 
Reynolds, 2014; Kircik, 2016). Acne vulgaris is a multi-factorial, complex condition of 
the pilosebaceous unit; perpetuated by abnormal androgen levels, sebaceous hyperplasia, 
microbial colonization, a cascade of inflammatory events and subsequent cornification of 
the follicular wall (Knutson, 1974); a process referred to as comedogenesis. The role that 
P. acnes plays in acne pathogenesis has remained elusive, however researchers continue 
to peel back the layers of complexity revealing evidence of the dynamic interplay 
between P. acnes and other factors (Das & Reynolds, 2014). 
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1.1.3.1.1 Pathogenesis 
Microbial Colonization 
In 1896, “acne bacilli” (P. acnes) were first detected in histological samples by Paul 
Gerson Unna while examining comedone specimens (Unna, 1896). Since then, 
colonization and hyperproliferation of P. acnes within the pilosebaceous unit has been 
identified as an essential process in acne pathogenesis. Follicular colonization is thought 
to be promoted by changes in the pilosebaceous environment resulting from excess 
sebum production; enhancing its capacity to foster P. acnes colonization. Increased 
nutrient availability (McGinley et al., 1980), abnormal sebum composition (Gribbon et 
al., 1993; Saint-Leger et al., 1986a, b), and the formation of a follicular plug (Burkhart & 
Burkhart, 2007; Jeremy et al., 2003; Knutson, 1974), create an ideal niche for P. acnes 
proliferation. 
The sebaceous gland, a component of the pilosebaceous unit, secretes sebum; a fluid 
protective barrier that is critical to the overall health of the skin and hair (De Luca & 
Valacchi, 2010). Androgen hormones directly influence sebum production by acting as 
agonists of sebocyte proliferation. An increase in androgen levels; typically occurring 
during adolescence and an indicator of puberty onset, activate hyperplasia of the 
sebaceous glands. Sebaceous glands function via holocrine secretory mechanisms, 
therefore, sebocyte hyperproliferation upregulates sebum secretion; inciting alterations in 
sebum composition (Strauss et al., 1962; Thiboutot, 2004). Changing sebum composition 
is implicated in comedogenesis and facilitates P. acnes colonization. Linoleic acid 
behaves as a barrier against microbial colonization (Elias et al., 1980). As sebum is 
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overproduced, linoleic acid concentration declines, resulting in failure to prevent 
migration of P. acnes into the follicular space. Similarly, decreased concentration of 
antioxidants result in elevated sebum levels of oxidized squalene and other lipid 
peroxidases, which reduce oxygen tension within the follicle thereby enhancing its 
suitability for colonization of anaerobic inhabitants (Saint-Leger et al., 1986a, b). 
Following colonization, lipase produced by P. acnes hydrolyzes sebum triglycerides. 
Glycerol molecules liberated from this hydrolysis reactiong provide valuable nutrient 
resources for the P. acnes while free fatty acids enhance its adherence to the follicular 
wall, preventing its removal with sebum secretions (Gribbon et al., 1993). Other factors 
contributing to microbial colonization involve the formation of a follicular plug, which 
may be indirectly modulated by altered sebum composition and biofilm formation of P. 
acnes (Burkhart & Burkhart, 2003; Coenye et al., 2007; Holmberg et al., 2009; Jahns et 
al., 2012). 
Microbial Immunomodulation and Virulence 
Development of acne lesions involve P. acnes virulence factors and host inflammatory 
responses to follicular colonization. Degradation and rupture of the follicular wall leads 
to innate immune responses resulting in inflammation—a hallmark of acne lesions. The 
pathogenic propensity of P. acnes is fueled by its extensive assortment of genome-
encoded virulence factors, which instigate follicular disruption and activate innate 
immune receptors, resulting in subsequent release of a proinflammatory cocktail of 
cytokines, oxidized lipids and bacteria into the surrounding dermal layers.  
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Host cell carbohydrate, protein and lipid components are hydrolyzed by various glycoside 
hydrolases, proteases and esterases expressed by P. acnes (Brüggemann et al., 2004; 
Brüggemann, 2005; Holland et al., 2010; Jeon et al., 2017; Miskin et al., 1997). Other 
tissue damaging virulence factors that are associated with immunostimulatory activity 
include porphyrins, sialidases and Christie, Atkins, Munch-Peterson (CAMP) factors 
(Brüggemann et al., 2004; Brüggemann, 2005; Jeon et al., 2017; Lang & Palmer, 2003; 
Lheure et al., 2016; Schaller et al., 2005). Porphyrins released by P. acnes are thought to 
exert cytotoxic effects on keratinocytes due to free radical generation by molecular 
oxygen-porphyrin interactions in environments of relatively elevated oxygen tension, 
ultimately leading to tissue damage (Brüggemann, 2005). A predominant porphyrin 
secreted by P. acnes—coproporphyrin III—has been shown to elicit proinflammatory IL-
8 expression by keratinocytes, leading to recruitment of lymphocytes, neutrophils and 
macrophages (Schaller et al., 2005). Similarly, the genome of P. acnes encodes five 
homologs of pore-forming toxic proteins, known as CAMP factors (Brüggemann, 2005; 
Lang & Palmer, 2003; Valanne et al., 2005), which act on host cells in the presence of 
host sphingomyelinase. A study by Nakatsuji et al. (2011) reports degradation and 
invasion of keratinocytes and macrophages due to interaction between CAMP factor 2 
and sphingomyelinase. Moreover, a recent study by Lheure et al. (2016) demonstrates 
upregulation of keratinocyte-secreted IL-8 by activation of TLR-2 by P. acnes CAMP 
factor 1. Another cause of host tissue degredation and inflammatory response is the 
action of P. acnes sialidases on host cells (Nakatsuji et al., 2008). Genome sequencing of 
P. acnes has revealed at least two genes encoding sialidases, which function by cleaving 
host cell sialoglycoconjugates to obtain energy sources (Brüggemann et al., 2004; 
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Brüggemann, 2005). Furthermore, activation of sebocytes by sialidases induce secretion 
of IL-8 (Nakatsuji et al., 2008; Oeff et al., 2006).  
Immunostimulatory activities of P. acnes also involves activation of pattern recognition 
receptors, such as the Toll-like receptors (TLRs), by pathogen-associated molecular 
patterns (PAMPs) of P. acnes, to stimulate release of proinflammatory cytokines and 
chemokines (Su et al., 2017; Takeda & Akira, 2004; Vowels et al., 1995). For example, 
P. acnes activates TLR2 pathways of keratinocytes and sebocytes, causing these cells to 
secrete interleukin-8 (IL-8), human β-defensin 2 (HβD2), NF-κB and AP-1 (Hisaw et al., 
2016; Nagy et al., 2005, 2006; Su et al., 2017). P. acnes-induced secretion of IL-8 and 
other chemotactic factors modulate neutrophil migration to the pilosebaceous unit, while 
HβD2 possesses Gram-negative microbicidal activity (Kim, 2005). Neutrophils attracted 
to lesion sites cause the follicular epithelium to rupture, which provokes inflammation 
(Webster et al., 1980) by monocytic secretion of cytokines and chemokines. Monocyte 
TLRs and nucleotide-binding oligomerization domain receptors are activated by P. acnes 
PAMPs, resulting in release of tumor necrosis factor alpha (TNFα), interleukin-12 (IL-
12), interleukin-1β (IL-1β) and IL-8 (Kim et al., 2002; Kistowska et al., 2014; Qin et al., 
2014; Vowels et al., 1995).  
In addition to its involvement during the later stages of lesion development and 
persistence, P. acnes may be a key factor in initiating comedogenesis. A distinctive 
comedonal feature (Ingham et al., 1992), elevated levels of interleukin-1α (IL-1α) have 
been attributed to P. acnes-activated secretion of IL-1α from human keratinocytes via the 
TLR-2-mediated pathway (Graham et al., 2004). Selway et al. (2013) showed that 
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specific PAMPs characteristic of Gram-positive bacteria, such as peptidoglycan and 
lipoteichoic acid, result in TLR-2-mediated IL-1α release from human keratinocytes. 
Interestingly, this study reported IL-1α-like mediated hypercornification of sebaceous 
glands, which provides evidence supporting the possible role of P. acnes during 
comedogenesis. 
1.1.3.1.2 Scarring 
Affecting up to 95% of acne patients (Layton et al., 1994), scarring is a common result of 
the inflammation associated with acne vulgaris and is influenced by the severity and 
duration of inflammation (Bourdes et al., 2015).  According to a classification scheme 
devised by Jacob et al. (2001), which is based on morphological characteristics together 
with associated treatment options, acne scarring is divided into the following three 
categories: icepick, rolling and boxcar; the latter of which may be subdivided into 
shallow (0.1 to 0.5 mm) or deep (≥0.5 mm) scars. Each type of scarring requires a certain 
level of treatment, all involving varying degrees of invasiveness and monetary cost. Scar 
treatment modalities requiring surgical procedures such as punch excision, punch 
elevation, subcision and laser skin resurfacing, offer permanent results albeit an inherent 
level of invasiveness compared to non-surgical procedures. Although typically yielding 
improvements that are temporary and/or requiring multiple treatments, non- and partially-
ablative procedures are less invasive as these approaches are limited to topical therapies, 
subcutaneous and dermal fillers, lasers that promote collagen remodeling and 
microscopic dermal injury via fractional resurfacing (Alam & Dover, 2006; Fife, 2016; 
Jacob et al., 2001). Based on various metrics, such as the Dermatology Quality of Life 
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Index, those suffering from atrophic scarring as a result of acne report an overall 
reduction with regards to quality of life (Reinholz et al., 2015).  
1.1.3.1.3 Social, psychological and economic impacts 
Acne vulgaris affects over 85% of adolescents (Balkrishnan et al., 2006a), thereby 
rendering it one of the most common skin disorders (Johnson & Roberts, 1978; Rea et al., 
1976; Wolkenstein et al., 2003). The effects of acne alone cause the United States to 
suffer a loss of productivity to the tune of 3 billion dollars per year (Bickers et al., 2006). 
Aside from the physical disfiguration, there is also a psychosocial aspect that 
accompanies the presence of acne, which has been reported to have a direct effect on 
work and educational performance (Gokdemir et al., 2011). In an era where self-worth is 
often dictated by aesthetics (Gordon et al., 2013), individuals stricken with visible signs 
of acne and/or scarring are likely to suffer psychologically and exhibit aberrant behavior 
because of this (Chuah & Goh, 2015).  
A report published by (Ritvo et al., 2011) described the tendency towards a negative 
perception of teens with acne by adults and teenagers. Therefore, it is not surprising that 
low self-esteem, depression, anxiety, bullying, and other psychosocial effects including 
suicidal tendencies decrease the quality of life with those suffering with acne (Krowchuk, 
2000; Law et al., 2010; Lee et al., 2006). Some metrics have even highlighted similarities 
of quality of life measurements between acne and those afflicted by psoriasis and 
debilitating conditions such as coronary heart disease, diabetes and chronic back pain 
(Cresce et al., 2014; Klassen et al., 2000). 
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1.1.3.2 Other notable pathologies 
Deep tissue infections caused by P. acnes are commonly preceded by surgical procedures 
in the presence, or absence, of an implanted foreign material or device (Jakab et al., 
1997). Post-operative infections are often characterized as chronic having a delayed-
onset, typically persisting due to microbial biofilms which coat the implant surface, 
protecting the infectious agents, such as P. acnes, from immune defence and antibiotic 
treatment  (Bayston et al., 2007; Coenye et al., 2007; Holmberg et al., 2009; Jakab et al., 
1997; Trampuz et al., 2003; Tunney et al., 1998). Examples of devices associated with P. 
acnes infection include intraocular lenses (Gopal et al., 2008), breast implants (Del Pozo 
et al., 2009; Rieger et al., 2013), neurosurgical hardware (Chu et al., 2001), 
cardiovascular devices (Das & Reynolds, 2014; Hinestrosa et al., 2007; Kanjanauthai & 
Kanluen, 2008; Kestler et al., 2017; Silva Marques et al., 2012; van Valen et al., 2016) 
and orthopedic implants (Butler-Wu et al., 2011; Drago et al., 2017; Figa et al., 2017; 
Frangiamore et al., 2015; Koh et al., 2016; Mook et al., 2015; Phadnis et al., 2016; 
Portillo et al., 2013; Rienmüller & Borens, 2016; Tunney et al., 1999; Wang et al., 2013; 
Zhang et al., 2015). Although relatively less frequent, there have been several reports of 
P. acnes deep tissue biofilm formation in the absence of implants and, in many cases, 
without prior surgical intervention (Berjano et al., 2016; Berthelot et al., 2006; Capoor et 
al., 2017; Chu et al., 2001; Coscia et al., 2016; Crowhurst et al., 2016; Daguzé et al., 
2016; Haruki et al., 2017; Kowalski et al., 2007; Kranick et al., 2009; Lavergne et al., 
2017; Nisbet et al., 2007). 
Clinical manifestations, as a result of most deep-seated P. acnes infection, are devastating 
due to the chronic nature of infection. For instance, the economic implications of 
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infections resulting from joint arthroplasty are immense (Sculco, 1993). According to a 
study conducted by Kurtz et al. (2012), the projected cost of infected knee and hip 
revisions in the year 2020 will exceed $1.62 billion in the United States.  
It is thought that P. acnes takes a role as an infectious agent, exercising 
immunomodulatory behavior, that contributes to the pathogenesis of multifactorial 
systemic disorders involving genetic and immunological components (Chen & Moller, 
2015; Rukavina, 2015). In 1978, Homma et al. (1978) observed elevated levels of P. 
acnes in biopsy specimens of sarcoid positive lymph nodes compared to controls. Since 
then, evidence of its participation in the etiology of the condition has continued to 
accumulate (Eishi, 2013; Hiramatsu et al., 2003; Nakamura et al., 2016; Negi et al., 
2012; Schupp et al., 2015; Werner et al., 2017; Zhao et al., 2017). Other complex 
pathologies that demonstrate evidence of association with the immunostimulatory 
behavior of P. acnes are “SAPHO” syndrome (synovitis, acne, pustulosis, hyperostosis, 
osteitis) (Berthelot et al., 2017; Colina et al., 2007; Nguyen et al., 2012) and prostate 
cancer (Bae et al., 2014; Cavarretta et al., 2017; Davidsson et al., 2016; Fehri et al., 
2011; Kakegawa et al., 2017; Olender et al., 2016; Sayanjali et al., 2016; Severi et al., 
2010; Shannon et al., 2006b; Shinohara et al., 2013; Yow et al., 2017).  
1.1.4 Current therapeutic approaches (acne vulgaris) 
Acne vulgaris is a dynamic condition owing its development to a variety of 
pathophysiological mechanisms. A wide range of treatment modalities are available and 
application in a combinatorial manner is encouraged to expediently address the distinct 
variables that contribute to the disease state. However, despite evidence of successful 
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clinical outcomes, there is no shortage of side effects and limitations associated with the 
existing treatments routinely recommended for the management of acne vulgaris.  
Establishing an effective therapeutic regimen is based on clinical assessment of acne 
severity (Thiboutot, 2000). Assessment of the proposed therapeutic approaches is 
accomplished in consideration of the patient’s candidacy measured against the risk of 
contraindication pertaining to prospective treatments. Concomitant approaches 
incorporate a combination of topical antimicrobial agents, topical retinoids, systemic 
antibiotics and systemic retinoids (Gollnick et al., 2003; Leyden, 2003); utilizing 
exclusive, complimentary mechanisms of action. Combination therapy is indicated for all 
levels of acne severity and early initiation of treatment is recommended (Alexis, 2008). 
Expert groups, such as the Global Alliance to Improve Outcomes in Acne, have 
published clinically relevant information with regards to the pathophysiology of acne 
vulgaris and comprehensive therapeutic guidelines (Gollnick et al., 2003; Thiboutot et 
al., 2009). The treatment algorithm presented by the Global Alliance to Improve 
Outcomes in Acne published by the Journal of the American Academy of Dermatology, 
is most commonly used by clinicians (Barber, 2011); therefore, details of the treatment 
modalities that follow are based on the recommendations published by this group, which 
align with those of the Academy’s most recently published care guidelines (Zaenglein et 
al., 2016).   
1.1.4.1 Topical treatments 
The first line of treatment for acne vulgaris is a topical retinoid with or without an 
antimicrobial agent. Monotherapy employing a topical retinoid product, such as 
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adapalene (a third generation retinoid), tazarotene (acetylated retinoid) and tretinoin 
(retinoic acid), is the primary course of treatment for mild, comedonal cases of acne. 
Recommended therapeutic regimens for the treatment of all other types and levels of 
severity incorporate topical retinoids in combination with topical and/or systemic 
antimicrobials. Topical antimicrobials include benzoyl peroxide and antibiotics; namely 
clindamycin and erythromycin. Aside from asserting antimicrobial action, topical 
antimicrobials exhibit anti-inflammatory properties. Topical retinoids act as mild anti-
inflammatory agents in addition to serving as comedolytic agents (Bikowski, 2005). 
A common, undesirable side effect of topical acne treatment is skin irritation. Despite its 
frequent use for the treatment of acne and maintenance, issues regularly arising as a result 
of benzoyl peroxide application are peeling, erythema and unpleasant skin sensations 
such as burning and itching (Bikowski, 2005; Mills et al., 1986). Women of childbearing 
age must be cautious as topical retinoids are contraindicated for use by pregnant women 
due to the risk of teratogenicity (Kaplan et al., 2015; Panchaud et al., 2012). Emergence 
of resistant microorganisms is highly possible when antibiotics are employed (Cunliffe et 
al., 2002) and decreases with the addition of complimentary treatment modalities (Alexis, 
2008; Del Rosso, 2016; Dréno et al., 2016a).  
1.1.4.2 Systemic treatments 
Antibiotics 
Despite the nature of infection, complications with regard to efficacy of therapeutics arise 
on the account of increasing antibiotic resistances (Oprica & Nord, 2005; Simpson, 2001) 
often resulting in persistent chronic infections. Lipophilic antibiotics have been employed 
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for treatment of acne vulgaris for roughly 60 years (Del Rosso, 2016), including 
tetracyclines, macrolides, clindamycin, trimethoprim/sulfamethoxazole and levofloxacin 
(Ochsendorf, 2006; Ross et al., 2003; Strauss et al., 2007; Zaenglein et al., 2016). Poor 
clinical response to antibiotic therapies and the prolonged nature of treatment is 
correlated with a rise in antibiotic resistance due to selective pressure against species 
susceptible to antibiotics, thereby selecting for resistant strains (Del Rosso & Zeichner, 
2016). The Scientific Panel of Antibiotic Usage in Dermatology (SPAUD) estimated nine 
million oral prescriptions are given per year to treat infectious skin disorders in the 
United States (1999–2003), predominately for the treatment of acne vulgaris and rosacea 
(Del Rosso & Kim, 2009; James Q. Del Rosso, 2006). This figure is troubling as resistant 
P. acnes strains seem to be easily acquired through previous antibiotic treatment in 
addition to contact with persons carrying resistant strains (Ochsendorf, 2006). A point 
mutation within the nucleotide region encoding 16S ribosomal RNA (rRNA) is 
responsible for acquired resistance to tetracyclines (Ross et al., 2001). Dictated by sub-
species phenotype, point mutations in the peptidyl transferase region of 23S rRNA is 
reported to yield varying levels of single and cross-resistance to erythromycin and 
clindamycin; both of which are ineffective against strains harboring erythromycin 
ribosome methylase resistance gene, erm(X), a result of transposon-mediated resistance 
(Ross et al., 1997, 2002). The rates of resistance varies between geographical regions as 
treatment regimens differ, however, in general, the abovementioned mutations are 
widespread with few mutations remaining unelucidated and limited to specific 
geographical regions (Schafer et al., 2013). P. acnes remains most sensitive to 
tetracyclines with higher levels of resistance against erythromycin and clindamycin 
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(Ochsendorf, 2006). Second generation tetracyclines, doxycycline and minocycline, are 
prominent treatment options with preference given to enteric-coated doxycycline to 
minimize the severity of adverse gastro-intestinal side effects (Kircik, 2010; Zaenglein, 
2015). For instance, European surveillance studies report that Finland has the highest 
outpatient use of tetracycline, which correlates with the high tetracycline resistance at 
11.8% (Schafer et al., 2013). Macrolides are most frequently used in Italy where 
resistance to erythromycin (42%) and clindamycin (21%) are very high (Oprica & Nord, 
2005). Recent studies from Europe, Mexico and Chile suggest resistance to 
trimethoprim/sulfamethoxazole is most common, with a highest reported rate of 68% 
(González et al., 2010; Oprica et al., 2004; Ross et al., 2001; Schafer et al., 2013).  
There are a vast array of detrimental side effects reported with prolonged antibiotic 
administration required for the treatment of acne such as gastrointestinal complications, 
photosensitivity, candidiasis, dizziness and lightheadedness, among others (Garner et al., 
2012; Kircik, 2010; Park & Skopit, 2016; Smith & Leyden, 2005). Multiply-resistant 
strains are also on the rise due to combinatorial therapies of systemic antibiotics and 
retinoids with topical microbicides (Ross et al., 2003). 
Oral retinoid 
Isotretinoin (Accutane), the only available orally-administered retinoid therapy, is 
regarded as the most effective treatment for acne vulgaris. It acts to decrease sebum 
levels by approximately 90%, thereby reducing P. acnes load and inflammation as a 
secondary effect (King et al., 1982; Leyden et al., 1986). Isotretinoin is reserved for the 
treatment of severe acne and/or for patients that are at risk for scarring; regardless of the 
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severity of their condition (Layton et al., 1997). Patients experiencing psychosocial 
impairment as a result of their condition may also be considered for oral retinoid therapy 
(Kellett & Gawkrodger, 1999). 
Despite its efficacy, contraindications of isotretinoin pose limitations to the range of 
patients eligible for treatment. Teratogenicity is the most severe and well-documented 
side effect of retinoid therapy (Dai et al., 1992). Despite efforts to reduce the incidence of 
pregnancy through extensive patient counselling and contraceptives, fetal exposure to 
isotretinoin remains a reality due to non-compliance (Collins et al., 2014; Shin et al., 
2011; Tan et al., 2016). Most patients experience skin dryness and cheilitis. Other side 
effects include conjunctivitis, hair loss, arthralgia and myalgia (Brito et al., 2010; Kellett 
& Gawkrodger, 1999). Minor infections by Staphylococcus aureus are a result of 
alterations of skin flora composition following retinoid therapy (Başak et al., 2013; 
Williams et al., 1992). Published reports regarding other adverse effects; including 
depression and inflammatory bowel disease, contain conflicting evidence  (Zaenglein et 
al., 2016). However, physicians are advised to remain mindful of the guidelines for 
evidence-based monitoring. 
Hormone therapy 
Hormone therapy targets androgen levels, which play a crucial role in the onset of acne 
vulgaris. Androgen-induced seborrheic hyperplasia can be reduced by introducing 
treatment with a combined oral contraceptive (COC), antiandrogen (AA), low-dose 
glucocorticoid (LDG) or gonadotropin-releasing hormone agonist (GRHA) (Bettoli et al., 
2015). Treatment modalities act via one or more of the following mechanisms: androgen 
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receptor blockage (COC and AA); 5-alpha-reductase inhibition (COC and AA); down-
regulation of adrenal androgen production (COC, AA and LDG); reduced production of 
ovarian androgens (COC, AA and GRHA); decreased levels of free testosterone in blood 
by upregulating sex hormone binding protein production (COC and AA); and suppression 
of ovulation-induced androgen production (COC) (Bettoli et al., 2015).    
Hormone therapies are recommended as an alternative to oral isotretinoin for the 
treatment of acne where scarring has occurred or there is a potential for scarring. It is also 
indicated as an alternative approach for the treatment of moderate to severe acne. Like 
other treatment methods, hormonal therapy is suggested in conjunction with a topical 
antimicrobial or oral antibiotic and/or topical retinoid. Hormone therapy is 
contraindicated for pregnant females or females wishing to become pregnant and is not a 
viable option for acne therapy in males (Sawaya & Hordinsky, 1993). In addition to 
several side effects, there is a risk of major adverse events while undergoing hormone 
therapy that must be considered when determining the suitability of the treatment for the 
individual (Bettoli et al., 2015; Gollnick et al., 2003). Possible serious side effects of 
hormone therapy include thromboembolism, hepatotoxicity, cardiovascular disease, 
cervical and breast cancer; more common effects include breast tenderness, headache, 
nausea, and irregular menstrual cycle (Bettoli et al., 2015; ESHRE Capri Workshop 
Group, 2013; Harper, 2016; Hughes & Cunliffe, 1988; Krunic et al., 2008; Miquel et al., 
2007; Park & Skopit, 2016; Plu-Bureau et al., 2013; Savidou et al., 2006; Shaw, 2000; 
Shaw & White, 2002; Zaenglein et al., 2016). Additional criteria, in relation to patient 
eligibility, extends the limitation of hormone therapy further; excluding patients with a 
history of and/or active blood clot disorders, diabetes, hypertension, cerebrovascular 
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disorders, cardiac disease, liver disease and breast, endometrial or liver cancer, amongst 
others (Barber, 2011; Bettoli et al., 2015; Harper, 2016).   
1.1.4.3 Alternative treatment: light therapies 
Light-based therapies have been under investigation as a fairly recent alternative option 
for acne treatment. The safety and efficacy of such methods are not well-known as off-
label use is detrimental to the initiation of clinical efficacy trials. Another impediment to 
supporting the validity of light therapies is that devices are not as stringently assessed in 
comparison to the evaluative protocols for regulatory clearance that pharmaceuticals are 
subject to (Thiboutot et al., 2009). Light-based therapy targets P. acnes and/or acts to 
disrupt sebaceous gland function via photochemical and/or photothermal effects, 
respectively (Momen & Al-Niaimi, 2015). Aside from persistent relapse, side effects that 
may deter patients from undergoing light therapy include discomfort, erythema, edema, 
pustular eruption, superinfection, blistering, crusting and peeling (Babilas et al., 2010; Jih 
et al., 2006; Momen & Al-Niaimi, 2015; Nestor et al., 2016; Taub, 2007; Wiegell & 
Wulf, 2006). 
1.1.4.4 Summary 
Motley & Finlay (1989) demonstrated that “willingness-to-pay” values for a cure by 
≥62% patients with acne, ranged from £100–£5000 (approx. $240–$17400 current US 
dollars, respectively). Monthly willingness-to-pay values of acne sufferers are reported to 
be higher than for individuals suffering from high cholesterol, hypertension, angina, 
atopic eczema and psoriasis (Parks et al., 2003). Therefore, it is imperative that 
therapeutics aimed at resolving acne be made available. 
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All of the abovementioned therapeutic approaches entail a certain level of patient 
adherence to obtain desirable results. Elevated incidence of treatment failure may be 
credited to a lack of patient adherence; often attributed to the daily demand of therapeutic 
applications, development of undesirable side effects or persistence of the condition (Lott 
et al., 2010; de Lucas et al., 2015). Conventional treatment modalities are associated with 
numerous contraindications, accompanied by a risk of mild to severe adverse effects, and 
typically yield results after a minimum of two months. In recent years, there has been an 
abundance of evidence promoting the importance of maintaining a healthy, human 
microbiome and its role in disease prevention (Muszer et al., 2015). Therapy-related 
consequences that impact the delicately-balanced composition of commensal flora have 
substantial implications (Başak et al., 2013).  
Therapeutic objectives sought in the treatment of acne are to eliminate lesions and to 
prevent relapse while taking all measures to avoid scarring (Thiboutot et al., 2009). 
Pathogenic factors must be addressed in such a way as to minimize side effects (Alexis, 
2008). Current approaches in acne therapy present numerous challenges that justify the 
pursuit of a viable therapeutic alternative; free of adverse effects, contraindications, 
potential for relapse and minimal necessity for patient adherence. 
1.2 Bacteriophage therapy: a viable alternative 
1.2.1 Historical background 
The first-ever report of bacteriophages published in a major journal was by Fredrick 
Twort (Twort, 1915). In this report published by The Lancet, Twort had not been able to 
describe the nature by which the unknown entity he observed killed bacterial cultures, 
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however, he considered the existence of an “ultramicroscopic virus” (Twort, 1915). Prior 
to this, similar findings had been reported by scientists in other regions (Gamaleya, 1898; 
Hankin, 1896). Twort’s suspicions regarding the viral nature of his unidentified substance 
was supported by observations presented by Felix d’Herelle during the meeting of the 
Academy of Sciences in 1917 (d’Herelle, 1917). D’Herelle described zones of clearance 
formed on bacterial lawns by bacteria-free filtrate of the stool of dysentery patients and 
coined the term “bacteriophage” to describe the agents of bacterial lysis (Duckworth, 
1976; d’Herelle, 1917). Just a short time after, phage therapy became globally 
implemented for the treatment of various life-threatening illnesses such as dysentery, 
cholera and bubonic plague, amongst others (d’Herelle, 1926). Beginning in the early 
1920’s, large-scale commercial production of phage preparations was underway in 
France, India, Brazil and the United States. In the late 1930’s, the American Medical 
Association set out to evaluate the value and safety of bacteriophage therapy. The lack of 
standardization of phage formulations with respect to aspects relating to safety and 
efficacy, coupled with a shortage of knowledge regarding the biological mechanisms of 
phage efficacy, raised concerns in the Western World (Summers, 2001).  
Leading up to the discovery of antibiotics, bacteriophages dominated the field of 
infectious disease treatment, however, just fifteen years following the discovery and 
initial applications of phage, antibiotics emerged and rapidly became the focus of 
attention for antimicrobial development. Phage therapy was so widely accepted at the 
time that the discovery of the new non-phage antimicrobials, e.g. penicillin, was 
dismissed by the Chairman of the Sir William Dunn School of Pathology of Oxford 
University and the project had remained dormant for several years prior to its 
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reinstatement (Friedman & Friedland, 1998). Nonetheless, concerns associated with 
phage therapy, newfound availability of broad-spectrum antibiotics and the necessity for 
such antimicrobials during World War II, initiated a massive push towards the 
development of antibiotics, resulting in near-abandonment of phage research in the 
Western World. Phage research and application persisted in the Soviet Union and Poland 
by virtue of economic and political value (Kutter et al., 2010). Return of phage research 
to Western countries is believed to have been hindered by a reluctance to share common 
practices with the Soviet Union (Summers, 2001). 
Since the late 1930’s, phage research remained overshadowed by antibiotics in Western 
countries, however, the emergence of antibiotic resistance prompted a revitalized interest 
in the field of phage therapy. Recent attention to the importance of a balanced, healthy 
microbiome, coupled with escalating rates of antibiotic resistance, have presented a 
growing global challenge in the treatment of infectious diseases. Development of novel, 
highly selective and easily produced antimicrobial products is crucial to initiating a 
paradigm shift towards adopting safer, more effective treatment strategies without the 
shortcomings and detrimental effects of conventional antibiotics. 
1.2.2 Important considerations and current state 
Bacteriophage-based antimicrobial therapeutic strategies offer a powerful alternative to 
conventional antibiotics. Bacteriophage preparations, often produced as “phage 
cocktails”, are comprised of multiple types of whole phage particles formulated to 
increase the likelihood of overcoming any naturally-occuring or evolved resistance 
among bacterial targets (Doss et al., 2017; Gill & Hyman, 2010). Phage products, such as 
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lytic enzymes, are also of interest by virtue of their relatively negligible toxicity and 
targeted host specificity (Trudil, 2015).  
Phage life cycles vary between lytic and temperate, the former is preferred for whole 
phage applications as the completion of the phage life cycle results in bacterial death, 
whereas the latter will result in persistence of both the host cell and the phage. The 
general sequence of events concerning the life cycle of a lytic phage begins with its 
attachment to the surface of its host. Prior to attachment, the interaction at the phage-host 
interface is at random, therefore selective attachment only occurs when components of 
the phage that confer specificity (most often the tail fibers) come into contact with a 
matching receptor on the surface of the host bacterium. Upon attachment, the phage 
inserts its genetic material into the host cytoplasm, initiating a cascade of phage-
modulated events. Redirection of host replicative and metabolic machinery favors 
exponential propagation of new phage particles, followed by subsequent lysis of the host 
and release of progeny phage.  
By virtue of its high degree of specificity, no threat to the delicate balance of the 
commensal microflora is imposed by treatment with defined phage formulations. The risk 
of human toxicity by phage is mitigated by the absence of tropism for eukaryotes 
combined with lacking the capacity to execute an infectious life cycle within mammalian 
cells (Mount et al., 2004; Parasion et al., 2014). Therefore, administration of phage may 
be given in higher doses than chemical antibiotics. However, high doses are not 
necessary as phages replicate exponentially. Therefore, unlike antibiotics, which 
experience exponential decay in the body, a single dose administration of phage would 
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suffice to rapidly eliminate the pathogen target (Doss et al., 2017). Moreover, resistance 
to phage is rare as spontaneous mutation in the phage during exponential replication 
confers dynamic control over any emerging resistant populations (Parasion et al., 2014). 
Therefore, phage therapy boasts a highly specific, natural, cost-effective approach to 
indiscriminately eliminating both antibiotic susceptible and resistant pathogens via 
mechanisms that can be either strain- or species-specific (Parasion et al., 2014). 
In the advent of rising concerns associated with chemical applications used for biocontrol 
of bacteria, there is a renewed interest in bacteriophages in the West; stimulating a 
revitalization of phage research and the development and implementation of commercial 
applications within agricultural, aquaculture and industrial sectors. Commercial 
applications currently in use include “Listex P100” and “ListShield”, “EcoShield” and 
“Salmofresh” phage preparations that are used to control foodborne human pathogens, 
such as Listeria monocytogenes, Escherchia coli O157:H7 and pathogenic Salmonella 
serotypes, respectively (Żaczek et al., 2015). To reduce loss of agriculutural crop yields, 
commercial preparations that target phytobacteria, such as “AgriPhage”, provide 
protection against bacteria that parasitize plant hosts (Żaczek et al., 2015). Making it 
possible to apply phage to food for human consumption, these phage preparations have 
been designated as “GRAS” (generally recognized as safe) by the American Food and 
Drug Administration (FDA). Nevertheless, certain stipulations must be adhered to; those 
of which relate to the nature of the phage state that the phage be lytic and must not 
possess any toxin or antibiotic resistance genes thus ensuring that horizontal virulent or 
resistance gene transfer will not occur between the phage and its bacterial hosts (Gill & 
Hyman, 2010; Nobrega et al., 2015). 
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Phage therapy in humans has persevered in regions of the former Soviet Union, however, 
its application has been limited to compassionate use provisions in Western countries 
(Kutter et al., 2010). Previous attempts were made to initiate clinical trials with phage in 
the past, however, lack of funding made it difficult to do so (Kutter et al., 2010). 
Recently, the first industry-standard clinical trials for bacteriophage therapy have begun 
and are currently underway in Europe and the United States (Kingwell, 2015). In 
Belgium, France and Switzerland, a project sponsored by the European Union called 
“Phagoburn” has initiated phase I/II clinical trials of two anti-infection therapies for burn 
victims against Escherichia coli and Pseudomonas aeruginosa (Kingwell, 2015; 
Pherecydes Pharma, 2016; Servick, 2016). Furthermore, an American company—
“AmpliPhi Biosciences”—has recently initiated clinical trials of a phage preparation for 
the treatment of chronic rhinosinusitis associated with infection by S. aureus (AmpliPhi 
Biosciences, 2016; Kingwell, 2015). Other studies have evaluated the safety of various 
phage preparations. Reports from Switzerland and Bangladesh have demonstrated the 
safety of oral E. coli phage preparations in healthy adults (Bruttin & Brüssow, 2005) and 
children hospitalized with acute bacterial diarrhea (Sarker et al., 2016), respectively. 
Another study reported the safety of phage application in patients with chronic venous 
leg ulcers, which targetted E. coli, S. aureus and P. aeruginosa (Rhoads et al., 2009). 
Supporting both the safety and efficacy of a phage preparation for the treatment of 
patients suffering from P. aeruginosa-associated chronic otitis, a report published in the 
United Kingdom by Wright et al. (2009) describes a significant decline in bacterial load, 
relief of symptoms and improved clinical presentation after just a single dose of the 
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phage preparation. Taken together, findings from these studies and others represent a 
positive direction and a promising future for antibacterial phage therapy. 
1.3 Phage therapy and acne vulgaris 
1.3.1 Current literature 
The first phage isolation against “C. acnes” was reported by Brzin in 1964. Subsequent 
reports of P. acnes phage isolations offered more detailed characterization in terms of 
host range, physical morphology, and genome sequencing (Brown et al., 2016; Brown et 
al., 2017; Farrar et al., 2007; Jong et al., 1975; Liu et al., 2015a; Lood et al., 2008; Lood 
& Collin, 2011; Marinelli et al., 2012; Webster & Cummins, 1978; Zierdt et al., 1968). In 
earlier reports, host ranges of phage isolates were determined and those with unique host 
ranges were used to serotype P. acnes isolates by exploiting the association between P. 
acnes serotypes and susceptibility to phage collections (Jong et al., 1975; Webster & 
Cummins, 1978). Later, morphological characteristics of P. acnes phage particles were 
characterized using transmission electron microscopy (TEM). Electron microscopy of P. 
acnes phages reveals only siphovirus morphology, with icosahedral heads of 
approximately 50 nm and a flexible, non-contractile tail approximately 150 nm in length 
(Ackermann, 2011; Brown et al., 2017; Farrar et al., 2007; Lood et al., 2008; Lood & 
Collin, 2011; Marinelli et al., 2012; Webster & Cummins, 1978).  
To date, seventy-three P. acnes phage genomes have been sequenced; none have been 
isolated from environmental sources (Brown et al., 2016; Brown et al., 2017; Farrar et 
al., 2007; Liu et al., 2015a; Lood & Collin, 2011; Marinelli et al., 2012). In 2007, Farrar 
et al. reported the first-ever P. acnes bacteriophage DNA sequence, phage PA6, which 
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was isolated from the skin of a patient in the United Kingdom. Four years later, two 
phages were induced from Swedish P. acnes isolates originating from deep tissue 
infection (PAD20) and skin surface (PAS50) for genome sequencing by Lood and Collin 
(2011). Eleven phage genomes sequenced by Marinelli et al. (2012) consisted of nine 
nasal skin isolates (Los Angeles, US) and two phages from the American Type Culture 
Collection (ATCC) 29399B phage stock obtained 30 years prior (Philadelphia, US). Liu 
et al. (2015a) sequenced forty-eight P. acnes phages collected from the retroauricular 
creases of acne patients and healthy individuals. More recently, a report published by 
Brown et al. (2016) presents the genome sequences of ten phages obtained from human 
facial skin swabbing. From these reports, we have learned that P. acnes phages are very 
similar in terms of their genome structure and organization. Phage DNA sequencing 
revealed genome lengths ranging between 29,017 to 29,806 base pair (bp) with guanine-
cytosine content (GC-content) of 53.70% to 54.73%—slightly lower than that of their P. 
acnes hosts (approximately 60%) (Brown et al., 2016; Farrar et al., 2007; Liu et al., 
2015a; Lood & Collin, 2011; Marinelli et al., 2012). Having a nucleotide identity greater 
than 85%, minimal genetic diversity exists at the nucleotide level across genome 
sequences (Brown et al., 2016; Liu et al., 2015a; Lood & Collin, 2011; Marinelli et al., 
2012). The lack of diversity is striking considering the phage collections vary 
significantly with respect to geographic location and temporal period of which they were 
collected (Brüggemann & Lood, 2013).  
Specific mechanisms that phages use to interact with P. acnes host cells during 
adsorption and initiation of the infective life cycle is very limited, despite the relative 
abundance of P. acnes bacteria and their phages. Approximately 50% of phage genomes 
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encode putative proteins homologous to those of other P. acnes phages (Marinelli et al., 
2012). The majority of remaining gene products have up to 50% amino acid identity to 
proteins expressed by phages of other Actinomycetales species; to which no functions are 
assigned (Lood & Collin, 2011; Marinelli et al., 2012). The genome organization and 
predicted products are similar to many mycobacteriophages that also exhibit siphoviral 
morphology (Lood & Collin, 2011; Marinelli et al., 2012). Further investigation based on 
phage DNA sequences and corresponding phage products in relation to host protein 
networks will help to solve the mechanisms exploited by phage during infection.  
Based on published sequences, about half of the genome (approximately 15 kbp) is 
comprised of structural genes and genes involved in phage packaging, located within an 
operon on the left side of the genome (genes 1 to 19), transcribed from left to right. The 
majority of genetic variation is found amongst the viral DNA replication genes located on 
the right side of the genomes that undergo leftward transcription using the 
complementary strand.  The far right side of the genomes harbor up to three genes, in 
addition to a large, variable, non-coding region of greater than 1kbp in length, possibly 
containing the origin of replication. Aside from within the far-right region, there is little 
non-coding DNA and there are no genes encoding tRNA. Additionally, a 13bp single-
stranded extension on both ends of the PA6 genome (Farrar et al., 2007) and 
PAS50/PAD20 genomes (Lood & Collin, 2011) have been reported. However, data 
presented by other groups suggest an 11bp extension on both ends of the phage genomes 
they reported (Brown et al., 2016; Liu et al., 2015a; Lood & Collin, 2011; Marinelli et 
al., 2012).  
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Genes 1 to 19 encoding putative structural proteins are all highly conserved at the 
nucleotide level, with the exception of putative minor tail protein encoded by ORF19. It 
appears to be highly variable in the 3’ region of the gene, with a corresponding variability 
in the C-terminal domain of the protein product, suggesting involvement in host 
specificity. Due to its proximity to the genes encoding tail proteins, it may encode a 
component of the tail structure and is predicted to play a role in attachment to P. acnes 
surface adhesins due to its homology to collagen chain precursors (Farrar et al., 2007).  
Another genomic region that has been suggested for its involvement with phage entry is 
ORF16 encoding gene product (gp) 16, a protein having a slight homology to protease 
enzymes known to bind nonpolar C termini (Farrar et al., 2007). Data suggests gp16 may 
be a minor structural protein (Marinelli et al., 2012) and due to its location, Farrar et al. 
(2007) suggested the possibility of its role in host entry via degradation of cell wall 
peptide linkages, if it is indeed a constituent of the tail fibers. Located close to the tail 
protein encoding region, gp17, encodes a protein with unknown function. However, its 
H-type lectin domain may be capable of associating with carbohydrates suggesting a role 
in host receptor binding (Lood & Collin, 2011). Following this first part of the genome is 
the lysis cassette: genes encoding the protein products required for the release of progeny 
viruses from the host cell; including holin and endolysin, for cell membrane rupture and 
peptidoglycan degradation of the cell wall (Liu et al., 2015a; Lood & Collin, 2011; 
Marinelli et al., 2012). 
With the exception of P. acnes phylotype III, all other P. acnes phylotypes have been 
represented among those isolated from acne lesions, the majority of which are classified 
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as type IA (Fitz-Gibbon et al., 2013). Therefore, P. acnes phages with a wide species-
specific host range are optimal for therapeutic phage preparations. Additionally, 
application of phages having broad host ranges will minimize the chance of survival of 
less sensitive P. acnes isolates. Majority of P. acnes phages observed to date, have been 
reported to exhibit a broad host range at the strain-level, thereby insinuating a low 
frequency of resistance to phage (Jong et al., 1975; Liu et al., 2015a; Marinelli et al., 
2012; Webster & Cummins, 1978; Zierdt et al., 1968). To date, sequenced genomes of 
bacteriophages isolated against P. acnes do not encode any protein products associated 
with a lysogenic life cycle (Marinelli et al., 2012) or any genes known to confer virulence 
to their bacterial hosts (Brüggemann & Lood, 2013).  
1.4 Scope of this study 
Reports of Propionibacterium acnes-specific bacteriophages, to date, provide evidence of 
their biological properties that are desirable for therapeutic applications. We hypothesize 
that phages and the antibacterial products they produce, are viable therapeutic alternatives 
for future acne treatment. To demonstrate proof of concept, we aim to acquire and test P. 
acnes-specific phages for the purpose of formulating minimal phage cocktails that have 
high levels of antibacterial activity against a wide range of clinically-relevant P. acnes 
isolates.  
To address our aim, the first objective of this project is to establish a collection of 
geographically diverse P. acnes clinical isolates from a variety of superficial and deep-
seated specimens, and further characterize them on the basis of their genetic properties 
and antimicrobial susceptibilities. The second objective is to establish a library of P. 
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acnes-specific bacteriophages, characterize them for their biological activities against the 
collections of clinical P. acnes isolates to determine their host ranges. The final objective 
of this project is to formulate candidate phage cocktails using phages that exhibit a broad, 
complementary variety of host range activities and to assess the biological properties of 
candidate phages through genome sequencing and deduced proteomics. 
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 Materials and Methods 2
2.1 Materials 
2.1.1 Bacterial strains and clinical isolates 
Standard control strains of P. acnes, ATCC 6919 and ATCC 29399 (Table C.1), were 
included in all experiments. Propionibacterium avidum ATCC 25577 and 
Propionibacterium granulosum ATCC 25564 were used as negative internal controls for 
phage host range analysis, molecular identification and phylotyping of clinical isolates. E. 
coli K-12 MG1655 and Streptococcus pyogenes ATCC 12204 were applied as positive 
and negative catalase controls, respectively. Bacillus subtilis ATCC 23857, Clostridium 
difficile ATCC 9689, E. coli K-12 MG1655, S. aureus ATCC 29923, Salmonella 
typhimurium TA1535 and S. pyogenes ATCC 12204 were used as negative external 
controls in phage host range analysis. Antibiotic susceptibility testing required quality 
control (QC) validation by evaluating minimal inhibitory concentration (MIC) values of 
standard QC strains, S. aureus ATCC 29213, Enterococcus faecalis ATCC 29212 and 
Streptococcus pneumoniae ATCC 49619, against published values. 
Clinical P. acnes isolates from patients across Canada associated with various systemic 
or deep tissue infections were obtained from the National Microbiology Laboratory 
(NML) in Winnipeg (Table C.1). Forty-five P. acnes isolates from skin surfaces of 
healthy patients (AS) and deep tissue infections (AD) were received and cultured from 
the collection of Dr. Anna Holmberg (Department of Clinical Sciences of Lund 
University, Sweden) (Table C.1). Clinical samples of swabbed skin surfaces and acne 
 
 
34 
 
lesion extracts were obtained from 91 patients of Dr. Lyne Giroux (Sudbury Skin 
Clinique, Canada) and 45 patients of Dr. Sharyn Laughlin (Laserderm, Ottawa, Canada) 
using M40 Transystem Amies Agar Gel swabs (Copan Diagnostics, Murrieta, USA). 
Bacterial stocks were maintained in 10% glycerol at -80 ºC for long-term storage, and 
working agar plates were used for daily culturing and short-term storage at 4 ºC.  
2.1.2 Culture media, supplements, antibiotics, reagents, enzymes and kits 
Columbia (CB) broth and Brain-heart infusion (BHI) broth dehydrated nutrient media 
and agar were purchased from Quelab (Montreal, Canada). CB and BHI were used for 
routine culturing of bacteria and solid CB/BHI media containing 1.6% bacteriological 
agar were used for colony isolation and short-term maintenance of cultures. CB/BHI 
media containing 0.7% bacteriological agar was used as top agar in plaque assay or for 
experiments requiring agar overlay. Refer to Appendix A for formulations and 
preparations.  
Antibiotic susceptibility was determined by Epsilometer test (Etest) purchased from 
bioMérieux (St. Laurent, Canada). The Etest panel consisted of the following antibiotics: 
azithromycin (AZ) AZ 256, benzylpenicillin (PGL) VB/PGL 32 (commonly referred to 
as Penicillin G), ceftriaxone (TXL) VB/TXL 32, clindamycin (CM) CM 256, daptomycin 
(DPC) DPC 256, doxycycline (DC) DC 256, erythromycin (EM) EM 256, levofloxacin 
(LE) LE 32, linezolid (LZ) LZ 256, minocycline (MC) MC 256, rifampicin (RI) RI 32, 
tetracycline (TC) TC 256, trimethoprim/sulfamethoxazole (TS) 1/19 TS 32 and 
vancomycin (VA) VA 256.  
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Brucella broth from BD Biosciences (Sparks, USA) and Mueller-Hinton (MH) broth 
from Oxoid (Basingstoke, UK), were used in antibiotic susceptibility testing. Nutrient 
media supplements required for all antimicrobial susceptibility testing included hemin 
(H9030) and vitamin K1, both of which were purchased from Sigma-Aldrich (Saint 
Louis, USA). To evaluate susceptibility to DPC, supplementation with calcium chloride 
(BioShop, Burlington, Canada) was necessary. Refer to Appendix A for formulations and 
preparations. Hydrogen peroxide (30%) was used in catalase test, pronase (Boehringer 
Mannheim GmbH, Germany) and Ribonuclease (RNase) A/T1 (2 mg/mL RNase A and 
5000 U/mL RNase T1) (Thermo Scientific) were used for  protein digestion and RNA 
degradation in genomic DNA (gDNA) isolation, respectively. Polyethylene glycol (PEG) 
8000 was used to precipitate and concentrate the phage particles (Bioshop Canada). A 
25:24:1 (v/v) mixture of phenol, chloroform and isoamyl alcohol (PCI) was used for 
phage DNA extraction (Appendix B.3). Restriction enzymes BamHI and HindIII were 
purchased from New England Biolabs (NEB; Ipswich, USA); Taq DNA polymerase (Taq 
Pol) (50 U/μl), 10 mM deoxyribonucleotide triphosphates (dNTPs), polymerase chain 
reaction (PCR) buffer without Mg+2 (10X) and 50 mM MgCl2 were purchased from 
Invitrogen (Carlsbad, USA). NEBNext Fast DNA Fragmentation & Library Preparation 
set for Ion Torrent (NEB), Agencourt AMPure XP Beads (Beckman Coulter Inc., 
Danvers, USA) and Ion Express Barcode Adaptors 17–32 Kit (Life Technologies) were 
used for preparations of phage DNA libraries for genome sequencing. The library quality 
was assessed with the Qubit 2.0 Fluorometer using the Qubit double-stranded DNA 
(dsDNA) High Sensitivity (HS) Assay Kit (Life Technologies).  Ion 316 Chip v2 and the 
Ion PGM Sequencing 200 Kit v2 (Life Technologies, Carlsbad, USA) were used for 
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sequencing phage genomes using the Ion Torrent Personal Genome Machine (Ion PGM) 
platform. Agarose gels (0.7%–2%) prepared in 1X tris-acetate-ethylenediaminetetraacetic 
acid (TAE) running buffer, 6X DNA loading dye, GeneRuler High Range (HR) DNA 
Ladder (Thermo Scientific) and/or 1 Kb Plus (1 KbP) DNA Ladder (Invitrogen) were 
used in DNA gel electrophoresis and the gels were stained in ethidium bromide (EtBr) 
(0.5 μg/mL) before imaging (Appendix B.6). 
2.1.3 PCR primers 
P. acnes gDNA-specific oligonucleotide primers were synthesized by Sigma-Aldrich 
(Oakville, Canada) and used for PCR amplification for identifying and phylotyping 
bacterial isolates (Table 2.2.1).  
2.1.4 Equipment and other tools 
Nunc OmniTrays (Thermo Scientific, Rochester, USA) and sterile 96-pin, 12 mm 
polypropylene replicators (Scinomix, Earth City, USA) were used for phage host range 
analysis in high throughput infection assay. 
Anaerobic incubation was carried out in the 855-AC Controlled Atmosphere Chamber 
(Plas Labs, Lansing, USA). Standard microaerobic incubation of bacterial cultures (85% 
N2, 10% CO2, 5% O2) was made possible using the Invivo2 500 Hypoxia Workstation 
(Baker Ruskinn, Sanford, USA). Candle jars were occasionally used with atmospheric 
concentration of CO2 adjusted to 5% (Oxoid, Basingstoke, UK). Bacterial morphology 
was assessed using the Axio Scope.A1 (Carl Zeiss Microscopy, Thornwood, USA). 
Bacterial cultures with volumes more than 2 ml were precipitated by centrifugation 
performed in the Beckman Coulter Allegra X-12 Benchtop Centrifuge fitted with the 
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SX4750A rotor (Palo Alto, USA). Centrifugation of liquid volumes ≤ 2 mL were 
performed using the Benchtop Sorvall Legend Micro 21R Centrifuge with the standard 
24-Place 1.5/2.0 mL Rotor (Thermo Scientific, Germany). PEG-precipitated phage 
particles were centrifuged using the Avanti J-E High-Performance Centrifuge fitted with 
the JA-25.50 Fixed-Angle Rotor (Beckman Coulter, Palo Alto, USA). Gel visualization 
and digital image acquisition were carried out using FluorChem FC3 imaging system 
with AlphaView Software. Concentration and purity of DNA was estimated by reading 
the absorbance values at 260 nm and 280 nm using a NanoDrop 2000c UV-Vis 
spectrophotometer (Thermo Scientific, Wilmington, USA) against double-distilled water 
(ddH2O) as a blank. The PTC-100 Programmable Thermal Controller (MJ Research Inc, 
Watertown, USA) was used to perform PCR. 
2.2 Methods 
2.2.1 Culture conditions and cryopreservation of standard strains and clinical 
isolates 
All standard bacterial strains and clinical isolates were cultured at 37 °C. 
Propionibacteria and C. difficile were incubated anaerobically in the 855-AC Controlled 
Atmosphere Chamber. Culturing S. pneumoniae required the use of Oxoid jars with 5% 
CO2 atmospheric adjustment. All other bacterial strains were grown under aerobic 
conditions. 
Columbia broth medium was used for recovery and maintenance of all standard bacterial 
strains and clinical isolates, with the exception of S. pyogenes and S. pneumonia grown in 
BHI medium.  
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Glycerol stocks of all standard bacterial strains and clinical isolates were prepared for 
long-term storage at -80 °C. Colony-purified bacteria were grown in 5 mL broth media 
under appropriate growing conditions for 3 to 5 days. Cultures were concentrated by 
centrifugation at 3250 x g for 20 min using the Allegra X-12 Benchtop Centrifuge. 
Bacterial pellets were resuspended in 500 μL CB broth and mixed with 500 μL 20% 
sterile glycerolto attain a final glycerol concentration of 10%. One millilitre concentrated 
glycerol stock was deposited into two 2 mL cryovials and stored at -80 °C. 
2.2.2 Isolation of P. acnes clinical isolates from Sudbury and Ottawa 
A combined total of 91 (Sudbury) and 45 (Ottawa) new and long-term acne patients 
served as sampling sources for P. acnes isolation. Patients were recruited to the study by 
informed consent following the Canadian Research Ethics Guidelines and approved by 
the Research Ethics Board of Health Sciences North (Sudbury, ON). Skin surface 
samples, denoted by SS (Sudbury Surface) and OS (Ottawa Surface), were collected by 
swabbing the skin surface. Samples of lesion exudate, denoted by SD (Sudbury Deep) 
and OD (Ottawa Deep), were collected by sampling the material from the extracts of acne 
lesions following sterilization around the site of infection with 70% ethanol or isopropyl 
alcohol. M40 Transystem Amies Agar Gel swabs were used for sample collection and 
transportation to the research lab.  
Samples were streaked for bacterial colony isolation onto CB agar plates and incubated at 
standard growing conditions for 15 days. One isolated colony of each colony morphology 
type was selected for further examination under oil immersion at 1000x using the Axio 
Scope.A1. Bacterial isolates exhibiting coryneform or pleomorphic rod morphology were 
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considered for further testing. Catalase testing was performed by transferring a loopful of 
the candidate colonies onto a microscope slide to which a drop of 30% hydrogen 
peroxide was added. S. pyogenes ATCC 12204 and E. coli K-12 MG1655 were used as 
negative and positive controls, respectively. Colonies were considered catalase positive 
by observation of gas production upon contact with hydrogen peroxide. All P. acnes 
candidates testing positive for catalase production and exhibiting the prescribed 
morphology were sub-cultured for colony purification via selection of a single colony and 
streaking onto CB agar plates followed by incubation under anaerobic conditions. Each 
isolated colony was sub-cultured a total of three times to eliminate contamination and 
propagate pure cultures. Following the final purification step, a single isolated colony 
was split and transferred to two separate tubes, both containing 5 mL CB broth and 
incubated under standard growing conditions. Both cultures were centrifuged using the 
Allegra X-12 Benchtop Centrifuge at 3250 x g for 15 min. The bacterial pellet from one 
tube was used to prepare long-term glycerol stock (see Section 2.2.1). The supernatant 
from the second tube was discarded and the bacterial pellet was washed once with 1 mL 
sterile ddH2O followed by centrifugation at 17000 x g for 5 minutes at 4 °C using the 
Benchtop Sorvall Legend Micro 21R Centrifuge. Pellets were stored at -80 °C prior to 
genome isolation.   
2.2.3 Genomic DNA extraction from presumptive P. acnes isolates 
Bacterial pellets prepared in Section 2.2.2 (stored at -80 °C) were thawed and 240 µL 
lysis cocktail containing 208 µL cell lysis buffer (CLB) (25 mM Tris-HCl pH 8.0, 2.5 
mM EDTA pH 8.0 and 1% Triton X-100), 6 µL 20 µg/µL pronase, 24 µL 10% SDS and 
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2 µL RNase A/T1 (2 µg/µL, 500 U/mL) were added and mixed thoroughly followed by 
overnight incubation at 37 ºC on a rotating mixer set to 2 rpm. Lysed cells were incubated 
in a water bath adjusted to 70 °C for 10 min followed by 30 min incubation at 37 °C. A 
volume of 120 µL 3 M potassium acetate pH 5.5 was added to each tube and mixed by 
inversions, followed by centrifugation in the Benchtop Sorvall Legend Micro 21R 
Centrifuge at 17000 x g for 15 min at 4 °C. A volume of 320 µL supernatant was 
carefully removed to avoid pelleted debris and 1200 µl ethanol/0.16 M sodium acetate 
was added to the supernatant followed by gentle mixing until the condensed 
chromosomal DNA was visible. Chromosomal DNA was pelleted by centrifugation using 
the Benchtop Sorvall Legend Micro 21R Centrifuge at 17000 x g for 15 min at 4 °C. The 
supernatant was discarded and the pellet was carefully washed with 600 µL 70% ethanol 
chilled to -20 °C. The tube was inverted onto an absorbent surface to dry for 20 min. 
Residual ethanol was further evaporated in a vacuum condenser chamber for 10 min. The 
DNA pellet was resuspended in 400 µL sterile ddH2O followed by qualitative and 
quantitative analysis by Nanodrop spectrophotometry and 0.7% agarose gel 
electrophoresis. Extracted gDNA was loaded in 5 µL volumes with 1 µL 6 X DNA 
loading dye and electrophoresed using 1 X TAE buffer against gDNA of P. acnes ATCC 
6919 (positive control) and 2.5 µL 1 KbP DNA ladder mixed with 2.5 µL HR DNA 
Ladder. DNA bands were stained with 0.5 µg/mL EtBr prior to visualizing and digital 
image acquisition using the short wave ultraviolet transilluminator function of the 
FluorChem FC3 imaging system with AlphaView Software. The prepared  gDNA 
libraries were stored at -20 °C until use.  
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2.2.4 Molecular identification and characterization of P. acnes clinical isolates 
Oligonucleotide primers specific to nucleotide sequences encoding P. acnes 16S rRNA 
and glycerol-ester hydrolase A (gehA) lipase genes (Table 2.2.1) were used to amplify 
fragments by PCR to confirm the identity P. acnes isolates. A select group of negative 
and positively-identified isolates were further verified and confirmed by Matrix Assisted 
Laser Desorption/Ionization Time-of-Flight (MALDI-TOF). Analysis by MALDI-TOF 
was performed at the laboratory of Dr. Tony Mazzulli, Department of Microbiology, 
Mount Sinai Hospital (Toronto, Canada) using the Vitek MS manufactured by 
bioMérieux S.A. (Marcy-l'Étoile, France). All P. acnes isolates were subjected to 
molecular phylotyping via PCR using phylotype IA, IB and II specific primers (Table 
2.2.1). Procedural details of identification and typing are given in the following sections.  
2.2.4.1 Molecular identification of P. acnes isolates: PCR amplification of gehA lipase 
gene and 16S rRNA DNA sequencesGenomic DNA of P. acnes ATCC 6919 and P. 
acnes ATCC 29399 served as positive controls, while gDNA from P. granulosum ATCC 
25564 and P. avidum ATCC 25577 served as negative controls. PCR amplification 
targeting P. acnes gehA gene (GenBank accession no. PPA2105) encoding a 
triacylglycerol lipase, and highly-conserved regions within three operons of 16S 
ribosomal DNA (rDNA) of candidate P. acnes clinical isolates, were used for molecular 
identification of the P. acnes clinical isolates. PCR primers for gehA and 16S rDNA, 
originally designed by (Nakamura et al., 2003), are listed in (Table 2.2.1). Primer 
specificity was verified by comparing nucleotide sequences to the alignment of the gehA 
gene and 16S rDNA nucleotide sequences of known P. acnes strains, P. avidum, P. 
granulosum, P. propionicum, and several S. aureus and E. coli strains. Exact nucleotide  
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Table 2.2.1: Molecular identification and phylotyping of P. acnes clinical isolates. Primer nucleotide targets are based on P. 
acnes reference strain KPA171202 (GenBank accession no. AE017283).  
 
Primer 
ID  Direction Primer sequence (5’3’) 
Primer 
modification Nucleotide Target Operon/type 
Amplified Region 
(5’3’) 
Fragment 
size (bp) Reference 
 Lip1 Forward TCACTGATGAAGATCAACGCAC - 
gehA - 
 
2279544…2279029 515 
Nakamura 
et al., 2003 
 Lip2 Forward ACTTCTCCTGCAAGGTCAAG - 2279306…2279029 277 
Pr
im
er
s f
or
 
Id
en
tif
ic
at
io
n 
Lip rev Reverse TGCGAATGTCCGACGACGTCGA 5’A17C 3’ - - 
PAS9 Forward CCCTGCTTTTGTGGGGTG - 
16S rDNA 
(3 operons) 
 
I 606230…607175 946 
II 1525296…1524351 
III 1801665…1800720 
PAS10 Forward CGCCTGTGACGAAGCGTG - I 606593…607175 583 
II 1524933…1524351 
III 1801302…1800720 
PAS rev Reverse CGACCCCAAAAGAGGCAC 5’ G16C 3’ - - - 
Pr
im
er
s f
or
 p
hy
lo
ty
pi
ng
 PR213 Forward GACGATTACTGGGGCAAGAA - sequence that encodes 
a solute-binding 
protein within an ABC 
peptide transporter 
operon 
Type IA 1579146…1579405 584 
Shannon et 
al., 2006 
PR216 Reverse GGGGTGAACTTGACGTTGAT - 
PR256 Forward GTCATCGGCTTCTGGATCAT - putative Y40U 
fragment 1 Type IB 948634–949358 725 PR257 Reverse CCTGGTTTCCACGATGTCTT - PR257G Reverse CCTGGTTTCCACGATGGCTT 5’ T17G 3’ 
PR245 Forward ATAAACCCATCGGCGGCTCGAT - two putative RHS-
family protein genes 
Type IA/IB 
Type II 246705–250694 
3990 
PR247 Reverse AGCAAGGGAGCATTCAGTGG - 537 2 
1 No significant nucleotide protein homology with any known sequence  
2 See Section 2.2.4.2 for explanation 
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matches were found exclusively in corresponding regions of the P. acnes genome with 
the exception of P. avidum where the lipase gene was also amplified by the gehA 
sequence-specific primers. The conditions were optimized for double primer screening of 
P. acnes candidates by multiplex PCR reactions in 96-well plates at a final volume of 50 
µL per reaction. Optimization for multiplexing the PCR reactions was achieved by 
adjusting the ratio of primers in order to produce nearly equivalent intensities of the 
amplified bands. Template DNA volumes, extracted as described in Section 2.2.3, varied 
between 1 µL and 5 µL to adjust for approximately 0.1 µg total DNA per reaction. Each 
reaction contained 1X master mix comprised of the following reagents: 5 µL Taq Pol 
PCR Buffer without MgCl2 (10X) and 1.5 µL 50 mM MgCl2, 1 µL 10 mM dNTPs and 1 
µL 5 U/µL Taq Pol, a volume of gDNA equivalent to 0.1 µg and adequate ddH2O to 
adjust the final reaction volume to 50 µL. Multiplex PCR amplifications of gehA and 16S 
rDNA were conducted separately with the following oligonucleotide primer sets (see 
Table 2.2.1): 0.6 µM Lip1, 0.2 µM Lip2, 0.4 µM Lip rev primers and 0.8 µM Pas9, 0.1 
µM Pas10, and 0.4 µM Pas rev primers, respectively. Reactions were performed with the 
PTC-100 Programmable Thermal Controller. Optimized multiplex PCR cycle conditions 
were as follows: an initial denaturation step of 5 min at 94 °C, 30 cycles of denaturation 
at 94 °C for 30 s, primer annealing at 53 °C for 30 s and primer extension at 72 °C for 60 
s, respectively. The reaction cycles were followed by a final extension step for 15 min at 
72 °C. Once complete, reactions were held at 4 °C. 
P. acnes identity of isolates was confirmed upon detection of DNA band sizes of 278 bp 
and 516 bp (corresponding with gehA) and 583 bp and 946 bp (corresponding with 16S 
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rDNA operon sequence targets), as determined by 1.5% gel electrophoresis. Amplified 
DNA was loaded in 10 µL volumes with 2 µL 6X DNA loading dye and electrophoresed 
using 1X TAE buffer against positive control strain P. acnes ATCC 6919, negative 
control strains P. avidum ATCC 25577 and P. granulosum ATCC 25564, and 3 µL 1 
KbP DNA ladder. Amplified DNA bands were stained and imaged as described in 
Section 2.2.3. 
2.2.4.2 Molecular phylotyping of P. acnes clinical isolates 
Genomic DNA was extracted (Section 2.2.3) from Swedish P. acnes isolates AS13 (type 
IB) and AD7 (type II), previously typed based on recombinase A (recA) gene sequences 
(Holmberg et al., 2009). Genomes of ATTC 6919 (type IA; (McDowell et al., 2005; 
Valanne et al., 2005) and Swedish isolates were used as positive controls for molecular 
phylotyping of all clinical isolates. P. granulosum ATCC 25564 and P. avidum ATCC 
25577 were used as negative controls. Polymerase chain reactions using unique primer 
sets (Table 2.2.1) developed by (Shannon et al., 2006a) to target various type-specific 
DNA sequences, yielded amplified PCR products that were analyzed to define each 
isolate as type IA, IB or II. 
Amplification of the phylotype-specific genomic regions were performed by PCR in 96-
well PCR plates by using single-primer sets for independent PCR reactions with a final 
concentration of 0.4 µM individual primer per 50 µL reaction. Template DNA volumes 
and 1X master mix formulation and preparations were as described in Section 2.2.4.1. 
Reactions were performed in the PTC-100 Programmable Thermal Controller. Optimized 
multiplex PCR cycle conditions were 30 cycles of DNA denaturation, annealing and 
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extension, executed under the following conditions: 94 °C for 30 s, 50 °C for 30 s and 72 
°C for 60 s, respectively. Preceded by an initial denaturation step of 5 min at 94 °C, the 
reaction cycles were followed by a final extension period of 15 min at 72 °C. Once 
complete, reactions were held at 4 °C. 
The isolates were confirmed as phylotype IA, IB or II based upon detection of 584 bp, 
725 bp and 537 bp bands, respectively, as determined by 1.8% agarose gel 
electrophoresis. Amplified DNA was loaded in 10 µL volumes with 2 µL 6X DNA 
loading dye and electrophoresed using 1 X TAE buffer against amplified type-specific 
DNA sequences of ATCC 6919 (type IA positive control), P. acnes AS13 (type IB 
positive control), or P. acnes AD7 (type II positive control) in addition to 3 µL 1 KbP 
DNA ladder. Amplified DNA bands were stained and imaged as described in Section 
2.2.3. 
2.2.4.3 Antibiotic susceptibility testing of P. acnes clinical isolates 
Antibiotic susceptibility of P. acnes isolates was determined by Etest. Protocols for 
testing, as described by the Clinical and Laboratory Standards Institute (CLSI) for 
susceptibility testing of anaerobic bacteria and the Etest package insert, were adhered to 
(bioMérieux, 2012a; Clinical and Laboratory Standards Institute, 2004). Susceptibility 
interpretation of MIC values for all antibiotics except DC and MC was based on 
breakpoints established by the CLSI and the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) (Clinical and Laboratory Standards Institute, 2015; 
EUCAST, 2016). Distribution of DC and MC MIC values for the P. acnes isolate 
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population were bimodal; breakpoints were determined to be the central MIC values 
falling within the troughs of the bimodal distributions (Kronvall et al., 2011). 
All susceptibility testing, except DPC and TS, was performed on Brucella 5% laked 
sheep blood agar supplemented with 5 mg/L hemin and 1 mg/L vitamin K1 (BBA) in 150 
mm diameter petri dishes. Effects of para-aminobenzoic acid (PABA) antagonists on TS 
activity was minimized by substituting MH base medium for Brucella base medium 
(bioMérieux, 2010). Susceptibility to DPC was evaluated on BBA, supplemented with 
0.1 g/L CaCl2 to increase Ca2+ concentration to levels sufficient for optimal DPC 
performance (bioMérieux, 2012b). To maintain consistent moisture levels, all media was 
prepared approximately 12 hours prior to testing and the thickness of agar medium was 
maintained at 0.4 mm.   
Cryopreserved isolates were subcultured at least twice on BBA prior to susceptibility 
testing. Isolated colonies from plates were cultured in Brucella broth supplemented with 
vitamin K1 and hemin and incubated for approximately 24 hours under anaerobic 
conditions. Etest strips were equilibrated to room temperature for a minimum of 30 min 
prior to opening the package. Broth cultures were standardized to a 1.0 McFarland 
turbidity standard and, if necessary, were diluted by adding hemin and vitamin K1-
supplemeted Brucella broth medium. Sterile, flocked swabs were used to sample the 
standardized bacterial suspension and streak the entire surface of the agar media three 
times, rotating the plate 60 degrees every time, to create an even lawn of bacterial 
growth. Etest strips were applied to dry plates according to standard Etest package insert 
(bioMérieux, 2012a). Immediately after placing the strips, plates were inverted and 
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incubated under anaerobic conditions at 35°C for approximately 72 h. MIC values were 
read and adjustments were made based on standard protocol as stated in the Etest package 
insert reading guide and customer information sheet “CIS007” (bioMérieux, 2012a, c).  
Quality control reference strains, E. faecalis ATCC 29212, S. aureus ATCC 29212 and S. 
pneumoniae ATCC 49619, were used to evaluate and monitor experimental conditions 
and antibiotic performance. Quality assessments, based on comparison of observed MIC 
values with published MIC ranges, were carried out according to Etest standard protocols 
(bioMérieux, 2013). Susceptibility testing of P. acnes ATCC 6919 was repeated regularly 
to ensure consistency of test conditions. 
2.2.5 Isolation of P. acnes bacteriophages 
A collection of P. acnes-specific phages was previously isolated by Jelena Trifkovic, a 
former technician of Dr. Reza Nokhbeh. In brief, sewage samples were periodically 
collected over a period of 12 months from Robert O. Pickard Environmental Centre in 
Ottawa and Gatineau Wastewater Treatment Plants. A 50 mL sample of the collected 
sewer was filtered through 0.22 µm sterile syringe filters to remove debris and cellular 
contents. Classical agar overlay method was used to isolate and purify phage plaques as 
follows: approximately 200–300 µL filtered sewage samples were mixed with 300 µL 
overnight P. acnes broth cultures—strains 1 to 6, ATCC 29399 and ATCC 6919—
followed by incubation at room temperature (RT) for 15 min. The mixture was added to 3 
to 4 mL 0.7% molten CB top agar, cooled down to approximately 50 ºC, and overlaid on 
CB agar (1.6%) plates. Plates were incubated under standard microaerobic atmospheric 
conditions. Phage plaques were removed as agar plugs and transferred into 1 mL CB 
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broth followed by vigorous vortexing to resuspend the phage particles. The phage 
suspension was filtered through sterile 0.22 µm syringe filters to remove cells and agar 
debris. Phage titres were determined by plating 100 μL triplicate samples from 10-fold 
dilution series in CB broth using agar overlay method. Following overnight incubation of 
plates, the resulting plaques were counted and the titre of phage stocks were calculated 
using the corresponding volume and dilution factors. The secondary phage stocks were 
prepared following isolation of a single plaque using the primary phage stocks as 
inoculum. Plaque purified secondary stocks were grown and titred as above and stored at 
4 ºC.  
Cutaneous P. acnes phages were isolated from the superficial swab samples of a patient 
in Sudbury, ON. After the sample was streaked onto CB agar for isolation of bacterial 
colonies (Section 2.2.2), 5 mL CB broth was inoculated using swabs and incubated at 
standard growing conditions overnight. Cultures were centrifuged using the Allegra X-12 
Benchtop Centrifuge at 3250 x g for 15 min. The supernatant was collected and filtered 
through sterile 0.22 µm syringe filters to remove cells. Classical overlay method was 
used to isolate and purify phages, as described above. 
2.2.6 Transmission electron microscopy of phages 
To characterize phages based on their morphology, phage particles were visualized by 
transmission electron microscopy (TEM). High-titre samples (108–109 PFU/mL) for TEM 
were prepared using agar overlay method by plating 100 μL volumes of 10-fold dilution 
series (in CB) from phage stocks. Phage on plates that exhibited confluent lysis were 
eluted into 2 mL sterile ddH2O deposited onto the agar surface, then incubated at room 
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temperature for 30 minutes. Eluate was removed from the plates, filter-sterilized and 
titred. Imaging services were provided by Dr. Tim Karnauchow (Children’s Hospital of 
Eastern Ontario, Ottawa, Ontario) and the Canadian Centre for Electron Microscopy, 
McMaster University (Hamilton, Canada). In short, 5 µL phage suspension was deposited 
onto formvar-coated copper grids and allowed to dry for two minutes. The sample was 
washed once with 100 µL ddH2O and blotted with filter paper to remove excess liquid. 
The sample was negatively stained with 1% uranyl acetate, applied for one minute prior 
to blotting dry. Samples were visualized at direct magnifications ranging from 50000x to 
200000x and micrographs were taken with the Philips CM12 microscope, operated at 120 
kV. 
2.2.7 Host range analysis of P. acnes bacteriophages 
High throughput spot infection tests were performed by mixing 1 mL overnight P. acnes 
cultures with 5.5 mL 0.7% molten CB agar overlaid on CB agar plates (1.6%) prepared in 
rectangular single-well, non-treated Nunc OmniTrays followed by inoculation of 1 to 2 
μL filtered phage stocks using a sterile 96-pin, 12 mm Scinomix polypropylene replicator 
in duplicate. Prior to performing spot infections, phage stocks were titred to ensure a 
concentration of 104 to 105 pfu/mL; ensuring that the volume of phage suspension (1 to 2 
μL) carried by individual pins would suffice to initiate infection of the target cells.  Plates 
were incubated under standard growing conditions for 24 to 48 h. Appearance of 
clearance zones around the point of inoculation by pins was considered as positive 
endpoint for infection. The procedure was repeated to assess the susceptibility of a set of 
negative controls including S. aureus ATCC 29923, S. typhimurium TA1535, E. coli 
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MG1655, S. pyogenes ATCC 12204, P. granulosum ATCC 25564 and P. avidum ATCC 
25577. 
Propionibacterium acnes strain #9 was naturally resistant to the isolated phages. 
Evolutionary derivation approach was followed to isolate a mutant phage from an 
existing phage stock with a wide host range (i.e. πα6919-4 phage). A 300 µL sample of 
P. acnes #9 overnight culture in CB broth was mixed with πα6919-4 stock at a 
multiplicity of infection (MOI) of ~1000 followed by incubation at RT for 15 minutes. 
Agar plate overlay method was utilized to isolate mutant phage plaques. Clear plaques 
were plucked, transferred to 1 mL CB broth and vortexed. The phage suspension was 
filtered through 0.22 µm syringe filter and titred. The secondary stocks were prepared as 
indicated above.   
2.2.8 Genetic characterization of bacteriophages 
In order to carry out genomic analyses, i.e. restriction enzyme fragmentation profiling 
and genomic sequence analysis, phages were propagated in P. acnes strains and the 
resulting lysate supernatants were collected. The cleared lysate supernatants were used to 
recover the phage particles, which were subsequently used for extraction of gDNA. The 
following sections provide the details of the procedures used for phage propagation, 
cleared lysate preparation, gDNA extraction, restriction enzyme fragment profiling and 
sequencing the phage genomes. 
2.2.8.1 Propagation of bacteriophages 
A volume of each bacteriophage stock, giving an approximate MOI of 0.1 to 1, was 
mixed with 1 mL P. acnes overnight cultures (~109 CFU/mL) of strains on which the 
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phages were originally isolated, followed by incubation at RT for 15 minutes. This 
preparation is conducted with the intent of establishing an initial infected population. The 
infected starter cells were mixed with 24 mL of P. acnes cultures in exponential growth 
phase and 20 mL sterile CB broth. A control set was also prepared in parallel that lacked 
the phage in the mixture. The phage-infected and control sets were incubated under 
standard growing conditions for P. acnes until complete bacterial lysis (clearance) was 
observed. The infected cultures were centrifuged at 2000 x g for 30 min at 4 ºC using the 
Benchtop Sorvall Legend Micro 21R Centrifuge and the lysate supernatant was filtered 
through sterile 0.22 µm vacuum filters. The filtrates were collected and stored at 4 °C. 
2.2.8.2 Precipitation of phages and extraction of genomic DNA 
A total of 25 mL filtered lysate supernatants were mixed with 5 mL 30% PEG 8000/3 M 
NaCl in 35 mL Corex tubes and incubated at 4 °C for 8 to 12 h. Phages were precipitated 
by centrifugation at 14 000 x g for 30 minutes at 4 °C using the Avanti J-E High-
Performance Centrifuge. The supernatant was drained completely and the phage pellet 
was resuspended in 1 mL 1X phage extraction buffer (100 mM sodium chloride, 100 mM 
Tris-hydrochloride pH 7.5 and 25 mM EDTA (Appendix B.4). A volume of 500 µL PCI 
(25:24:1, v/v) solution (Appendix B.3) was added to 500 µL phage suspension and mixed 
vigorously for roughly 3 min followed by centrifugation at 14000 x g for 10 min at 4 ºC 
using the Benchtop Sorvall Legend Micro 21R Centrifuge. The DNA-containing aqueous 
phase was carefully transferred to a new epitube without disturbing the proteinaceous 
interphase and organic lower layer. The PCI extraction procedure was repeated one more 
time and the DNA was precipitated from the second aqueous phase by adding 1.5 mL 
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ethanol/0.16 M sodium acetate and incubated at -20 °C for 8 to 12 hours. The gDNA 
pellet was obtained by centrifugation at 14000 x g for 15 min at 4 °C and the supernatant 
was poured off. The DNA pellet was washed with 400 µL 70% ethanol (chilled to -20 
°C) and the residual ethanol was evaporated in a vacuum evaporator for10 minutes. The 
dried gDNA pellet was resuspended in 50 µL sterile ddH2O followed by qualitative and 
quantitative analysis by spectrophotometry and 0.7% agarose gel electrophoresis. Two 
microliters of the phage gDNA preparation was mixed with 4 µL 1X DNA loading dye 
and electrophoresed as indicated in Section 2.2.3 against isolated gDNA of bacteriophage 
πα33 (positive control). 
2.2.8.3 BamHI restriction digestion of phage genomic DNA 
Phage gDNA concentrations and the purity of preparations were estimated by the 
NanoDrop spectrophotometer. Digestion of the phage gDNA was carried in a 1.5 mL 
sterile eppendorf tube, at a total reaction volume of 50 uL. A volume of phage DNA 
equivalent to 2 µg was used, to which 5 µL bovine serum albumin (BSA) (1 mg/mL) and 
5 µL 10X NEBuffer 3 were added, followed by volume adjustment with sterile ddH2O, 
for a total of 49 µL. The reaction was started by adding 1 µL BamHI (20 U/µL), giving a 
final reaction volume of 50 µL, followed by mixing and incubation at 37 °C for 1 h. After 
incubation, the tubes were immediately placed on ice and BamHI restriction banding 
patterns were assessed via DNA gel electrophoresis using 0.7% agarose gel as described 
in Section 2.2.3. Wells were loaded with 10 μL digested phage DNA mixed with 2 μL 6X 
DNA loading dye then run against πα33 BamHI digested genome (positive control) and 
2.5 μL 1 KbP DNA ladder combined with 2.5 μL HR DNA Ladder. BamHI digested 
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DNA bands were stained and imaged as described in Section 2.2.3. Banding patterns of 
the digested phage DNA were inspected and visually clustered. 
2.2.8.4 Phage genome sequencing and analysis 
Genomic libraries were prepared by Jenna Graham and Nya Fraleigh. Genome 
sequencing, assisted by Nya Fraleigh, and sequence assembly/annotation were done by 
Dr. Gustavo Ybazeta as follows. 
2.2.8.4.1 Preparation of phage genomic libraries 
Phage genome libraries were constructed using the NEBNext Fast DNA Fragmentation & 
Library Prep Set for Ion Torrent. To prepare the libraries, the concentration of each 
purified phage DNA sample was measured using the Qubit accompanied by the HS 
dsDNA for Qubit kit. Double-stranded DNA reagent was diluted into dsDNA HR buffer 
at a ratio of 1:200. DNA standards of 0 ng and 10 ng were prepared for the Qubit read 
and were made using 190 μL diluted dsDNA reagent combined separately with the 10 μL 
standard. One microliter DNA sample was mixed with 199 μL dilute dsDNA reagent and 
analyzed. The amount of DNA used for library preparation was 100 ng at a maximum 
volume of 15.5 μL per DNA sample. Fragmentation and end repair of DNA was 
conducted as indicated in the NEBNext Fast DNA Fragmentation and Library Prep 
protocol for approximate target fragment size of 200 to 300 bp.  
The standard protocol for the preparation of adapter ligated DNA was modified to 
accommodate for the use of Ion Torrent barcode adaptors 17–32 kit. Added to the 
fragmented phage DNA samples was 9 μL sterile ddH2O, 4 μL 10X T4 DNA Ligase 
Buffer (NEB), 1 μL P1 DNA Library Adaptors and 1 μL Barcode Adaptors (Life 
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Technologies), 1 μL Bst 2.0 Warm Start DNA Polymerase (NEB) and 4 μL T4 DNA 
Ligase (NEB). The tube content was mixed well and incubated in the Eppendorf 
Mastercycler Pro thermal cycler for 15 min at 25 °C, 5 min at 65 °C then reduced to a 
resting temperature of 4 °C. Stop Buffer (10X; NEB) was added at a volume of 5 μL and 
mixed well followed by the addition of 55 μL 0.1X TE buffer (NEB). Approximately 200 
to 300 bp fragments were selected for via AMPure XP Bead-based dual bead size 
selection as recommended in the manufacturer’s standard protocol.  
PCR amplification and cleanup of adaptor ligated DNA was performed according to the 
standard protocol using 40 μL adaptor ligated DNA, 4 μL NEBNext DNA Library 
Primers for Ion Torrent (NEB), 6 μL sterile ddH2O and 50 μL NEBNext High-Fidelity 
2X PCR Master Mix (NEB). PCR cycling conditions were as described by the NEB 
protocol for 8 cycles. Genomic library quality was assessed using the Qubit with 5 μL 
genomic library sample mixed with 195 μL dilute dsDNA reagent as described above 
against 0 ng and 10 ng standards. 
2.2.8.4.2 Sequencing, assembly and annotation 
Genomes of P. acnes bacteriophages were sequenced using the Ion PGM System (Ion 
PGM Sequencer and PGM Torrent Server). Once fragment libraries were prepared, 
template preparation was performed using the Ion OneTouch 2 system and the Ion PGM 
OT2 Template 200 Kit. Sequencing was performed with the Ion PGM Sequencing 200 
Kit v2 with the Ion 316 Chip Kit v2, with variable numbers of genome samples per chip. 
Raw data processing and analysis was conducted with the Torrent Suite Software.  
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Genome assembly was accomplished with the program MIRA version 4.0.2 (Chevreux et 
al., 1999), using the reference Propionibacterium acnes phage PA6 –GenBank entry 
NC_009541.1 (Farrar et al., 2007).  Draft genomes were visually inspected for sequence 
artifacts using gap5 v1.2.14-r (Bonfield & Whitwham, 2010). Genome sequence format 
changes and visualization were done with Artemis v 16.0.0.1 - Standard (Rutherford et 
al., 2000). The graphical user interface (GUI) Mauve (Darling et al., 2004) and 
progressive Mauve (Darling et al., 2010) were used for multi-genome alignment among 
the draft genomes for comparative genome analysis.  
Genome annotation was performed using the Prokka pipeline v 1.11 set for bacterial 
genomes (Seemann, 2014). This pipeline was run with the dependencies for searches 
against DNA and protein databases using BLAST 2.2. 29 + (Camacho et al., 2009), to 
conduct similarity searches for protein-coding predictions, using protein family profiles 
Prodigal v2.6 (Hyatt et al., 2010) and HMMER v3.1 (Finn et al., 2011). Bioperl was used 
to transform file formats for input and output (Stajich et al., 2002). Downloaded from 
GeneBank (Nov-10-2015), a P. acnes phage sequence database was created to assist 
Prokka annotation (Table E.1). A Multiple genomic loci comparison graph was 
composed using GUI Easyfig v2.2.2 (Sullivan et al., 2011).  
2.2.8.4.3 Major tail proteins: phylogenetic analysis, homology and structure 
prediction 
The Bio neighbour joining (BioNJ) algorithm (Gascuel, 1997) was used in Seaview to 
construct a phylogenetic tree based on sequences of the major tail proteins (MTPs) 
among the P. acnes phages sequenced in this study. Alignment maps of MTP sequences 
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were produced by Jalview v. 2.10.1 (Waterhouse et al., 2009) and DNAMAN v. 9 
(Lynnon Biosoft, n.d.).    
To identify homologous protein sequences, sequence similarity searches were conducted 
using standard protein BLAST (blastp) from the National Center for Biotechnology 
Information (NCBI) (Altschul et al., 1990) within non-redundant protein sequence 
database. To search for structural homologs of MTP sequences within the protein data 
bank (PDB), the MPI Bioinformatics Toolkit integrative platform was used (Alva et al., 
2016). Structural protein homology searches were conducted with HHPred (Söding et al., 
2005) using multiple sequence alignment (MSA) generation method HHblits (Remmert et 
al., 2011). To further validate the structural alignment results produced by the MPI 
Bioinformatics Toolkit, the MTP sequences were uploaded to LOMETS (Local Meta-
Threading-Server), a meta-server that runs several protein homology detection programs 
for the prediction of protein structure (Wu & Zhang, 2007). LOMETS conducts 
secondary structure prediction and threading using multiple programs and algorithms 
(FFAS-3D, HHsearch, MUSTER, pGenTHREADER, PPAS, PRC, PROSPECT2, SP3, 
and SPARKS-X ). The multiple sequence alignment results with predicted secondary 
structures for each protein were returned, accompanied by the most probable matches 
among those within the PDB database. The MSA output was used by the server to model 
three-dimensional protein structures using MODELLER (Webb & Sali, 2016). The final 
PDB formatted files from LOMETS were visualized using PyMOL v.1.8 (Schrödinger, 
LLC, n.d.) to produce images of the predicted three-dimesional protein structures. 
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2.2.9 Statistical analyses  
2.2.9.1 Categorical data 
Statistical analysis of categorical data was performed using the GraphPad QuickCalcs 
Web site: http://www.graphpad.com/quickcalcs/contingency1/ (accessed March 2016), to 
construct two-way contingency tables and determine statistical significance through 
generation of p-values using Fisher exact test.  
2.2.9.2 Concordance of P. acnes identification methods 
Unweighted  Cohen’s kappa statistics (Cohen, 1960) was determined to assess the level 
of agreement between two different methods used to identify P. acnes isolates.  
The kappa coefficient was generated at 95% confidence level with GraphPad QuickCalcs 
software (Web site: http://www.graphpad.com/quickcalcs/kappa1), using the probabilities 
of observed (Po) and expected random (Pe) agreements in detecting the true positive and 
negative results (Cohen, 1960).  
Validity of the multiplex PCR identification method with respect to MALDI-TOF 
reference method was determined and the corresponding sensitivity (proportion of true 
positives), specificity (proportion of true negatives) and positive and negative predictive 
values were calculated using GraphPad InStat Software (GraphPad InStat version 3.10, 
32 bit for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com).   
2.2.9.3 Concordance testing of P. acnes phage host range and major tail protein 
sequence diversity  
Responsible for host cell receptor recognition and binding, bacteriophage tail structures 
are determinants of host specificity (Fokine & Rossmann, 2014; Sassi et al., 2013). The 
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Congruence Among Distance Matrices (CADM) test was applied to examine the level of 
concordance between the distance matrices of phage activity spectra and phage tail-
associated protein sequences equivalent to P. acnes phage PA6 gp11, gp14, gp15, gp16 
and gp17, using gp1 (small terminase subunit) as a positive control for the null 
hypothesis (H0) characterized by discordance among distance matrices (Campbell et al., 
2011; Legendre & Lapointe, 2004). The detailed process of CADM test and the statistical 
analysis is explained below. 
2.2.9.3.1 Distance matrices 
Multiplatform GUI ‘SeaView’ v.4.6.1 (Gouy et al., 2010), was used to write host range 
binary strings and aligned protein sequences (twelve sequenced phage genomes) in 
PHYLIP file format to use in R v.3.3.2 software environment for statistical computing 
and graphics (R Core Team, 2016). First, host range profiles of all sequenced phages 
were converted to binary strings and written to FASTA format; binary code was denoted 
by successful lysis “1” and absence of lysis by “0”. SeaView was used to convert FASTA 
files to PHYLIP format. Individual protein sequences of interest were written to FASTA 
format, and aligned using SeaView—Clustal Omega (Sievers et al., 2011) and MUSCLE 
(Edgar, 2004)—and exported to PHYLIP format.  
Within the R software environment, package SeqinR v.3.3-3 (Charif & Lobry, 2007) was 
used to read host range binary strings from PHYLIP files using function 
read.alignment and create a full character matrix based on the binary strings using 
function as.matrix. With function dist.gene and argument  method = 
percentage, package APE v.4.0 (Paradis et al., 2004) was used to calculate the 
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proportion of sites that were different between two sequences (p-distances) based on 
pairwise combinations of binary sequences representing host ranges for each of 
sequenced phages; using the p-distances calculated, a full distance matrix was written 
with function as.matrix for use in congruency analysis (Section 2.2.9.3.2). Similarly, 
package phangorn v.2.1.1 (Schliep, 2011) was used to read protein sequence alignments 
from PHYLIP files using function read.phyDat with argument type = AA. Protein 
sequences were then written as objects of class phyDat with function as.phyDat. For 
each pairwise combination of sequenced phages, computation of uncorrected p-distances 
was achieved with the dist.hamming function excluding pairwise sites having missing 
or ambiguous states. These calculations were based on the protein sequences written as 
objects of class phyDat in conjunction with arguments ratio = TRUE and exclude = 
pairwise. Distance matrices were written using function as.matrix for use in 
congruency analysis based on protein sequences (Section 2.2.9.3.2).   
2.2.9.3.2 Congruence Among Distance Matrices (CADM) 
Global congruence and Mantel tests were performed using the APE package in R by 
pairwise CADM tests of distance matrices derived from the phage host range dataset and 
tail-associated protein sequence datasets (Section 2.2.9.3.1). Prior to congruence analysis, 
distance matrices were bound using function rbind. For each set of variables tested, 
function CADM.global was used to generate an overall concordance statistic (Kendall’s 
coefficient of concordance, W) and a test statistic (Friedman’s X2ref), which was used for 
permutation test to determine the one-tailed probability (P-value) of the data falling under 
the H0 (Legendre & Lapointe, 2004). Mantel tests were performed using Spearman’s 
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correlation coefficient, rs, as generated by function CADM.post with argument 
mantel=TRUE, producing one-tailed P-values based on ranking of permuted distance 
matrices (Legendre & Lapointe, 2004). 
The global concordance statistic, Kendall’s W (Kendall & Smith, 1939), indicated the 
level of discordance among distance matrices and ranged between 0 (incongruent) and 1 
(completely congruent). To test the significance of W, Friedman’s X2 (Friedman, 1937) 
test statistic (X2ref) was calculated using W and then analyzed against a distribution of 
permuted X2 values (X2*) falling under H0 (complete incongruence). Distributions of  X2* 
statistics were generated by the global CADM test through 9999 random permutations 
across the distance matrices in question (Campbell et al., 2011; Legendre & Lapointe, 
2004). Based on a level of significance α=0.05, a X2ref statistic greater than or equal to 
95% of X2* values under H0 returned a one-tailed probability P ≤0.05, resulting in 
rejection of H0 and acceptance of the alternate hypothesis, H1, which represents 
congruence among distance matrices (Campbell et al., 2011; Legendre & Lapointe, 
2004). Therefore, when P≤0.05, the variables under test—datasets corresponding to 
phage host range and a tail-associated protein sequence—were considered congruent at a 
level inferred by Kendall’s W.  
Mantel tests were performed to compliment the global test statistics associated with 
congruent matrices (H1) only (Campbell et al., 2011; Legendre & Lapointe, 2004). 
Similar in process to the global CADM test, the probability of incongruent matrices (H0) 
was determined by calculating Spearman’s correlation coefficient (rs) and testing it 
against a distribution of the statistic (rs*) under permutation to obtain a one-tailed P-value 
(Legendre & Lapointe, 2004).   
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 Results 3
3.1 Participating patients from Sudbury and Ottawa  
Samples were collected from the skin surface and exudate of acne lesions from 45 
patients in Ottawa and 91 patients in Sudbury. The overall highest prevalence of acne 
was observed in participants aged 17 years (11.8%). Those aged between 12 and 21 years 
accounted for 71.3% of the overall patient population, while 20.6% were between the 
ages of 22 and 31. The remaining 8.1% of patients fell within the age range of 32–50 
years (Figure 3.1). Although the overall number of female participants of both patient 
populations was slightly higher than that of male participants (54.4%), the difference was 
not significant (p=0.544). The proportion of male subjects aged between 12 to 18 (59.4%) 
is higher than female subjects (p=0.001), whereas there are a higher proportion of female 
subjects (68.7%) over the age of 18 than there are males (p=0.001). Based on 47 patient 
records, the mean duration of acne was 4.9 years, with a median of 4 years. Thirty-eight 
patients (81%) reported having acne for up to eight years, and the remaining patients 
were suffering from acne for 8–17 years (Figure 3.2).  
The most commonly affected areas of body were the face, back and chest; with the 
highest incidence of 42.5% affecting face/back/chest simultaneously, followed by face 
only (31.3%) and face/back simultaneously (17.5%). Sixty-eight patient records indicate 
that 73.5% of patients had only one lesion type; predominantly closed comedones. Other 
patients exhibited a combination of lesion types as listed in Table 3.1. Overall, the 
majority of lesion types exhibited by patients were closed comedones (57.4%). Incidence 
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of cystic and/or pustule lesions was 45.6% and open comedones was 8.8%. Based on 65 
patient reports, 63.1% of patients had scarring due to acne lesions (Table 3.1). 
The majority of patients were treated with a combination of antibiotics, retinoids and 
benzoyl peroxide; less frequent treatment combinations are listed in Table 3.1. Out of 114 
patient treatment records, 99 patients (86.8%) underwent treatment with topical and/or 
oral retinoid(s) and 80 patients (70.2%) with topical and/or oral antibiotics. Treatment 
with benzoyl peroxide was also reported for 80 patients, and 2 patients (1.7%) underwent 
photodynamic therapy (Table 3.1). Out of 100 female patient treatment records, oral 
contraceptives and spironolactone (antiandrogen), were used by 19 (19%) and 6 (6%) 
patients, respectively. Patients treated with antibiotics were exposed to a maximum of 3 
different types of antibiotic (Figure 3.3). Use of specific antibiotics are detailed in Table 
3.2. Having a 7-month mean treatment duration, the most frequently used topical 
antibiotic was clidamycin (CM) (58.8% of patients using antibiotics). The most 
commonly used oral antibiotic was minocycline (MC) (28.8%), followed by doxycycline 
(DC) (23.8%). Mean duration of treatment with oral MC was 6.2 months and DC for 7.5 
months.  
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Figure 3.1: Age distribution of Ottawa and Sudbury patient populations 
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Figure 3.2: Duration of acne persistence among acne patients. 
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Table 3.1: Clinical presentation and treatment of acne vulgaris. 
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Figure 3.3: Frequency of antibiotic use among Ottawa and Sudbury patient populations. 
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Table 3.2: Antibiotic use among Sudbury and Ottawa patient populations (n=80 antibiotic-
treated patients). 
Topical     Topical & Oral     Oral   
CM 21   CM(T)/DC(O) 10   MC 15 
DPS 3  CM(T)/MC(O) 6  DC 5 
EM 1  CM(T)/TC(O) 2  EM 3 
CM/EM 3  CM(T)/EM(O) 2  MC/TC 2 
   CM(T)/EM(T)/TC(O) 1  TC 1 
   CM(T)/DPS(T)/DC(O) 1  TM 1 
   CM(T)/DC(O)/TC(O) 1  DC/EM 1 
   DPS(T)/DC(O) 1    
(T), topical; (O), oral; CM, clindamycin; DC, doxycycline; DPS, dapsone; EM, erythromycin; MC, minocycline; 
TC, tetracycline; TM, trimethoprim 
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3.2 P. acnes isolate collections 
A total of 222 clinical P. acnes isolates from various geographical regions and two 
ATCC strains were included in this study. Forty-five P. acnes isolates from Sweden were 
used in this study; this included 17 isolates from the foreheads of non-acne patients, and 
28 isolates recovered from the tissue surrounding various types of deep-seated infections 
(Holmberg et al., 2009). Eleven P. acnes isolates, recovered from systemic infection 
sources, superficial and deep-seated infections across Canada, were also incorporated into 
this study. See Table C.1 for isolate-specific details.  
P. acnes isolates from Ottawa and Sudbury comprise the majority of the overall 
collections. Out of 91 patients from Sudbury, only the isolates derived from the first 76 
sets of samples (SS1/SD1 to SS76/SD76) were characterized, which resulted in 110 
confirmed P. acnes isolates from Sudbury. Similarly, out of 45 patients from Ottawa, 
only the isolates derived from the first 40 sets of samples (OS1/OD1 to OS40/OD40) 
were characterized, yielding 56 confirmed P. acnes isolates from Ottawa. See Table 3.3 
for details pertaining to all P. acnes isolate collections. 
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Table 3.3: Propionibacterium acnes clinical isolate collections from a variety of sources and geographical regions 
Geographical Origin Patients Sample Origin Isolates Total1 Collection Period Source Reference 
Various locations, 
Canada 11 
Superficial infection 2 
11 2001-20076 NML2 - Deep tissue infection 3 
Systemic 6 
Sweden 45 
Skin surface, non-lesional (AS) 28 
45 2005-20076 CSLU3 Holmberg et al., 2009 Deep tissue infection (AD) 17 
Sudbury 74 
Lesion surface (SS) 45 
110 2013 - 2014 Sudbury Skin Clinique4 This study Lesion exudate (SD) 65 
Ottawa 40 
Lesion surface (OS) 19 
56 2013 - 2014 Laserderm5 This study 
Lesion exudate (OD) 37 
1NML and CSLU isolates were recovered from different patients. Single and multiple isolates were recovered from Sudbury and Ottawa patients. 
2NML, National Microbiology Laboratory (Winnipeg, Canada), courtesy of Ms. Kathryn Bernard 
3CSLU, Department of Clinical Sciences of Lund University (Lund, Sweden), courtesy of Dr. Anna Holmberg   
4Courtesy of Dr. Lyne Giroux 
5Courtesy of Dr. Sharyn Laughlin 
6approximate  
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3.2.1 Isolate screening 
P. acnes isolates from Ottawa and Sudbury were acquired from 76 and 40 patients, 
respectively. Patient sampling was performed by swabbing, separately, the skin surface 
and exudate of acne lesions.  Samples were cultured as described in Section 2.2.2 and 186 
isolates were presumptively identified as P. acnes based on their coryneform morphology 
and positive catalase activity (Section 2.2.2); representative images of isolated colonies 
and microscopic morphology are given in Figure 3.4 and Figure 3.5. 
As described in Section 2.2.4.1, identities of presumptive clinical isolates were confirmed 
by molecular characterization, accomplished by PCR, using P. acnes-specific primer sets. 
In order to efficiently screen the large number of presumptive isolates, the PCR-based 
method designed by (Nakamura et al., 2003) for P. acnes identification was adapted for 
double-primer screening via multiplex PCR. Two genetic targets were used to 
differentiate P. acnes isolates from other species with a high level of accuracy—gehA and 
16S rDNA. Primers “Lip1”, “Lip2” and “Lip rev” are complementary to sequences 
encoding GehA (Figure 3.6), a lipase gene specific to P. acnes and closely-related 
Propionibacteria. Incorporation of primers that are complementary to gehA gene allows 
for identification of both P. acnes and P. avidum as the primer set is also capable of 
amplifying the lipase gene of P. avidum, but not P. granulosum  (Nakamura et al., 2003). 
Primers “Pas9”, “Pas10” and “Pas rev” are complementary to sequences of the three 16S 
rRNA operons (rrn operons) of P. acnes only (Figure 3.6). Primer sets were comprised of 
three primers- two forward primers (one external and one internal) and one reverse 
primer (Table 2.2.1). Using internal primers for PCR improves the specificity of this  
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Figure 3.4: Sample plate showing colonies of P. acnes isolate “SS75-2”, 
recovered from a sample taken of a lesion surface from a patient in 
Sudbury. 
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Figure 3.5: Image taken of P. acnes isolate "SS75-2", recovered from a 
sample taken of a lesion surface from a patient in Sudbury. 
Coryneform morphology confirmed by visual inspection at 400X 
magnification. 
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(i) Primer nucleotide targets for amplification of gehA lipase gene and the expected 
amplicon sizes (bp). 
 
(ii) Primer genome targets for amplification of 16S rRNA gene and the expected 
amplicon sizes (bp). 
 
Figure 3.6: Primer targets for PCR-based identification of P. acnes clinical isolates. 
Alignments are based on reference strain P. acnes KPA171202 (NCBI Reference 
Sequence NC_006085.1).  
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screening method; it is unlikely that any nonspecific products will contain sequences 
complementary to the external and internal primers. Moreover, the longer amplicon 
produced by the external primers will serve as the template for internal primers, 
contributing to the diagnostic value of the amplified bands. 
Shown in Figure 3.7, multiplex PCR was optimized using ATCC 6919 DNA as a 
template for all reactions with variable ratios of forward primers for each primer set—
Lip1:Lip2 and Pas9:Pas10. The volume of the external forward primers (Lip1 and Pas9) 
ranged from 1–4 µL and volumes of the corresponding internal forward primers (Lip2 
and Pas10) and reverse primers (Lip rev and Pas rev) remained constant at 1 µL and 2 
µL, respectively. For positive controls, single-primer PCR was performed using all 
forward primers in separate reactions at a ratio of 1:1 for forward primer:reverse primer.  
To determine the optimal ratio of forward primers for use in a single multiplex PCR 
reaction, products giving clear bands of equal intensity were considered ideal. Bands 
produced by the gehA-associated primer set were as expected, exhibiting amplicon 
lengths of 516 bp and 278 bp (Figure 3.6), with equal intensities achieved using 3:1 and 
4:1 ratios of Lip1:Lip2 (Figure 3.7a). As shown in Figure 3.7b, the lengths of the double 
primer products of reactions using the rrn operon-specific primer set were 946 bp and 
583 bp, as expected (Figure 3.6). Although no bands of equal intensity were present for 
any of the primer ratios, 4:1 ratio of Pas9:Pas10 produced clear bands for both internal 
and external primers. Positive control and single-primer reactions gave clear bands and 
all products were as expected. The optimal forward primers ratios were determined to be 
4:1 for Pas9:Pas10 and 3:1 for Lip1:Lip2.  
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Figure 3.7: Agarose gels showing double primer optimization for multiplex PCR 
amplification of (a) gehA and (b) 16S rDNA, using ATCC 6919 genome template. Primer 
ratios (in µL) are indicated above each lane. Reverse primer volumes were consistent across 
all reactions (2 µL) with the exception of single primer reactions (1 µL). 1 KbP, 1 Kb Plus 
DNA ladder. See Section 2.2.4.1 for PCR and gel electrophoresis conditions. 
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All clinical isolates were screened under the optimized multiplex PCR conditions. As 
described above, clinical isolates were confirmed to be P. acnes based on the presence of 
amplified PCR products of gehA and rrn operon sequence targets depicted in Figure 3.6. 
P. acnes ATCC 6919 was used as the positive control, P. granulosum ATCC 25564 as 
the negative control for both primer sets, and P. avidum ATCC 25577 as the negative 
control for primers targeting rrn operon sequences only. Isolate screening returned 166 
PCR-verified P. acnes isolates; 110 confirmed P. acnes isolates from the Sudbury patient 
population and fifty-six from Ottawa. As expected, P. avidum ATCC 25577 tested 
positive for the presence of the gehA gene only; 16 out of 20 P. acnes-negative isolates 
demonstrated banding patterns consistent with P. avidum (see example Figure 3.8). 
The validity of screening of clinical isolates by multiplex PCR with reference to MALDI-
TOF analysis of a sample population of 72 isolates was determined by generating kappa 
statistics. See Figure 3.9 for a sample of MALDI-TOF output spectra, representative of P. 
acnes ATCC 6919 and P. avidum ATCC 25577. As indicated in Table 3.4, results of both 
methods were in an excellent agreement at 95% confidence level with a kappa value of 
0.824 (standard error =0.0760). Furthermore, calculated high sensitivity, specificity, PPV 
and NPV values (Table 3.4) supported the suitability of multiplex PCR as a rapid and 
relatively inexpensive method of choice for identifying the correct P. acnes isolates. 
Further evaluation of the identity of the isolates was confirmed by their susceptibilities to 
infection by P. acnes aspecific phages. All PCR-confirmed P. acnes isolates  were 
sensitive to P. acnes bacteriophages and were successfully genotyped (further discussion  
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Figure 3.8: Agarose gels showing multiplex PCR screening of presumptive P. acnes 
clinical isolates. 1 KbP, 1 Kb Plus DNA ladder; A, P. granulosum ATCC 25564; B, 
P. avidum ATCC 25577; C, P.acnes ATCC 6919; D, SD26-3; E, SS27-1; F, SS27-2; 
G, SS27-3; H, SD27-1; I, SD27-2; J, SD27-4; K, SS29-2; L, SD29-2; M, SS30-1. See 
Section 2.2.4.1 for PCR and gel electrophoresis conditions. 
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(i) 
 
(ii)  
 
Figure 3.9: Examples of MALDI-TOF results. (i) P. acnes ATCC 6919 (positive control), 
and (ii) P. avidum ATCC 25577 (negative control). Note the differences in overall m/z peaks 
patterns between positive and negative controls and the presence of a distinctive signal at 
~4000 m/z in P. acnes ATCC 6919. 
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Table 3.4: Validation of Multiplex PCR results with reference to MALDI-TOF results for    
identification of P. acnes isolates. 
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+ 50  2  52  
- 3  17  20  
 
Total 53  19  72  
 Statistical Analysis Output 
 Sensitivity 
 
0.9615 
 Specificity 
 
0.8500 
 Positive predictive value 
 
0.9434 
 Negative predictive value 
 
0.8947 
 Kappa value 
 
0.8240 
 SE of Kappa   0.0760 
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of typing results to follow). Conversely, non-P. acnes isolates were neither typable nor 
sensitive to P. acnes bacteriophages.    
3.2.1 Classification 
P. acnes isolates from Sweden have been typed, previously, by recA sequence analysis 
(Table C.1) (Holmberg et al., 2009). Typing of Canadian isolates was carried out using 
the PCR-based approach for molecular phylotyping of P. acnes isolates, as described in 
Section 2.2.4.2. Type-specific primers amplified regions of the genome that correspond 
to sequences known to be exclusive to each type (Table 2.2.1).  
The primer set PR213/PR216 targets a sequence within an ABC-type peptide uptake 
operon of an 8.7 kb region specific only to type IA isolates (GenBank accession no. 
DQ208967). Type IB isolates were identified based on amplification with primer sets 
PR256/PR257 and PR256/PR257(G) wherein a nucleotide substitution, T→G at position 
17, was introduced within the reverse primer sequence based on analysis of alignment 
with known P. acnes sequences. These primer sets amplify the nucleotide sequence 
encoding a putative Y40U fragment, which is divergent from type IA and not present or 
varies considerably in type II. Primer set PR245/PR247 amplifies a region within gDNA 
coding for two rearrangement hotspot (RHS) family proteins, which function to promote 
genetic diversity by genomic rearrangement (Jackson et al., 2009; Tomida et al., 2013). 
Type II isolates were distinguishable from IA and IB isolates due to an approximate 3450 
base pair deletion within this region (Shannon et al., 2006a). Types were distinguished by 
detection of PCR products with lengths of 584 bp (type IA), 725 bp (type IB) and 537 bp 
(type II) (Figure 3.10; Figure 3.11). 
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(i) Primer genome targets for amplification of phylotype IA specific amplicon and 
the expected amplified fragment size (bp) 
 
(ii) Primer genome targets for amplification of phylotype IB specific amplicon and 
the expected amplified fragment size (bp) 
 
(iii) Primer genome targets for amplification of phylotype II specific amplicon and the 
expected amplified fragment size (bp) 
 
Figure 3.10: Primer targets for PCR-based phylotyping of P. acnes clinical isolates. 
Alignments are based on the following reference strains: (i) P. acnes33 (type IA; 
GenBank accession no. CP003195); (ii) P. acnes KPA171202 (type IB); (iii) P. acnes 
ATCC 11828 (type II; GenBank accession no. CP003084).  
 
 
82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.11: Agarose gel showing PCR phylotype screen of P. acnes clinical isolates. 1 KbP, 1 Kb 
Plus DNA ladder. P. acnes Type IA positive control: ATCC 6919; P. acnes Type IB positive 
control: AS13; P. acnes Type II positive control: AD7. See Section 2.2.4.1 for PCR and gel 
electrophoresis conditions. 
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Table 3.5: Distribution of P. acnes isolate phylotypes across a variety of sources and geographical origins. 
Collection Isolates Sample Origin Isolates Type IA Type IB Type II 
NML 11 
Superficial infection 2 0 1 1 
Deep tissue infection 3 2 0 1 
Systemic 6 3 2 1 
Sweden 45 Skin surface, non-lesional (AS) 28 14 8 6 
Deep tissue infection (AD) 17 9 3 5 
Sudbury 110 Skin surface (SS) 45 37 7 1 
Lesion exudate (SD) 65 55 7 3 
Ottawa 56 Skin surface (OS) 19 17 0 2 
Lesion exudate (OD) 37 34 1 2 
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The distribution of P. acnes phylotypes is given in Table 3.5. With an overall 
representation of 77.03%, the greatest proportion of isolates from each group was type 
IA. Type IB isolates represented 13.06% of the combined collections, followed by 9.91% 
type II isolates. P. acnes type IA isolates comprised 51.11% of the Swedish collection, 
followed by equal proportions of type IB and type II isolates (both 24.44%). Similarly, 
45.45% of NML P. acnes isolates were type IA, followed by equal proportions of type IB 
and type II isolates (both 27.27%). Type IA isolates represented 83.64% and 91.07% of 
the Sudbury and Ottawa collections, respectively. From Sudbury, type IB isolates 
(12.73%) represented a larger proportion of the collection than type II isolates (3.64%). 
Conversely, type II isolates (7.14%) of the Ottawa collection represented a larger 
proportion of the collection compared to type IB isolates (1.74%). Unequal distribution of 
P. acnes phylotypes across both Sudbury and Ottawa populations was determined to be 
significant by chi-square analysis (p<0.001 for both). 
Contigency tables were used to assess the independence of P. acnes phylotype from 
sampling source (lesion surface versus lesion exudate) for Sudbury and Ottawa 
collections. Results indicate that isolate phylotypes from both Sudbury and Ottawa 
collections were independent of the sampling source (p=0.633 and p=0.612, 
respectively). Therefore, there was no bias for phylotype distribution among samples 
from either the lesion surfaces or exudates.  
Antibiotic susceptibility of P. acnes isolates are given in the following section 3.2.2. 
Contingency tables were used to assess the independence of P. acnes antibiotic resistance 
to one or more antibiotics from phylotype. Results indicate that P. acnes resistance to one 
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or more antibiotics is independent of phylotype for both Sudbury (p=0.316) and Ottawa 
(p=0.836). 
3.2.2 Antibiotic susceptibility of clinical P. acnes isolates 
Susceptibility of Sudbury, Ottawa and Lund P. acnes isolate collections (211 total P. 
acnes isolates), to a panel of clinically-relevant antibiotics was determined. Fourteen 
antibiotics, commonly indicated for treatment of superficial, deep tissue and systemic P. 
acnes infections, were selected for testing. Choice of antibiotics for treatment of acne 
included AZ, CM, DC, EM, MC, TC and TS (Tan & Tan, 2005). Preferred antibiotics for 
treatment of deep tissue infection are PGL, TXL or combination therapy using VA and 
RI (Brook, 2002; Levi et al., 1997; Osmon et al., 2013; Schreffler et al., 2002; 
Viraraghavan et al., 2004). Alternatives include CM, DPC, DC, EM, LE, LZ, MC, TC or 
VA (Brook, 2002; Olsson et al., 2012; Osmon et al., 2013; Portillo et al., 2013).  
P. acnes isolates susceptibility to the abovementioned antibiotics was assessed by first 
determining the MIC values by Etest, then by evaluating the MIC values against the 
clinical breakpoints listed in Table D.1. As described in Section 2.2.4.3, Etest strips 
impregnated with a concentration gradient of antibiotic, were laid over P. acnes-swab 
spread on agar medium. Antibiotic activity against P. acnes was visualized by the 
appearance of an ellipse-shaped zone of inhibition, a result of antibiotic diffusion from 
Etest strips through agar medium (Figure 3.12). 
Endpoint MIC values were read according to Etest guidelines (bioMérieux, 2012a). 
Shown in Figure 3.12, the values printed on the front of the strips, indicated the antibiotic 
MIC at standard-two fold dilutions, as well as midpoint values. MIC values were read at 
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the point of intersection between the strip and the zone of inhibition (ellipse). MIC values 
of antibiotics having a bactericidal mode of action were read at the point of complete 
inhibition. Endpoints of antibiotics having a bacteriostatic mode of action were read at 
80% inhibition, except linezolid which was read at 90% inhibition (bioMérieux, 2012a).  
In accordance with Etest protocol, quality control measures were implemented. Strip 
performance was confirmed by achievement of acceptable MIC values for the standard 
strains E. faecalis ATCC 29212, S. aureus ATCC 29213 and S. pneumoniae ATCC 
49619 (bioMérieux, 2013). Propionibacterium acnes strain ATCC 6919 was used 
routinely as an internal quality control. 
Erythromycin and azithromycin 
Overall, the highest frequencies of resistance observed were to antibiotics of the 
macrolide class. Of the whole isolate population, 19.9% were resistant to EM; closely 
followed by AZ with an overall frequency of 18.6%. The proportion of EM-resistant 
isolates from Sudbury was 2.3-fold and 4.3-fold greater than that of the Ottawa and Lund 
collections, respectively (p=0.002). A similar pattern was observed for resistance against 
AZ, with Sudbury having a frequency of resistance 2.5-fold and 4.1-fold greater when 
compared to Ottawa and Lund, respectively (p=0.003).  
Clindamycin  
Subsequent to macrolide resistance, 11.7% of isolates demonstrated resistance to CM, an 
antibiotic of the lincosamide class. Sudbury isolates have over two-fold higher frequency 
of CM resistance (16%) in comparison to those from Ottawa (7.3%) and from Lund 
(6.7%) (p=0.129) (Table 3.6).  
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Figure 3.12: Sample photograph of antibiotic susceptibility test results for P. acnes clinical isolate 
SS18-2, from Sudbury. Etests were performed as described in Section 2.2.4.3; shown here are MC, 
TC, VA and RI. MIC values taken for susceptibility interpretation are shown in µg/mL. 
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Tetracycline, doxycycline and minocycline 
P. acnes isolates, having TC MIC values extending beyond the clinical breakpoint value, 
were classified as “intermediate” or “resistant” (Table D.1). None of the Lund isolates 
were TC-resistant, however isolates from Ottawa (8.9%) and Sudbury (5.5%) did exhibit 
TC-resistance with a 1.6-fold difference in frequency with no significant difference 
(p=0.132). The proportion of “intermediate” isolates from Lund (4.4%) closely resembled 
those from Sudbury (4.5%) and Ottawa (5.4%) (p=0.968).  
Similar patterns of resistance against MC and DC was observed across all three P. acnes 
isolate collections (Table 3.6). The proportion of MC-resistant Ottawa isolates (14.3%) 
was at least 2-fold greater than those from Sudbury (7.3%) and Sweden (p=0.026). The 
frequency of Ottawa isolates that exhibited DC resistance (14.3%) was at least 2.2-fold 
larger compared with those from Sudbury (6.4%) and Lund (p=0.019). 
Rifampicin and Trimethoprim/sulfamethoxazole 
The lowest frequencies of antibiotic resistance were observed for RI and TS, each 
accounting for 0.5% of the total isolate population. Resistance to RI was observed for one 
P. acnes isolate of the Lund collection (2.2%); and resistance to TS was observed for one 
isolate from the Ottawa collection (1.8%).  
Overall resistance among three collections 
Overall, 21.3% of P. acnes isolates from Sudbury, Ottawa and Lund combined were 
resistant to a minimum of one antibiotic from the panel. The overall frequencies of 
resistance, including isolates with intermediate MIC values, are listed in the final column 
of Table 3.6. The overall frequency is based on the total number of Etests performed on 
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isolates across each collection and includes only tests with antibiotics indicated in the 
table. The frequency of Sudbury P. acnes resistant isolates was 12%, which was 1.3-fold 
larger than 9.4% of Ottawa isolates and 3.6-fold larger than Lund isolates with the lowest 
frequency of resistant isolates at 3.3% (p=0.0005). 
Multiplicity of resistance 
Overall frequencies of singly- and multiply-resistant isolates are shown in Figure 3.13a 
and are further stratified on the basis of geographical origins in Figure 3.13b. Overall, 
only 2.2% of the antibiotic resistant P. acnes isolate population were resistant to one 
antibiotic (Ottawa collection); and 97.8% were clustered into categories of resistance to 
multiple antibiotics with the majority of isolates resistant to 2 or 3 antibiotic types 
(64.4%) (Figure 3.13a). The highest proportion of multiply-resistant P. acnes isolates is 
from Sudbury (71.1%), followed by Ottawa (22.2%) and Lund (6.7%) (Figure 3.13b). 
Isolate collections from Sudbury, Ottawa and Lund demonstrated patterns of multiple 
resistances that are significantly different from one another (p<0.001). Out of the overall 
proportion of isolates that were resistant to 2 or 3 antibiotics 82.8% were from Sudbury, 
accounting for over half of all resistant Sudbury isolates, followed by 10.3% and 6.9% 
from Ottawa and Lund, respectively (Figure 3.13b). With a frequency of 9%, isolates 
with resistance to 5 antibiotics are exclusively from Sudbury. Out of the overall 
proportion of isolates that were resistant to 4 or 6 antibiotics 54.5% were from Ottawa, 
followed by 36.4% and 9.1% from Sudbury and Lund, respectively (Figure 3.13b).    
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P. acnes  collection EM AZ CM TC TC (I)1 MC DC RI TS
Sudbury 29.1 27.3 16.0 5.5 4.5 7.3 6.4 0.0 0.0 12.0 (876)
Ottawa 12.5 10.9 7.3 8.9 5.4 14.3 14.3 0.0 1.8 9.4 (446)
Lund 6.7 6.7 6.7 0.0 4.4 0.0 0.0 2.2 0.0 3.3 (360)
Overall 19.9 18.6 11.7 5.2 4.7 7.6 7.1 0.5 0.5 9.5 (1682)
2 Bracketed value represents the total number of individual antibiotic/isolate tests performed with the antibiotics given in the table.
Type of Antibiotic Resistance
Overall2
EM, erythromycin; AZ, azithromycin; CM, clindamycin; TC, tetracycline; MC, minocycline;  DC, doxycycline;  RI, rifampicin; TS, trimethoprim/sulfamethoxazole.                           
1 Value represents proportion of total isolates that expressed intermediate, "I", MIC values. 
Table 3.6: Incidence of antibiotic resistance across P. acnes isolates from Sudbury, Ottawa and Lund. Observed resistance was 
limited to the antibiotics listed in this table; P. acnes isolates were susceptible to all other antibiotics tested. 
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Antibiotic exposure 
Frequencies of acne-related antibiotic exposure corresponding to P. acnes isolates from 
Sudbury and Ottawa are represented in Figure 3.14. The proportion of antibiotic resistant 
isolates from Sudbury patients treated with one or more antibiotics (96.8%) was 2.3-fold 
greater than Ottawa (40%) (p<0.001).  
Based exclusively on acne-related antibiotic exposure data, outcome of resistance among 
P. acnes isolates from Sudbury and Ottawa was associated with overall antibiotic 
exposure (p<0.001). Single or combined exposure to antibiotics interfering with the 23S 
rRNA—EM and/or CM—was associated with P. acnes isolate resistance to CM 
(p=0.0280), AZ (p=0.0052) and EM (p=0.0019). A positive correlation was also 
identified between the overall frequency of isolate resistance and exposure to antibiotics 
that interfere with the 16S rRNA—TC, MC and/or DC (p=0.0233).   
3.3 Propionibacterium acnes bacteriophage library 
3.3.1 Phage isolation 
Seventy of the P. acnes phages in this study were from a collection that was isolated 
previously by Jelena Trifkovic, from sewage sources in Ottawa and Gatineau via agar 
overlay method (Section 2.2.5) using bait strains ATCC 6919, ATCC 29399 and NML P. 
acnes strains #1 through strain #6 (Table C.1). Five cutaneous phages were isolated from 
one patient in Sudbury, ON (Section 2.2.5) and evolutionary derivation approach was 
used to isolate a single phage variant with extended host range (Section 2.2.7). To isolate 
lytic phages, attention was paid to select phages producing clear plaques, as shown in 
Figure 3.15.  
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Figure 3.13: Multiplicity of antibiotic resistance among resistant P. acnes clinical isolates from Sudbury, 
Ottawa and Lund. Overall frequency of multiply-resistant isolates (a); stratified by geographical origin (b). 
Columns represent the frequency of isolates that have antibiotic MIC values above clinical breakpoint(s) 
and/or have intermediate MIC values (only tetracycline). 
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Figure 3.14: Frequency of Sudbury and Ottawa P. acnes isolates from patients treated with 0, 1 or 2 antibiotics. 
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Figure 3.15: Photograph of clear plaques formed by P. acnes #3 
infection with πα33 via agar overlay method. 
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3.3.2 Morphological characterization of phage virions 
To determine bacteriophage morphology, transmission electron micrographs were 
acquired as described in Section 2.2.6. On the basis of previous reports of P. acnes phage 
morphology (Farrar et al., 2007; Lood et al., 2008; Marinelli et al., 2012; Webster & 
Cummins, 1978), all phages visualized were classified as members of the siphoviridae 
family of phages (Ackermann & Eisenstark, 1974). TEM imaging showed that they have 
non-enveloped icosahedral heads and long non-contractile tails with tail fibers extending 
from the tails (Figure 3.16). Dimensions of phages imaged in this study were comparable 
to those reported by others and similar to one another, having a mean (n=7) head 
diameter of 54.6±7.2 nm and mean tail length and diameter of 133.1±10.2 nm and 
11.2±3.2 nm, respectively (Figure 3.16).  
3.3.1 Biological activity of the bacteriophage library against P. acnes isolates  
As described in Section 2.2.7, in vitro biological activity of the phage library was 
assessed by evaluating phage host range through high throughput spot infection tests 
against each P. acnes isolate. Phage stocks were titred prior to infection to ensure 
sufficient PFU/mL for infection by pin drop. P. acnes ATCC 6919 exhibited 100% 
sensitivity to all phage isolates and was employed as a positive control to monitor test 
conditions. The example of a spot infection test shown in Figure 3.17a demonstrates the 
appearance of clearance zones surrounding  inoculation spots on agar plates, which were 
taken as a positive result, indicating successful infection of the bacterial isolate by the 
phage in question.  
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Figure 3.16: Transmission electron micrographs of negatively stained P. acnes phages πα34, 
πα55, πα63 and πα59. All phages belong to siphoviridae. 
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Figure 3.17: High throughput bacteriophage spot infection tests of (a) P. acnes ATCC6919 (100% phage sensitivity) and (b) P. acnes #9 (sensitivity to 
mutant phage πα9-6919-4). Spot infection tests were used to determine biological activity of phage collection against P. acnes clinical isolate population. 
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Infection test results were tabulated for each P. acnes isolate /phage combination; 
successful infections were denoted by “+” and unsuccessful infections by “-” (Figure 
3.18). Phage host range was characterized by the number of P. acnes isolates that were 
susceptible to infection by a particular phage. Phages with identical host ranges were 
clustered into host range groups (HRGs) consisted of 9 (HRG1), 8 (HRG2), 4 (HRG3) 
and 2 (HRG4) phage isolates, possibly representing multiple isolates of similar phages. 
The rest of the phages showed unique host range profiles that were different from the 
phages grouped by host range. Rows in the phage-host interaction matrix (Figure 3.18) 
represent phage host range across the entire P. acnes population; host ranges were diverse 
across the various HRGs and other unique phage isolates. The overall maximum phage 
host range was 99.6% and the minimum was 78.1% with a median of 97.5%. Frequency 
analysis of phage host ranges (Figure 3.19a) was skewed to the left and revealed that 
86.8% of phages could infect greater than 90% of the P. acnes isolate population. 
Therefore, a large proportion of phages were capable of infecting a large proportion of 
the P. acnes isolate population (Figure 3.19a). Despite diversity across the phage host 
range profiles (Figure 3.18), the phage collection exhibited a propensity for infection of a 
wide range of P. acnes isolates. 
Each column of Figure 3.18 represents P. acnes isolates sensitivity to the phage 
collection. P. acnes isolates with identical sensitivities were stratified into one of the nine 
phagovar groups (PVGs), while those with unique sensitivity profiles are shown 
separately. Belonging to PVG1, 67.9% of P. acnes isolates demonstrated maximum 
sensitivity to 100% of phages and isolates of PVG2-PVG9 showed sensitivity to phages  
  
99 
   
Figure 3.18: Matrix representation of phage-host interactions. Columns correspond to P. acnes hosts and include isolates belonging to phagovar 
groups (PVGs) 1 to 9 and those not belonging to PVGs (isolates with unique phage sensitivity profiles). Rows represent bacteriophages falling into 
specific host range group (HRG) categories 1 to 4 and phages with unique host range profiles. Green “+” cells indicate successful infection and white “-
” cells denote an absence of infection. 
  
100 
 
  
Figure 3.19: Frequency distribution of (a) phage host range (propensity of phages to infect P. acnes 
isolates) and (b) sensitivity of the P. acnes isolate collection (susceptibility to phage infection). 
  
101 
 
in the range of 77% to 98% (Figure 3.18).  Frequency distribution of P. acnes isolate 
sensitivity to phages was skewed to the left and revealed 82.6% of P. acnes isolates were 
sensitive to greater than 90% of phages (Figure 3.19b). Although sensitivity of bacteria to 
a greater number of phages and broad host range of the phages are favorable for 
formulation of numerous phage cocktails, it does not necessarily provide an immediate 
solution to naturally occurring phage resistant bacteria. However, given the dynamism of 
phage-bacteria interplay it is possible to isolate mutant phages from the existing stocks 
that counter the naturally resistant bacteria. For example, initially, P. acnes #9 (Table 
C.1) exhibited natural resistance to all isolated phages. Evolutionary derivation approach 
was followed to isolate a mutant phage from an existing phage stock with a broad host 
range (i.e. πα6919-4 phage). A sample of P. acnes #9 overnight culture in CB broth was 
mixed with πα6919-4 stock at MOI of  ~1000 followed by incubation at RT for 15 min. 
Agar plate overlay method was utilized to isolate a limited number of mutant phage 
plaques (total of 7 plaques). A single plaque was removed and processed as described in 
Section 2.2.5. High throughput spot infections were repeated in duplicate using all phage 
isolates (including the newly-isolated mutant phage, “πα9-6919-4”) against P. acnes #9. 
As anticipated, P. acnes #9 was infected exclusively by the mutant phage, and the host 
range of the isolated phage was expanded to include strain #9 (Figure 3.17b).  
In conclusion, phage libraries showed overlapping broad host ranges and the bacterial 
isolates were sensitive to multiple phages, which is advantageous to formulation of 
multiple phage cocktails. 
3.4 Molecular characterization of bacteriophages 
3.4.1  Restriction enzayme analysis of phage genomes 
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A basic evaluation of the genomic diversity across P. acnes phages was carried out using 
DNA fragment patterns produced by BamHI restriction digest of phage DNA (n=64). 
Included were 88.7% of phages that had unique host range profiles as well as 
representatives from all HRGs, accounting for 77.8% of HRG1, 75% of HRG2, 100% of 
HRG3 and 50% of HRG4. Digestion of phage genomes revealed a diverse array of 
restriction fragment banding patterns. Phages were grouped into 9 clusters (Figure 3.20) 
based on analysis of their BamHI restriction patterns (Section 2.2.8.3). Within the clusters 
were phages that had unique host range profiles as well as those associated with one or 
more HRGs; therefore, the biological activity varied between individual phages 
representing any single cluster. Analysis of the BamHI digested genomes from phages 
within separate HRGs and having unique host range profiles revealed banding patterns 
that were diverse as well as sets of identical banding patterns. For example, although 
phages πα15 and πα615 have identical banding patterns, they do not share identical host 
range activity. However, phages πα33 and πα3-SS3-1 have both identical banding 
patterns and host range activity. Diversity was also observed across banding patterns 
produced from genomes of the phages having unique host range profiles, however, sets of 
identical fragment sizes were also observed. For example πα32 and πα315 exhibit 
different banding patterns and host range activity, while πα33 and πα314 have different 
banding patterns and the same host range activity. Therefore, the overall biological 
activity across the collection of P. acnes phage isolates is not represented by that of the 
restriction fragment banding patterns. Diversity among BamHI restriction patterns is an 
indication of diversity across phage genomes, therefore, representatives from various 
clusters (Figure 3.20) were selected for genome sequencing. 
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Figure 3.20: DNA gel electrophoresis of BamHI digested P. acnes phage DNA. Representatives (n=12) from 9 BamHI digested phage 
genome clusters are shown here (Section 3.4.1). Digested phage genome banding patterns within the white boxes appear to be identical 
and are grouped into a common cluster. Other unboxed DNA banding patterns belong to phage grouped into separate clusters.    
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3.4.2 Genome sequencing of bacteriophages 
Twelve phages (Figure 3.20) were further characterized for their genomic and proteomic 
properties as described in Section 2.2.8.4. At the time of this report, sequence analysis 
was based on genomic sequence reads produced by the Ion PGM System and were 
restricted due to gaps and unresolved bases present in the sequence assemblies (Table 
3.7). Extensive genomic analysis will be made possible by correction of inaccuracies 
using sequence reads recently produced by two additional platforms—MinION (Health 
Sciences North Research Institute) and Illumina HiSeq (McGill University and Génome 
Québec Innovation Centre). 
A summary of sequencing and assembly results are presented in Table 3.7. Having an 
average coverage between 22.66 to 222.47 reads per base, each genome was assembled 
into one contig using MIRA v4.0.2 (Chevreux et al., 1999) against reference genome of 
P. acnes phage PA6 (Farrar et al., 2007). Length of the assembled genomes ranged from 
29539 to 29891 base pairs, having 53.8% to 54.5% GC-content and an average of 42 
open reading frames (ORFs) (Table 3.7).  
3.4.2.1 Genome structure and annotation 
Genome sequences provided sufficient information for functional annotation of 
approximately half of all gene products via Prokka pipeline v 1.11 (Seemann, 2014) 
using a database of 84 P. acnes phage reference sequences (Table E.1) according to 
Section 2.2.8.4.2. Sequenced phages were determined to be members of siphoviruses 
(TEM images) with linear dsDNA genomes based on the sequence homology searches. A 
summary of functional annotations for predicted gene products (gp) of sequenced phages  
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Table 3.7: General features and sequencing details of P. acnes bacteriophage 
genomes.  
 
 
Phage ID 
Genome 
Length 
(bp)  
GC- 
Content 
(%) 
Coding 
DNA (%) Genes 
Average 
Coverage 
Unresolved 
Bases 
 Assembly 
Gaps 
πα15 29539 54.24 87.17 46 88.44 0 1 
πα27 29740 53.85 86.76 43 222.47 109 4 
πα28 29762 54.18 83.85 41 65.12 119 3 
πα33 29712 54.06 82.2 42 33.21 0 1 
πα35 29825 54.34 73.54 38 72.53 1221 24 
πα310 29724 53.95 83.85 40 36.14 56 1 
πα59 29732 54.17 84.59 41 71.46 253 6 
πα615 29736 54.41 87.99 47 75.56 472 8 
πα6919-4 29728 54.01 84.63 44 22.66 0 2 
πα9-6919-4 29891 54.07 84.79 42 55.5 0 2 
πα3-SS3-1 29705 54.53 80.14 40 99.75 933 27 
πα29399-1 29689 54.38 74.28 40 71.34 636 19 
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is given in Table 3.8. Although the function of most proteins encoded by ORFs in the 
right arm remain to be determined, those assigned a putative function are involved in 
regulatory functions (Table 3.8). Nearly all gene products encoded by ORFs in the left 
arm of phage genomes have been assigned functions or have properties associated with 
structure and virion assembly (Table 3.8).  
As shown in Figure 3.21, a multiple genomic loci comparison map of all sequenced 
phages and reference P. acnes phage PA6 (Farrar et al., 2007) was created using GUI 
Easyfig v2.2.2 (Sullivan et al., 2011) to compare and contrast gross genome features. 
Having an overall organization analogous to other published P. acnes phage genomes 
(Farrar et al., 2007; Lood and Collin, 2011; Marinelli et al., 2012; Liu et al., 2015; 
Brown et al., 2016), Figure 3.21 illustrates a division of predicted ORFs into two 
clusters— genes of the right arm (transcribed right to left) and genes of the left arm 
(transcribed left to right).  
Annotated open reading frames in the right arm of P. acnes phage genomes encode 
putative gene products involved in transcription, DNA replication and regulation. Sigma 
factors facilitate gene transcription by guiding RNA polymerase to promoter sites. A 
putative protein encoded by ORF equivalent of orf24PA6 contains a sigma domain that 
may coordinate the transcription of phage genes by directing P. acnes host RNA 
polymerase to promoter elements on the phage genome (Farrar et al., 2007). 
Downstream, putative nucleases are encoded by regions corresponding to orf27PA6 and 
orf37PA6. Homologous to proteins of the calcineurin-like phosphoesterase superfamily, 
gp27PA6 is suspected of having nuclease activity associated with DNA repair 
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Table 3.8: Putative functions of predicted P. acnes phage gene products. Phage PA6 gene products are given as reference. 
 
Terminase 
small 
subunit
Terminase 
large 
subunit
Portal 
protein
Head 
scaffold 
protein
Major 
head 
(capsid) 
protein
Major tail 
protein
Tail 
assembly 
chaperones
Tape 
measure 
protein
Minor tail 
subunits
Collagen-like 
protein
Endolysin Holin Sigma 
factor
DNA repair 
nuclease
DNA 
primase
DNA 
helicase
Exonuclease 
PA6A gp1 gp2 gp3 gp5 gp6 gp11 gp12,13 gp14 gp15,16,17,18 gp19 gp20 gp21 gp24 gp27 gp31,32 gp34 gp37
πα15 gp1 gp2 gp3 gp5 gp6 gp11 gp12,13 gp14 gp15,16,17,18 gp19 gp20 gp21 gp24 gp27 gp31 gp34,35 gp38,39
πα27 gp1 gp2 gp3 gp5 gp6 gp11 gp12,13 gp14 gp15,16,17,18 gp19 gp20 gp21 gp23 gp26 gp30 gp32 gp35
πα28 gp2 gp2 gp3 gp5 gp6 gp11 gp12,13 gp14,15 gp16,17,18 gp19 gp20 gp21 gp22 gp26 gp30 gp32 gp35
πα33 gp1 gp2 gp3,4 gp6 gp7 gp12 gp13,14 gp15,16 gp17,18,19 gp20 gp21 gp22 gp24 gp27 gp31 gp32 gp35
πα35 gp1 gp2 gp3,4 nk gp5 gp10 gp11 gp13 gp14,15,16 gp17 gp18 gp19 gp21 gp24 gp26 gp28 gp31
πα59 gp1 gp2 gp3 gp5 gp6 gp11 gp12,13 gp14,15 gp16,17,18,19 gp20 gp21 gp22 gp24 gp27 gp31 gp33 gp36
πα615 gp1 gp2 gp3 gp6 gp7 gp12 gp13,14 gp15,16 gp17,18,19 gp21 gp22 gp23 gp25 gp28 gp33 gp36 gp40
πα6919-4 gp1 gp2 gp3 gp5 gp6 gp11 gp12,13 gp14,15 gp16,17,18,19 gp20,21 gp22 gp23 gp25 nk gp32 gp34 gp37
πα9-6919-4 gp1 gp2 gp3 gp5 gp6 gp11 gp12,13 gp14 gp15,16,17,18 gp19 gp20 gp21 gp23 nk gp30 gp31 gp34
πα3-SS3-1 gp1 gp2 gp3,4 nk gp7 gp12 gp13,14 gp15 gp16,17,18 gp19 gp20 gp21 gp23 gp26 gp29 gp30 gp33
πα310 gp1 gp2 gp3 gp5 gp6 gp11 gp12,13 gp14 gp15,16,17 gp18 gp19 gp20 gp22 gp25 gp29 gp31 gp34
πα29399-1 gp1 nk gp3 gp5 gp6 gp11 gp12,13 gp14 gp15,16,17 nk gp18 gp19 gp21 nk nk nk gp32
AFarrar et al ., 2007
"gp", gene product; "nk", not known
Putative gene products: left arm of genome (rightward transcription)
Phage ID
Putative gene products: right arm of genome (leftward transcription)
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Figure 3.21: Schematic representation of P. acnes phage genome assemblies with annotated 
open reading frames. Dark blue arrows in the left arm of genomes correspond to ORFs 
encoding putative proteins involved in DNA packaging, and structure and assembly of the 
capsid. Dark purple arrows represent ORFs that encode products associated with phage tail 
structure and assembly. 
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(Aravind & Koonin, 1998), while gp27PA6 shares sequence homology with a RecB family 
exonucleases (Farrar et al., 2007). Putative DNA primase and helicase are encoded by 
ORFs equivalent to orf31-32PA6 and orf 34PA6 and are involved with phage DNA 
replication (Farrar et al., 2007). 
At the left end of all sequenced genomes, orf1 and orf2 encode putative small and large 
terminases, respectively. Immediately downstream of orf2, a putative portal protein 
equivalent to gp3 of PA6 (gp3PA6) is encoded. The portal protein functions as a 
gatekeeper by effectively “plugging” the sole entry/exit point of the icosahedral capsid—
a single, open vertex. Prior to tail attachment, the terminase proteins unite and interact 
with the portal protein to drive phage DNA through the portal opening for packaging into 
the capsid head (Farrar et al., 2007; Fokine & Rossmann, 2014; Sassi et al., 2013). 
Equivalent to gp5 PA6 and gp6 PA6, all sequenced phage genomes produce putative head 
scaffold protein and major head protein, respectively. The head scaffold protein provides 
a framework for assembly of the head proteins and is likely degraded once the capsid is 
assembled  (Fokine & Rossmann, 2014).   
Genes equivalent to orf11 PA6 through orf18 PA6, are responsible for construction of the 
phage tail and are involved in host cell recognition and binding. Minor tail proteins 
(gp15PA6 through gp18 PA6) assemble to form the tail tip complex onto which the tape 
measure protein (TMP; gp14 PA6) attaches followed by elongation of the phage tail until 
the end of the TMP has been reached (Fokine & Rossmann, 2014). Tail assembly 
chaperones (gp12 PA6 and gp13 PA6) associate with the tape measure protein (TMP; gp14 
PA6) to assemble major tail proteins (MTP; gp11PA6) around the entire length of the TMP 
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(Stockdale et al., 2015).  Putative minor tail proteins that are thought to be associated 
with the phage tail structure are encoded by orf15 PA6 to orf18 PA6 (Farrar et al., 2007; 
Lood and Collin, 2011; Marinelli et al., 2012; Liu et al., 2015; Brown et al., 2016).  The 
gene located immediately downstream of the tail-associated ORFs (orf19 PA6), encodes a 
putative collagen-like protein that may be involved in structural stabilization of the phage 
tail or may have a role in host cell attachment (Farrar et al., 2007). Tail-associated 
structural proteins were independently evaluated for their involvement in host range 
determination (Section 3.4.2.2). 
During the final stages of phage assembly, the capsid and tail structures are joined at the 
portal-occupied vertex of the capsid (Fokine & Rossmann, 2014). Once progeny phage 
particles have accumulated, holin (gp21 PA6) and N-acetylmuramoyl-L-alanine amidase 
(gp20 PA6) form pores in the host membrane and degrade the peptidoglycan wall, 
respectively, resulting in host lysis and release of progeny phage (Farrar et al., 2007).  
3.4.2.2 Congruence analysis of phage host range activity and protein sequences 
The Congruence Among Distance Matrices (CADM) test was used to identify 
components of the phage tail that act as determinants of phage host range by comparison 
of distance matrices derived from datasets corresponding to independent protein 
sequences and host range for all sequenced phages (Section 2.2.9.3.2). Concordance 
among different types of variables can be identified by the CADM test because the test 
uses distance matrices (CADM input) derived from individual datasets to calculate 
concordance statistics (CADM output) (Campbell et al., 2011; Legendre & Lapointe, 
2004). Partial or complete congruence of datasets indicate a significant level of mutual 
 
111 
 
agreement or conformity among the variables associated with the datasets (Legendre & 
Lapointe, 2004). Therefore, the CADM test is an appropriate method to determine 
existing relationships between different types of variables, such as phage host range and 
protein sequences.  
Seven distance matrices, comprised of pairwise p-distances between all P. acnes phages 
sequenced in this study, were constructed with respect to reliable, tail-associated protein 
sequences (equivalent to gp11PA6, gp14PA6, gp15PA6, gp16PA6 , and gp17PA6), small 
terminase subunit sequences (gp1PA6) and host range (Section 2.2.9.3.1). The small 
terminase subunit is known not to come into contact with the host cell, therefore, it was 
selected as a negative control for congruency testing as it lacks involvement in the host 
recognition/adsorption process. 
To determine the overall degree of concordance between phage host ranges and the 
proteins of interest, the global test of Congruence Among Distance Matrices (CADM) 
was performed. Complimentary Mantel tests (Campbell et al., 2011; Legendre & 
Lapointe, 2004) were carried out to test for concordance among pairwise groups of 
individual distance matrices associated with host range against those associated with 
protein sequences. The global CADM test produced a concordance statistic—Kendall’s 
coefficient of concordance, W—that estimated the level of congruence, between 0 (no 
congruence) and 1 (complete congruence), among distance matrices. Under H0, the 
CADM test considers the concordance statistic “insignificant” and all matrices 
completely incongruent when P > 0.05 (Legendre, 2010). The alternate hypothesis, H1, 
accepts the concordance statistic as “significant” and partial or complete congruence 
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among distance matrices when P ≤ 0.05 (Legendre, 2010; Legendre & Lapointe, 2004). 
To determine the probability of discordance among matrices (H0), Friedman’s X2 was 
calculated using W, then tested against a distribution of X2* values derived from random 
permutations of all distance matrices of permuted values (Campbell et al., 2011; 
Legendre & Lapointe, 2004). To support rejection of H0, Mantel tests of distance 
matrices containing concordant data (H1) generated one-tailed permutational probabilities 
based on the Spearman coefficient of correlation (rs) statistic (Legendre & Lapointe, 
2004).   
As shown in Table 3.9a, results of the global CADM test revealed partial congruence 
among at least two distance matrices (W = 0.2705912; P = 0.0009). To determine which 
protein(s) demonstrated a probable association with host range, Mantel test results (Table 
3.9b) were limited to those corresponding to pairwise combinations of distance matrices 
associated with host range versus individual protein sequences. Having an rs value of 
0.41520944 supported by a P-value of 0.0356, the Mantel test result represented a 
probable association between gp11PA6 and host range (X2 falling under H1). All other 
Mantel tests produced p-values greater than 0.05. Therefore, out of all phage tail-
associated proteins evaluated for their role in host recognition, the MTP was the only 
component that was shown to act as a determinant of phage host specificity. 
3.4.2.3 Major tail protein: sequence diversity and role in host specificity of P. acnes 
phages 
Shown in Figure 3.22b, construction of a phylogenetic tree using the BioNJ algorithm in 
Seaview v.4.6 (Section 2.2.8.4.2) demonstrates the evolutionary distance based on the 
MTP sequence diversity among all P. acnes phages sequenced in this study. Tree  
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Table 3.9: Results of (a) overall (global) CADM test and (b) complimentary Mantel tests, using distance 
matrices derived from the host range and protein sequence datasets. One-tailed P-values were calculated by 
permutation test (9999 permutations) of Friedman’s X2 (CADM test) or Spearman’s coefficient of correlation, 
rs (Mantel tests). 
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Figure 3.22. Amino acid sequence diversity of major tail proteins (MTP) associated with sequenced P. acnes 
phages. The condensed protein sequence alignment given in (a) displays non-conserved amino acids separated 
by breaks lines (blue) where regions of complete sequence consensus have been collapsed. The histogram 
under the alignment represents the consensus frequency relative to 100% (longest bars). Evolutionary distance 
based on the major tail protein sequences are represented by (b) a phylogenetic tree constructed using BioNJ 
algorithm with 1000 bootstrap replicates (bootstrap values are as indicated).  
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topology and differences in branch lengths is reflective of the diversity across the MTP 
sequences, as represented by a map of aligned non-conserved amino acids produced 
using Jalview v.2.10.1 (Section 2.2.8.4.2) given in Figure 3.22a. The majority of these 
phages exhibit differences among their MTP sequences (Figure 3.22a) that are translated 
into corresponding branch length differences of the phylogenetic tree (Figure 3.22b).  
Based on congruence analysis results, variation across the host range profiles of all 
sequenced P. acnes phages (Figure 3.18) is reflected in the phylogenetic analysis of the 
MTP (Figure 3.22a). For example, two phages— πα33 and πα3-SS3-1—exhibited 
identical host range (Figure 3.18) and branch lengths (Figure 3.22a), based on identical 
MTP sequences (Figure 3.22b), as expected. Interestingly, one pair of sequenced 
phages— πα6919-4 and πα35—demonstrated identical host range against the collection 
of P. acnes isolates used in this study, despite variation among their MTP sequences 
(Figure 3.22b). It is possible that, if tested against an expanded collection of P. acnes 
isolates, they may demonstrate alternative host specificity. Despite this, the level of 
concordance among the MTP sequence and host range datasets was powerful enough to 
overcome any instance of discordant data.  
Derived from P. acnes phage πα6919-4, mutant phage πα9-6919-4 demonstrated 
extended host range as it was capable of completely lysing the P. acnes strain #9 that was 
naturally resistant to the entire P. acnes phage collection (Section 3.3.3). Upon sequence 
analysis of the phage πα9-6919-4 in comparison to its parental phage πα6919-4 mutations 
leading to changes in one or more protein sequences implicated in phage-host interaction 
were detected. A condensed map of the πα6919-4 and πα9-6919-4 MTP alignment was 
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generated using DNAMAN v. 9 (Section 2.2.8.4.2). A relatively diverse clustered 
variations in MTP sequences across the sequenced phages were observed (Figure 3.22b), 
however, located in a fairly-conserved region of the MTP, Figure 3.23 illustrates the 
sequence variation between MTPs of πα6919-4 and πα9-6919-4 compared with all other 
known sequenced P. acnes phages. Figure 3.23a shows three missense mutations in the 
gene encoding the MTP of πα6919-4 —G314→A; T316→C; T321→A (gp11 nucleotide 
numbering)—resulted in three tandem, non-conserved amino acid substitutions in the 
MTP of πα9-6919-4 (equivalent to phage PA6 bases G311, G313 and T318). Based on 
πα6919-4 MTP amino acid numbering, the substitutions are G105→E; S106→P; D107→E 
(equivalent to phage PA6 MTP amino acids G105, S106 and D107) . Amino acid 
substitutions in the MTP sequence of πα9-6919-4 were unique compared to all other 
sequenced P. acnes phages to date (Figure 3.23b).  
3.4.2.4 Structural modeling of the major tail protein: implications in P. acnes phage 
host range  
To investigate the mechanism of tail tube-associated host specificity of P. acnes phages 
(especially for πα6919-4 and πα9-6919-4) and in order to conduct structural modeling of 
phage major tail proteins (MTPs), a thorough homology search within protein databases 
was required (Section 2.2.8.4.2). Matching entries with similar functions and with 
structural data (NMR or X-ray crystallography) can be used in 3D structural modeling. A 
blastp search using the παMTP sequences (214 amino acids) within the non-redundant 
protein sequence database identified a few proteins with related functions that 
demonstrated relatively moderate homology with major tail proteins of various  
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Figure 3.23. Sequence variation in a conserved region of P. acnes phage major tail proteins. (a) Three 
missense mutations present in orf11 of πα9-6919-4 resulted in substitution of three amino acids in gp11 
(major tail protein). (b) Map displaying the region where sequence variation occurred in the major tail 
proteins of parental P. acnes phage πα6919-4, and its mutant progeny πα9-6919-4 (underlined blue), 
aligned with eighty-eight P. acnes MTP sequences.  
(a) 
(b) 
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Lactococcus lactis p335-group phages (p335MTPs), including ΦTIFN7 (Erkus et al., 
2013), r1t (van Sinderen et al., 1996) and ΦLC3 (Blatny et al., 2004), having the highest 
mean sequence identity with ΦTIFN7 (30.3% ± 0.3, e = 2.13x10-4 ± 6.78x10-5). An 
example alignment of πα6919-4 MTP with ΦTIFN7 MTP is shown in Figure 3.24 . 
Sequence alignments of p335 MTPs started either at the first or forty-third παMTP N-
domain residues, covering roughly 60% or 80% of the παMTPs, respectively. Homology 
was expected in the N-terminal region of the MTPs because N-terminal domains of 
siphovirus MTPs are conserved as they are the primary constituents of the 
homohexameric rings comprising the phage tail tube structures and are likely to share a 
common ancestor together with bacterial type VI secretory system (Leiman et al., 2009; 
Pell et al., 2009). Tail decorating C-terminal domains (C-domain) are absent in p335-
group phages as the host adsorption strategy employed by phages of the p335 group does 
not involve the tail tube structure (Bebeacua et al., 2013a). Therefore, aligned regions of 
homology between p335 MTPs and παMTPs excluded the far C-domain residues of the 
παMTPs, which accounted for approximately 20% of the entire παMTP length.  
Having only partial alignment with low homology and, more importantly, a lack of 
structural data, could not support use of these proteins for structural modeling. Therefore, 
we sought structural alignment of παMTP sequences with those of known structure from 
within the PDB database. Powerful algorithms are used to generate alignments using the 
query protein sequence (target) and those within the PDB database (templates), ranking 
target-template alignments by best fit, to identify evolutionarily distant proteins that share 
a common ancestor and are likely have similar function, in order to produce a model of 
the target. Using HHPred of the MPI Bioinformatics Toolkit integrative platform, a  
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Figure 3.24: Protein sequence homology search result using blastp for πα6919-4 MTP. 
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structural homology search for πα6919-4 MTP was conducted (Section 2.2.8.4.2). This 
search was based on an initial phase of secondary structure  prediction (SSPred) for 
segments of the primary sequence followed by aligment to proteins within PDB database 
with consideration of both primary sequence and secondary structure data. The παMTP 
returned a match with the N-domain of E. coli λ phage major tail tube protein (λ gpVN) 
that only covered the first 156 amino acids of the πα6919-4 MTP, corresponding to its N-
domain. No further match extending to its C-domain was available thus restricting our 
analysis to include only the N-domains of the παMTPs, which we considered useful for 
our analysis directed to πα6919-4 and its mutant derivative, πα9-6919-4, with extended 
host range. An example of the structural alignment report from the HHPred server is 
shown in Figure 3.25. A glance through the predicted secondary structures (ss_pred) and 
the known secondary structure (SS) data (ss_dssp) for λ gpVN provides confidence for the 
SS predictions of the παMTP given in the MSA output. Sequence alignment showed 6% 
primary sequence identity with a relatively high probability of 67% and matching 
confidence score of 24.11 suggestive of significant structural and functional relatedness 
between λ gpVN and πα MTPs. The πα6919-4 MTP included insertion of a stretch of 18 
amino acids at the D104 position corresponding to the λ gpVN sequence. This inserted 
stretch of amino acids was shared and highly conserved among all of our sequenced 
phages. It was also noted that the non-conservative tandem triple mutations in the πα9-
6919-4 MTP as compared to the MTP of its parental phage πα6919-4 (G105→E; S106→P; 
D107→E) was mapped to this additional 18 amino acid region.  
Conducting similar searches with παMTPs using the HHSearch2 threading program via 
the LOMETS server predicted secondary structures and generated target-template  
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Figure 3.25: Structural alignment of πα6919-4 MTP and λ gpVN (2K4Q). Secondary structures were predicted by HHPred 
search using Bioinformatic Toolkit and aligned to λ gpVN. ss_pred: predicted secondary structure; ss deep: secondary 
structure based on NMR atomic coordination data.
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alignments with protein structures from the PDB database, generating παMTP-λ gpVN 
MSA output comparable to that of HHPred. We additionally used the primary sequence 
of λ gpVN, derived directly from its PDB file (2K4Q), as an internal control to validate 
the accuracy of the prediction and modeling by LOMETS. The MSA output from 
LOMETS was used to produce a PDB output file using onsite MODELLER program. 
The predicted 3D model for λ gpVN produced high confidence score (C-score) for the 
accuracy of model and Z-score of 86.693 (cutoff threshold of 0.0339-0.0733) verifying 
statistical significance of the modeling process (Wu & Zhang, 2007). The predicted 
models for N-domains of πα6919-4 and πα9-6919-4 MTPs also had high C-scores and 
significant Z-scores of 11.964 and 12.991, respectively, indicating the reliability of the 
predicted models (Figure 3.27). Shown in Figure 3.26, we further tested the accuracy of 
the models by functional alignment of the amino acid sequences of our παMTAs to λ 
gpVN sequence to identify the highly conserved hydrophobic residues that constitute the 
protein’s hydrophobic core essential for its assembly and function (Pell et al., 2009).  
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Figure 3.26: Mapping of N-domain hydrophobic core residues of παMTPs with reference to λ gpVN sequence. Thirteen out of 
fourteen conserved hydrophobic residues of λ gpVN that take part in protein’s hydrophobic core are conserved in παMTPs 
(blue boxes). Stretch of 18 amino acids among that are present in παMTPs is shown as a gap in λ gpVN sequence. 
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Figure 3.27: Three dimensional models of λ gpVN, πα6919-4 and πα9-6919-4 MTP 
N-domains modelled by LOMETS. Models were built using the λ gpVN NMR data; 
A-C: sideview and D-F: top to bottom view. 
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 Discussion  4
Propionibacterium acnes is a resident microflora of the human skin (Funke et al., 1997; 
Grice & Segre, 2011). Pilosebaceous units of the head and trunk provide a habitable 
environment that is well-suited for this lipophilic, facultative microaerophilic anaerobe 
(Bek-Thomsen et al., 2008; Grice & Segre, 2011; Leeming et al., 1984; Roth & James, 
1988). P. acnes has gained notoriety as an opportunistic pathogen (Brüggemann et al., 
2004; Brüggemann, 2005) and is mainly recognized as the primary etiologic agent 
associated with acne vulgaris (Das & Reynolds, 2014). Acne affects over eighty percent 
of individuals at least once in their lifetime and is generally considered to be a chronic 
condition that manifests during adolescence and early adulthood (Balkrishnan et al., 
2006b). Disadvantages of existing acne treatments include a wide range of adverse side 
effects, development of bacterial antibiotic resistance, limitations imposed by 
contraindications, and treatment costs, amongst others. To overcome the drawbacks 
associated with existing treatments, novel therapeutic modalities need to be sought. 
Phage therapy offers a targeted, fast-acting, cost-effective alternative to conventional 
antimicrobials. As a proof of concept study, the in vitro potential of bacteriophages as an 
alternative to antimicrobials and a potential future therapy for treatment of acne vulgaris 
is discussed.  
Study participants and treatment history 
Patients seeking dermatological consultation for acne in Sudbury and Ottawa (Canada), 
served as the largest sources of P. acnes isolates used in this study. The P. acnes 
collection was diversified further by the addition of donated isolates recovered from 
either deep tissue infections or from forehead sampling of healthy individuals from 
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Sweden (Table 4.1, Appendix C). The participant populations of Sudbury and Ottawa 
were comparable to those of other epidemiological acne studies (Aksu et al., 2012; 
Augustin et al., 2011; Bissek et al., 2012; Dréno et al., 2016b; Goulden et al., 1997, 
1999; Han et al., 2016; Henderson, 1996; Kilkenny et al., 1998; Layton et al., 1994; 
Perera et al., 2000; Shahzad et al., 2011; Shaw & White, 2001; Shen et al., 2012; Tan, 
2004; Tan & Bhate, 2015; Tanghetti et al., 2014; Thiboutot et al., 2009; Yentzer et al., 
2010; Zouboulis, 2014), suggesting that the recovered P. acnes isolates used in this study 
comprise a representative collection of clinically-relevant, acne-associated phage target 
hosts. Consistent with reports concerning the average age of acne onset, persistence 
(Augustin et al., 2011; Bissek et al., 2012; Henderson, 1996; Perera et al., 2000; Shen et 
al., 2012; Tan, 2004; Tan & Bhate, 2015), anatomical distribution of lesions (Dréno et 
al., 2016b; Tan, 2004) and chronic duration (Dréno et al., 2016b; Tan, 2004; Thiboutot et 
al., 2009; Zouboulis, 2014), the majority of study participants were adolescents and 
young adults (12-50 years old, with 90th percentile at 30 years of age). Patients in their 
mid-teens to early-twenties were mostly male compared to the female patient population, 
which exhibited a broader age distribution. The higher prevalence of adult acne among 
women compared to men has also been noted by several other research groups (Aksu et 
al., 2012; Goulden et al., 1999; Han et al., 2016; Kaur et al., 2016; Kilkenny et al., 1998; 
Shahzad et al., 2011; Shaw & White, 2001; Shen et al., 2012; Tanghetti et al., 2014; 
Yentzer et al., 2010). Patients presented with lesions located on their faces in 
combination with the chest and/or back, whom have been afflicted with the condition for 
at least two years. Sixty-five participants (47.8%) reported presence of scarring; of these, 
the majority (63.1%) did indicate that they had developed scars as a result of acne (Table 
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3.1), which was expected as scarring is common among acne sufferers (Dréno et al., 
2016b; Goulden et al., 1997; Layton et al., 1994; Tanghetti et al., 2014).  
Used by 86.6% of treated patients, retinoids (oral and/or topical) were the most common 
treatment modality followed equally by both benzoyl peroxide and topical and/or oral 
antibiotics, both used by 70.2% of treated patients (Table 3.1). These treatments were 
expected to be used most often among study participants as they are indicated for all 
levels of acne severity (Zaenglein et al., 2016), with retinoids being the first line of 
defense for all types of acne (Thiboutot et al., 2009). Oral contraceptives and 
spironolactone are only indicated for the female population as an alternative treatment for 
moderate to severe acne (Thiboutot et al., 2009; Zaenglein et al., 2016), thus they have a 
relatively lower usage frequency of 19% and 6% of the treated female population, 
respectively (Table 3.1). Employed by only 1.75% of treated patients, photodynamic 
therapy has been recognized and evaluated as a supplementary alternative acne treatment, 
however, its off-label use for acne has proven successful (Haedersdal et al., 2008; 
Thiboutot et al., 2009; Zaenglein et al., 2016). Similar to other studies (Tan, 2004; 
Yentzer et al., 2010),  the largest group of patients receiving treatment (31.6%) were 
using a combination of retinoids, benozyl peroxide and antibiotics (Table 3.1). Physicians 
regularly adopt combinatorial therapeutic approaches for resolving acne to address a 
variety of factors contributing to acne pathogenesis and attempt to reduce development of 
antibiotic resistance (Thiboutot et al., 2009).  
As shown in Table 3.2, topical clindamycin was the most frequently-used antibiotic 
among study participants (58.8%), followed by oral minocycline (28.8%) then oral 
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doxycycline (23.8%). This was as expected as these antibiotics are most commonly-
employed, with topical clindamycin being indicated for all levels of acne severity and 
oral tetracyclines being indicated for moderate to severe acne (Del Rosso et al., 2016; 
Zaenglein et al., 2016). Regardless of whether antibiotics are used in conjunction with 
other treatment modalities, evidence does suggest that exposure to antibiotics can cause 
damage to the natural microbiome and impose selective pressure on P. acnes (Grech, 
2014) and other bacteria in the microflora (Başak et al., 2013; Lesens et al., 2007; Levy 
et al., 2003; Margolis et al., 2005, 2012; Mills et al., 2002; Ozuguz et al., 2014; Raum et 
al., 2008), resulting in negative treatment outcomes (Del Rosso et al., 2016; Leyden, 
2012; Simonart & Dramaix, 2005; Thiboutot et al., 2009). With this in mind, it is 
worrisome that over half of the study participants underwent acne therapy with one or 
more antibiotics (Figure 3.3) for an approximate mean duration of seven months (Section 
3.1).  
Demonstrating wide representation in terms of antibiotic exposure, use of other treatment 
modalities, age, sex, duration of acne and primary location of lesions (sampling), 
Sudbury and Ottawa patient populations together with isolates from Sweden served as 
diverse sources of clinically-relevant P. acnes hosts for in vitro evaluation of the 
candidate phage collection.  
Propionibacterium acnes clinical isolates 
Indiscriminate lytic capacity of the phage cocktail candidates was determined by 
evaluating their propensity to infect and kill a diverse pool of two hundred twenty-four P. 
acnes isolates (Table 3.3). The collection of P. acnes isolates represent a variety of 
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populations contrasted by geographical origin, anatomical source of isolation, antibiotic 
susceptibility patterns and genetic properties. Comprising nearly seventy-five percent of 
the total P. acnes isolate pool, the largest source of clinical isolates used in this study 
were derived from acne patients in Sudbury and Ottawa (Table 3.3). The pool was 
expanded to include P. acnes isolates from a range of clinical sources, originating from 
Sweden and across Canada (Table C.1). To the best of our knowledge, this is one of the 
largest, most diverse pool of clinically-relevant P. acnes isolates assessed in terms of 
sensitivity to a phage collection, to date.  
Genetic diversity among P. acnes isolates 
Rapid, PCR-based phylotyping of both Sudbury and Ottawa clinical isolate collections 
revealed representation of P. acnes isolates belonging to major phylogenetic clades IA, 
IB, and II (Section 3.2.1). All PCR-confirmed P. acnes isolates were successfully 
grouped into clade IA, IB or II;like other reports, there was no evidence of type III P. 
acnes isolate recovery from acne lesions (Lomholt & Kilian, 2010; McDowell et al., 
2008, 2011, 2012, 2013). Corroborated by findings from several other studies that 
employed alternate typing schemes (Fitz-Gibbon et al., 2013; Lomholt & Kilian, 2010; 
McDowell et al., 2011, 2012, 2013), type IA isolates were frequently isolated from acne 
and comprised 86.14% of Sudbury and Ottawa combined P. acnes collections. Types IB 
and II isolates had lower rates of recovery from acne lesions (Table 3.5), comprising 
9.04% and 4.82% of Sudbury and Ottawa combined P. acnes collections. Type IA  P. 
acnes isolates are associated with acne, while type IB and type II isolates are associated 
more frequently with healthy skin and deep tissue infection (McDowell & Nagy, 2015). 
 
130 
 
Therefore, characterized by an elevated proportion of type IA isolates and lower 
frequencies of types IB and II isolates (p<0.001, Section 3.2.1), the pool of P. acnes 
isolates used in this study represents the phylogenetic composition expected from a 
clinically-relevant P. acnes population, thus this collection is a suitable target for testing 
the efficacy of phages as the potential antibacterials.  
Statistical analysis of the frequency of P. acnes phylotypes recovered from lesion 
surfaces versus exudates revealed no bias of phylotype distribution among samples from 
either of these sampling sites from patients in Sudbury (p=0.633) and Ottawa (p=0.612) 
(Section 3.2.1). These findings suggests that P. acnes phylotype composition on the skin 
of acne patients does not vary between the surface and the interior of the acne lesion. 
Therefore, it is reasonable to suggest that the same P. acnes strains within the lesion are 
also on the skin surface. Phages applied to the skin surface will replicate exponentially 
upon application thus increasing the likelihood of treatment success by increasing the 
number of progeny phage particles that are capable of infecting strains on both the 
surface and within the lesion.  
Statistical analysis of the P. acnes phylotypes revealed no bias relating to the presence or 
absence of antibiotic resistance among isolates from Sudbury (p=0.316) and Ottawa 
(p=0.836) (Section 3.2.1). This was expected, as phylogenetic associations between 
specific strain types and resistance phenotypes (Lomholt et al., 2017; McDowell et al., 
2012) require the use of a typing methodology with a higher resolution, which could 
identify phylotype subgroups, clonal complexes and strain types. 
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Antibiotic susceptibility of P. acnes isolates 
Antibiotic therapy was used by over half of the combined population of Sudbury and 
Ottawa patients; resistance among P. acnes isolates from these patients was determined 
to be linked to antibiotic exposure (p<0.001; Section 3.2.3). Other studies have 
documented geographical correlations with the magnitude of antibiotic exposure and 
corresponding resistance rates of P. acnes and other bacteria (Del Rosso, 2016). For 
instance, use of antibiotics with similar mechanisms of action, such as EM (macrolide) 
and CM (lincosamide), are associated with in vivo recovery of EM (p=0.0019), AZ 
(p=0.0052) and/or CM (p=0.0280) cross-resistant P. acnes in this study (Section 3.2.3), 
and in others (Borglund et al., 1984; Grech, 2014; Oprica et al., 2004; Ross et al., 2003; 
Schafer et al., 2013). Similar to other reports (Borglund et al., 1984; Oprica et al., 2004; 
Ross et al., 2003), the present study revealed an association between patient exposure to 
one or more tetracycline-class antibiotics and recovery of P. acnes isolates demonstrating 
resistance to tetracycline, doxycycline and/or minocycline (p=0.0233; Section 3.2.3).  
Out of two hundred eleven P. acnes isolates evaluated for antibiotic susceptibility, forty-
five  were resistant to at least one antibiotic (Section 3.2.3). Frequencies of clindamycin 
and erythromycin use, combined, represent the largest proportion of antibiotics used that 
share similar mechanisms of bacterial inhibition (Table 3.2). Therefore, given that the 
chronic aspect of acne and the necessity for long-term and frequent usage of antibiotics 
such as clindamycin and macrolides (erythromycin and azithromycin) resistance  might 
have been descended clonally in the population, it was not surprising that the highest 
frequencies of resistance were to erythromycin and azithromycin, followed by 
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clindamycin (Table 3.6)—a trend that is corroborated by similar studies (Crane et al., 
2013; Fan et al., 2016; Giannopoulos et al., 2015; Grech, 2014; Moon et al., 2012; 
Nakase et al., 2012; Oprica & Nord, 2005; Ross et al., 2003; Schafer et al., 2013; Walsh 
et al., 2016).  
Macrolide and lincosamide antibiotics disrupt peptide synthesis by causing dissociation 
of peptidyl-tRNA from the 23S rRNA by either partial masking of the substrate-binding 
region of the peptidyl transferase (CM) or by blocking the ribosomal P-site used as an 
exit path for newly-synthesized peptide chains through induction of conformational 
change by binding of a region nearby the peptidyl-tRNA binding site (EM and AZ) 
(Dinos et al., 2001; Mao & Robishaw, 1972; Tenson et al., 2003). Having similar 
mechanisms of action, cross-resistance to macrolides (EM and AZ), lincosamides (CM) 
and streptogramin B antibiotics is common (Coates & Vyakrnam, 2002; Gübelin et al., 
2006; Ishida et al., 2008; Ross et al., 2003; Schafer et al., 2013). In this study, over half 
of macrolide-resistant P. acnes isolates were cross-resistant to clindamycin, whereas all 
clindamycin-resistant isolates were cross-resistant to a macrolide (EM and/or AZ).  
Resistance to macrolides, streptogramin B and/or lincosamides are often the result of a 
target modification by methylation or target alteration by mutation in the peptidyl 
transferase located within domain V of the 23S rRNA in the 50S large subunit of 
bacterial ribosomes (Sigmund et al., 1984; Sigmund & Morgan, 1982; Weisblum, 1995). 
Having a variety of resistance mechanisms, such as conformational changes of the 23S 
rRNA secondary structure and introduction of ribosomal methyl-transferase targets 
(Leclercq, 2002; Vannuffel et al., 1992; Weisblum, 1995), majority of P. acnes macrolide 
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and lincosamide resistance phenotypes are associated with distinct 23S rRNA mutations 
at E. coli bases 2058 (resistance group I), 2057 (group III), 2059 (group IV), or 2611, or 
by acquisition of the Tn5432 transposon (group II), which carries the erm(X) resistance 
gene that encodes 23S dimethylase (Nakase et al., 2016; Ross et al., 1997, 2001, 2002, 
2003; Weisblum, 1995). Having cross-resistance to erythromycin, azithromycin and 
clindamycin, twenty-two P. acnes isolates may belong to resistance groups I (E. coli 
A2058G), II (erm(X) resistance gene) or IV (E. coli A2059G)—all of which are 
characterized by a high-level of macrolide resistance and moderate (group IV) to high 
(groups I and II) levels of clindamycin resistance (Ross et al., 1997, 2002). Due to the 
maximum concentration of antibiotic on the Etest strips, MIC readings above 256 ug/ml 
could not be resolved, therefore, categorization into specific resistance groups remains 
uncertain. Despite this, it is clear that the isolates used in this study demonstrate a diverse 
range of susceptibility phenotypes to macrolides and clindamycin. 
As seen in other reports, P. acnes rates of resistance to tetracycline-class of antibiotics in 
this study was lower than to macrolides and clindamycin (González et al., 2010; Gübelin 
et al., 2006; Kurokawa et al., 1999; Moon et al., 2012; Oprica et al., 2004; Ross et al., 
2001, 2003; Sardana et al., 2016; Walsh et al., 2016) and the combined usage frequency 
of tetracycline-class antibiotics was linked to recovery of resistant P. acnes (Nakase et 
al., 2014; Oprica et al., 2005; Oprica & Nord, 2005; Ross et al., 2003). Tetracyclines 
inhibit protein synthesis by interfering with aminoacyl-tRNA binding to the A site of 16S 
rRNA, of the 30S ribosomal subunit, by disruption of its tertiary structure (Chopra et al., 
1992; Schnappinger & Hillen, 1996). Sharing the same mechanism of action, the majority 
of tetracycline-resistant isolates were cross-resistant to doxycycline and/or minocycline. 
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Cross-resistance between tetracyclines has been documented by other studies (González 
et al., 2010; Gübelin et al., 2006; Kurokawa et al., 1999; Sardana et al., 2016). Common 
mechanisms of tetracycline resistance include efflux pumps that function to decrease the 
concentration of tetracycline inside the cell, ribosomal protection proteins that interfere 
with the tetracycline’s capacity to inhibit aminoacyl tRNA binding, chemical 
modification of the tetracycline molecules and base mutations in the 16S rRNA 
(Chukwudi, 2016; Salyers et al., 1990). Not all mechanisms of tetracycline resistance in 
P. acnes have been documented, however, there is evidence that a single base mutation in 
the 16S rRNA at E. coli equivalent position G1058C has been shown to confer resistance 
to tetracyclines in P. acnes (Giannopoulos et al., 2015; Nakase et al., 2014; Oprica et al., 
2005; Ross et al., 1998, 2001), as well as an amino acid substitution in ribosomal protein 
S10 encoded by the rpsJ gene, which reduces susceptibility to tetracyclines prior to 
development of complete resistance as conferred by the G1036C mutation in 16S rRNA 
(Nakase et al., 2017). Most studies that have attempted to elucidate the mechanism of P. 
acnes resistance to tetracycline class antibiotics have targeted the 16S rRNA of resistant 
P. acnes isolates (Giannopoulos et al., 2015; Nakase et al., 2014; Oprica et al., 2005; 
Ross et al., 1998, 2001). Recent studies have shown that tetracyclines are capable of 
binding to random, double-stranded RNA sequences, which would explain the inhibitory 
action of tetracyclines against non-bacterial targets (Chukwudi, 2016; Chukwudi & 
Good, 2016) and variation with regards to the patterns of tetracycline class antibiotic 
cross-resistance. 
Rifampicin resistance was unexpected as the only report of in vivo resistance comes from 
a study involving a pool of 684 P. acnes strains isolated from a variety of specimen types 
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sampled from hospital patients—five of which were rifampicin-resistant (Aubin et al., 
2014). Rifampicin interferes with transcription via interaction with the β-subunit of RNA 
polymerase (Campbell et al., 2001). Point mutations in the gene that encodes the β-
subunit—rpoB— have been shown to confer in vitro resistance to P. acnes (Furustrand 
Tafin et al., 2013). Resistance to rifampicin was demonstrated by only a single P. acnes 
isolate, derived from an infection involving a hip prosthesis originating from Lund (Table 
C.1; (Holmberg et al., 2009)). Rifampicin is capable of penetrating S. aureus and P. 
acnes biofilms, which are involved in implant-associated infections, thus it is used in 
combination with other antibiotics to treat infections of this nature (Achermann et al., 
2014; Furustrand Tafin et al., 2012; Zimmerli, 2014). Therefore, it is possible that the 
rifampicin-resistant P. acnes isolate originated from a patient treated with this antibiotic.  
Contrary to two reports of high rates of resistance to trimethoprim/sulfamethoxazole 
(TS)—68% (González et al., 2010) and 26.3% (Schafer et al., 2013)—only one TS-
resistant P. acnes isolate was recovered in this study (Table 3.6), similar to other reports 
(Cunliffe et al., 1999; Moon et al., 2012; Ross et al., 2001). The mechanism of P. acnes 
resistance remains unknown. In this study, TS susceptibility testing was performed using 
MH media with low thymidine concentration to ensure that thymidine from an exogenous 
source was not available for conversion to thymine by P. acnes that may result in evasion 
of the inhibitory effects of TS on folate synthesis. In other studies, thymidine content of 
the media used for TS susceptibility testing was not indicated, therefore it is possible that 
the TS-resistant P. acnes isolates may have been less susceptible to inhibition by TS if 
exogenous sources of thymidine were available.  
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With the exception of TS, the resistance frequencies determined in this study follow 
Global antibiotic resistance trends as summarized in a comprehensive review by (Sardana 
et al., 2015), which suggests that the general prevalence of P. acnes resistance to 
macrolides, TS and CM is greater than rates of resistance to tetracyclines. As reported by 
many other studies (Crane et al., 2013; Goldstein et al., 2003, 2004; Olsson et al., 2012; 
Oprica & Nord, 2005; Ross et al., 2001; Shames et al., 2006), all isolates were 
susceptible to benzylpenicillin (penicillin G), ceftriaxone, levofloxacin, linezolid, 
vancomycin and daptomycin.  
Twenty of the forty-five antibiotic resistant P. acnes isolates were multiply-resistant to 
combinations of macrolides and tetracyclines—all of which lacked susceptibility to both 
erythromycin and a tetracycline-class antibiotic (Figure 3.13). Other studies have 
documented multiply-resistant P. acnes isolates (Giannopoulos et al., 2015), however, 
none as many as reported by the present study. This is troubling as therapeutic failure of 
various antibiotics, such as erythromycin (Eady et al., 1989) and tetracycline (Ozolins et 
al., 2004), has been associated with recovery of antibiotic resistant P. acnes. Having a 
subpopulation of antibiotic resistant clinically-relevant P. acnes isolates was relevant to 
this study as it provides a justification for evaluating the efficacy of the phage cocktail 
candidates against a group of isolates that may otherwise be associated with treatment 
failure in a clinical setting. 
Given the antibiotic resistance properties and the phylogenetic diversities found among 
our P. acnes clinical isolates it appeared as a plausible question to address whether there 
exists a pattern for phage susceptibility among these clinical isolates. In the following 
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sections we discuss the biological properties of the phage isolates followed by their 
functional properties as potential antibacterials.  
Phage isolates 
To this end, seventy-six P. acnes bacteriophages were isolated and evaluated for their 
lytic properties against two hundred twenty-four Propionibacterium acnes clinical 
isolates that were recovered from clinical samples collected from sources across Canada 
and Sweden (Table 4.1, Appendix C). A large collection of highly diverse P. acnes 
phages were isolated using agar overlay method (Figure 3.15). Seventy phages from 
sewage samples of urban wastewater treatment plants (Ottawa, ON and Gatineau, QC) 
comprised the majority of our phage collection, five phage isolates were obtained from 
patient samples, and one isolate via evolutionary derivation approach (Section 3.3.1 and 
Section 3.3.3). Imaging by TEM revealed typical siphovirus morphology for all imaged 
phages (Figure 3.16). Intact virion structures were characterized by the presence of a non-
enveloped icosahedral head that spanned a diameter of approximately 55 nm, which was 
attached to a non-contractile tail that was roughly 133 nm long, 11 nm in diameter and 
possessed short tail fibers (Figure 3.16). To date, all reports of P. acnes phage structures 
that have been resolved by TEM have described phages belonging to siphoviridea  with 
comparable dimensions (Ackermann & Eisenstark, 1974; Farrar et al., 2007; Lood et al., 
2008; Marinelli et al., 2012; Webster & Cummins, 1978). Predicted structural protein 
homology between the P. acnes phages in this study and well-characterized proteins 
belonging to other siphoviruses will be discussed. 
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Having an overall median host range of  97.5% (Section 3.3.3), high throughput phage 
spot infections (Figure 3.17) revealed that the phages in our collection have an overall 
propensity for lytic activity against the diverse population of clinical P. acnes isolates 
(Figure 3.19a), with no preference for a specific P. acnes phylotype or antibiotic 
susceptibility properties. Similar to other studies (Pulverer et al., 1973; Jong et al., 1975; 
G F Webster and Cummins, 1978; Lood et al., 2008; Marinelli et al., 2012; Liu et al., 
2015), all phages demonstrated broad host ranges (maximum and minimum host ranges 
of 99.6% and 78.1%, respectively) and were unable to infect a variety of common Gram-
positive and Gram negative commensals and pathogens—P. granulosum ATCC 25564, 
P. avidum ATCC 25577, E. coli MG1655, S. aureus ATCC 29923, S. typhimurium 
TA1535 and S. pyogenes ATCC 12204 (Section 2.2.7) (Bek-Thomsen et al., 2008; Fitz-
Gibbon et al., 2013; Grice & Segre, 2011; Leeming et al., 1984; Puhvel et al., 1975; Roth 
& James, 1988). Accounting for only 30.2% of phages, four host range groups (HRGs) 
were established (HRG1,11.8%; HRG2, 10.5%; HRG3, 5.3%; and HRG4, 2.6%), each 
containing phages with identical activity spectra against the population of P. acnes used 
in this study. The rest of the phages (69.8%) that comprosed the  majority of phages 
exhibited entirely unique activity spectra. Contrary to previous studies which described 
P. acnes phages as highly similar (Pulverer et al., 1973; Jong et al., 1975; Webster and 
Cummins, 1978; Lood et al., 2008; Marinelli et al., 2012),  our phage collection 
demonstrated a high degree of variation in their activity spectra (host ranges) (Figure 
3.18), which reflects the relatively high level of biological diversity among phages in this 
collection. The limited genomic and biological diversity among other phage collections is 
in part due to the limitation in the sampling strategies that other groups established to 
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isolate their phages. For example, most reports describe isolation of P. acnes phages from 
samples taken from a limited number of human subjects (Brown et al., 2016; Farrar et al., 
2007; Marinelli et al., 2012).  
Overall, P. acnes isolates were sensitive to infection by the majority of the members of 
our phage collection (Figure 3.19b). Sensitive to the entire phage collection, P. acnes 
isolates of PVG1 (phagovar group 1) comprise the majority of the P. acnes population 
(67.9%). Other PVGs vary in terms of their level of susceptibilities, however, all were 
susceptible to at least 77% of the phage collection (Figure 3.18).  Only three isolates were 
sensitive to under 50% of the phage collection (Figure 3.18); of these, a single isolate—
P. acnes #9—was naturally-resistant to all phages prior to evolutionary derivation of a 
phage with extended host range that was able to infect #9 (Section 3.3.3).  
Compared to other studies, the proportion of P. acnes isolates that were sensitive to less 
than 50% (below median) of the phages in this study (1.3%) was over three times less 
than that  of P. acnes isolates described by other reports (10.3%, Jong et al., 1975; 
12.1%, Lood and Collin, 2011; 7.4%, Marinelli et al., 2012; 4.5%, Liu et al., 2015). 
These groups of insensitive P. acnes isolates (Pulverer et al., 1973; Jong et al., 1975; 
Webster and Cummins, 1978; Lood et al., 2008; Marinelli et al., 2012) have challenged 
the prospect of developing phage-based cocktail formulations for acne treatment. The 
relative proportion of P. acnes phages in all except one (Marinelli et al., 2012) of these 
studies is larger than the relative proportion of phages in this study (Jong et al., 1975; Liu 
et al., 2015b; Lood & Collin, 2011); therefore, simply increasing the proportion of P. 
acnes phages relative to the number of hosts will not reduce the small groups of highly-
insensitive isolates. Thus, the variation between the level of sensitivity observed for P. 
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acnes in this study compared to others is by virtue of composition (diversity), not size, of 
the phage collection. Previous studies have cited direct cutaneous sampling of a limited 
number of human subjects, spontaneous lysis or induction of pseudolysogens from P. 
acnes using mitomycin C, as sources for isolation of P. acnes phages, which have been 
characterized by limited variation in terms of host activity spectra and genome sequence 
(Pulverer et al., 1973; Jong et al., 1975; Webster and Cummins, 1978; Farrar et al., 2007; 
Lood et al., 2008; Lood and Collin, 2011; Marinelli et al., 2012; Liu et al., 2015; Brown 
et al., 2016). The bacterial composition of the pilosebaceous units are regularly limited 
to, or overwhelmingly dominated, by P. acnes (Puhvel et al., 1975; Leeming et al., 1984; 
Roth and James, 1988; Bek-Thomsen et al., 2008; Grice and Segre, 2011; Marinelli et al., 
2012; Fitz-Gibbon et al., 2013). The pilosebaceous unit provides a unique, protected 
niche where P. acnes (and their phages) can survive and proliferate with minimal 
challenge by selective pressures that may otherwise function to diversify the species and 
its phage populations. Therefore, based on previous studies, P. acnes phages derived 
from sources of limited microbial diversity will not challenge naturally-resistant P. acnes 
isolates.  
Frequency of P. acnes isolates with phage insensitivity is reduced by increasing the 
genetic diversity across phages. Based on this assumption, increasing the level of 
diversity across the phage collection further skews the frequency distribution of P. acnes 
sensitivity presented in Figure 3.19b leftward, resulting in an overall higher level of 
sensitivity among P. acnes isolates. Thus, overcoming acquired or natural resistance of P. 
acnes strains to bacteriophage infection requires access to a diverse range of P. acnes 
phages and is necessary for development of a phage-based cocktails for application in 
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future acne treatment. Obtaining P. acnes phages from sewage was the underlying reason 
for the diversity among our phage collection. The raw sewage is a dense milieu of richly 
diverse microbial populations (Sulakvelidze & Barrow, 2004). The larger and multi-
ethnically diverse the human communities become as in metropolitan cities, the more 
globally diverse microbial communities will be represented in the raw sewer. . Therefore, 
choosing the raw sewer of a large multi-ethnically populated urban area of over one 
million inhabitants such as Ottawa-Gatineau resulted in a diverse collection of phages 
with a broader activity spectra against P. acnes isolates, which would otherwise be more 
insensitive to less diverse phage collections.  
Phage diversity can also be increased through evolutionary derivation of mutant phages. 
Defined as the number of mutations per base pair per replication, the rate by which phage 
mutants are generated is roughly two orders of magnitude above that of their bacterial 
hosts (Drake, 1991; Drake et al., 1998). Therefore, in an actively replicating population 
of phages, production of mutant phage progeny can serve to infect emergent and/or 
naturally-resistant bacterial hosts that may have otherwise evaded phage infection 
(Kysela & Turner, 2007). Demonstrating the ease by which resistance can be 
counteracted absolute insensitivity of P. acnes strain #9 to all phages was overcome by 
exploiting the dynamism of the phage-host interaction using a phage that had the broadest 
P. acnes host range—πα6919-4; and  a high-titre phage stock. High titre phage inoculum 
was generated via infection of P. acnes ATCC6919 by phage πα6919-4 giving rise to a 
sub-population of mutant phage derivatives. Inoculation of resistant cells with a high titre 
dose of πα6919-4 made it possible to select for and isolate a few plaques of variant phage 
with extended host range that had the capacity to successfully lyse naturally-resistant P. 
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acnes #9 (Figure 3.17). The in vitro evolutionary selection of variant phage πα9-6919-4 
in this study proved the value of application of a high-density phage inoculums to directly 
select for a limited number of mutant phages that were capable of infecting the initial 
population of resistant P. acnes #9, while minimizing the likelihood of emergence of 
further naturally-resistant P. acnes populations. Kysela and Turner showed that peak 
population sizes of initial and emergent bacterial populations can be controlled by the 
titre of the initial phage inoculum administered (Kysela & Turner, 2007). This principle 
has a great applied value in practicing phagetherapy. Administration of a highly-dense 
initial dose of phage decreases peak populations of both the initial and emergent bacterial 
populations, whereas administration of a low titre phage inoculum increases the 
exponential replication of phage in situ and decreases the peak population of emergent 
bacteria (Kysela & Turner, 2007). Therefore, to eliminate both initial and emergent P. 
acnes populations, the ideal phage cocktail preparation would be a dense inoculum of 
phages that, when combined, demonstrate complete, overlapping host range coverage of 
all P. acnes isolates used in this study. The importance of evolutionary derivation of 
mutant phages with modified properties can be understood further if one assumes that it 
is almost analogous to a derivation of modified antibiotics from a pool of parental 
formulations with highly valuable advantages as; i) the derivation process is extremely 
cost effective (a few plates and high-titre phage stock), while the derivation of antibiotics 
with modified chemistry requires at the least about half a billion to one billion dollars in 
investment, ii) the duration of time needed for phage derivation is less than 48 hours, 
while for antibiotics it takes an average of about 5 years of continuous work, iii) phages 
are considered GRAS and therefore, regulatory hurdles to drive them to application is 
 
143 
 
highly simplified and mitigated, and iv) modern medicine is trending towards application 
of  personalized treatments, which is in excellent alignment with application of 
personalized phage cocktails.     
Overall, the phages assessed in this study demonstrated broad (Figure 3.19a) and diverse 
activity spectra against clinical P. acnes isolates (Figure 3.18), which were highly 
variable in terms of their antibiotic susceptibility profiles (Table 3.6), geographical 
origin, anatomical site of isolation and phylotype (Table 3.5).Thus, majority of phages in 
this collection are ideal candidates for minimal cocktail formulations due to their highly-
targeted inter-species specificity combined with indiscriminate intra-species lytic 
activities. To be evaluated in future in vivo studies, the following demonstrate broad, 
overlapping lytic activities against the P. acnes isolates used in this study, making them 
ideal candidates for minimal phage cocktail formulations for acne treatment: the 
formulation will include phages of any member of “HRG1” (πα32; πα33; πα314; πα54; 
πα6919-3; πα6919-8; πα29399-3; πα3-SS3-1; πα3-SS3-2), a member from phages of 
group “HRG3” (πα35; πα313; πα6919-4; πα29399-4), πα315, πα43 and πα9-6919-4 
(Figure 3.18).  
Molecular characterization of phages 
According to previous studies, sequence diversity among the P. acnes phage genomes is 
relatively low, especially in comparison to the level of diversity demonstrated within 
Mycobacterium, Staphylococcus and Pseudomonas phage groups (Marinelli et al., 2012). 
However, based on the diverse range of activity spectra (host range) demonstrated by 
phages in this study,  diversity at the genomic level was expected. Digestion of sixty-four 
P. acnes phage genomes with BamHI produced an array of restriction fragment banding 
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patterns (Figure 3.20); phages were visually grouped into nine clusters based on their 
banding patterns. Such a diverse restriction banding patterns coincides with differences in 
the number and positions of BamHI restriction recognition sites, thereby it can be an 
indication of sequence diversity among the P. acnes phage genomes in our collection. To 
further examine the level of diversity at the genomic level and to gain insight into the 
genetic determinants of functional activity, phage isolates with a variety of host ranges 
were selected from each BamHI clusters for genome sequencing. 
Sequencing of twelve P. acnes phage genomes revealed a high degree of structural (Table 
3.7) and organizational (Figure 3.21) similarities, but vast diversities at nucleotide and 
amino acid levels among those sequenced in this study and compared with other available 
sequences. Shown in Table 3.7, average genome length (29732 bp), G-C content 
(54.52%) and number of open reading frames (42) were within the ranges of those 
previously reported (Farrar et al., 2007; Lood and Collin, 2011; Marinelli et al., 2012; 
Liu et al., 2015; Brown et al., 2016). Described in detail in Section 3.4.2.1, gross 
arrangement and annotation of ORFs corresponding to phage genomes sequenced in this 
study were similar to those of other P. acnes phage genomes, with orf1PA6 to orf21PA6 in 
the left arm transcribed rightward and encoding gene products involved in assembly and 
host lysis, while orf22PA6 to orf48PA6 in the right arm were transcribed leftward and 
encoded gene products having regulatory functions (Figure 3.21; Table 3.8). Due to gaps 
and unresolved bases present in the sequenced genomes, overall sequence identity among 
the sequenced phage genomes cannot be determined at the time of this writing, however, 
it was possible to analyze reliably complete individual gene sequences. 
Although the prevalence of phage-resistant P. acnes is relatively rare, naturally-resistant 
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strains commonly demonstrate widespread insensitivity to infection by phages that have 
been reported by other studies (Figure 3.19b; Marinelli et al., 2012). Broad susceptibility 
patterns of P. acnes isolates to phages is in part due to the diversity of P. acnes phages. 
Therefore, resistance can be overcome by diversifying the phage components involved in 
host specificity. Phage receptor mutations commonly result inimpairment of phage 
adsorption to host leading to resistance to phage (Labrie et al., 2010). Resistance may be 
evaded by counter-mutations leading to conformational alteration of phage tail structures 
involved in receptor recognition and binding. Previous studies have speculated on the 
roles of various P. acnes phage tail components in host cell adsorption (Farrar et al., 
2007; Lood et al., 2008; Marinelli et al., 2012; Brüggemann and Lood, 2013; Liu et al., 
2015; Brown et al., 2016), this study sought to reveal evidence of functional associations 
between tail components and host range of P. acnes phages.  
Molecular basis of phage host range diversity 
Several of the structural genes in the left arm of the genome (orf1PA6-orf22PA6) were fully 
sequenced without error (Figure 3.21). Tail-associated proteins equivalent to gp11PA6, 
gp14 PA6, gp15 PA6, gp16PA6, gp17 PA6, gp18 PA6 and gp19 PA6, are functional at the phage-
host interface during infection (Table 3.8). Reliable sequences were available for all 
except for two proteins encoded by orf18PA6 and orf19PA6. To gain insight into the 
structural determinant(s) of P. acnes phage host range, the level of congruence between 
known amino acid sequences of tail-associated components—gp11PA6, gp14 PA6, gp15 PA6, 
gp16PA6, and gp17 PA6—were assessed against phage host range data using global CADM 
analysis and complimentary Mantel tests, with gp1PA6 as a negative control. As shown in 
Table 3.9, results of the global CADM test (W = 0.2705912; P = 0.0009) followed by 
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Mantel test, revealed concordance among the datasets corresponding to phage host range 
and gp11 (rs=0.4152, P=0.0356). Spanning genome bases 7172 to 7813 (P. acnes phage 
PA6 numbering), orf11PA6 encodes gp11—the major tail protein (MTP). As the primary 
structural component of the siphovirus tail, MTPs assemble into homohexameric rings 
that stack on top of one another to form the hollow tail tube assembled around and in 
contact with the tape measure protein extended from the base of the icosahedral head to 
the lower tail components (Fokine & Rossmann, 2014; Pell et al., 2009). The role of the 
phage tail tube in host range determination has not been a focus of P. acnes phage 
studies. However, previous studies have speculated on the involvement of the tail tube 
with host adsorption based on the presence of protrusions that decorate the outer surface 
of the tail tubes of some siphoviruses, namely B. subtilis phage SPP1 (Auzat et al., 2008), 
E.coli phage λ (Pell et al., 2010), Lactococcus lactis phage p2 (Bebeacua et al., 2013b), 
and Mycobacterium abscessus subsp. bolletii phage Araucaria (Sassi et al., 2013). 
Comprised of MTP C-terminal domain residues (C-domain), the protrusions on the 
external surfaces of the hexameric rings are presumed to mediate phage adsorption onto 
e.g. the sugar moieties on the cell walls of Gram-positive hosts (Auzat et al., 2008; 
Bebeacua et al., 2013b; Pell et al., 2010; Sassi et al., 2013). This initial adsorption, which 
lands the phage horizontally on the cell surface, is mediated by the MTP C-domain and 
positions the phage in the vicinity of the receptor involved in inititation of infection that 
is mediated by the tail fibers providing strong interaction and binding to the receptor. 
There is no report that N-terminal domain of MTP plays a role in this process.     
To gain insight into involvement of MTP in host specificity and host range of phages, 
especially the πα9-6919-4 that had extended host range, we sought to identify some of the 
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MTP homologs that preferably would have reported structural data. As shown in results 
Section 3.4.2.4, there was only a handful of proteins identified by BlastP search, neither 
of them had a PDB file to provide structural information. Moreover, homology 
alignments were restricted to only the N-domain of the MTPs and no matches were found 
to C-domain. Having no significant homology with proteins of other phage groups that 
use the C-domain for cell adsorption, the C-domain residues of the παMTPs may confer 
specificity to the P. acnes phages together with tail fibers through interaction with the 
surface receptor on P. acnes hosts.  
Since blastP homology search failed to identify significant alignments to other phage 
MTPs that use the C-domain protrusions for host cell adsorption, we reasoned that a 
search additionally based on domain secondary structure prediction may identify distant 
proteins with related functions, which can also be used for structural modeling. Structural 
similarity search of πα6919-4 MTP with HHPred (according to Section 2.2.8.4.3) using 
the entire παMTP amino acid sequence was conducted to identify MTP homologues of 
phages. Full-length παMTP exhibited low sequence homology (i.e. 6% identity) with the 
gpVN, of phage λ, which encodes the N-domain of phage λ MTP, but not the C-domain 
consisted of 48 amino acid residues (Figure 3.25). Lack of alignment of MTP C-domain 
is considered as the specificity of this domain for P. acnes confirming the blastP results. 
Regardless of the role that C-domain might play in host recognition and possibly the 
intraphage differences with regard to their host ranges, the lack of structural information 
hindered us from further analysis. However, involvement of N-domain in host 
recognition has not been reported for any of known phages. Therefore, it appeared that 
we could only investigate the differences between πα6919-4 and πα9-6919-4 MTPs. 
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Hydrophobic side chains of fourteen highly-conserved residues of λ gpVN are essential 
components of the hydrophobic gpVN core (Pell et al., 2009). HHPred search based 
structural alignment map identified hydrophobic residues in πα6919-4 MTP and πα9-
6919-4 MTP corresponding to those in phage λ gpVN.  Across all παMTP sequences, 
hydrophobicity is conserved for thirteen παMTP residues aligned to core hydrophobic 
gpVN residues (Figure 3.26).  Moreover, structural alignment consistently identified 
insertion of an 18 consecutive amino acids within N-domains of παMTPs at D104 
corresponding to gpVN numbering (Figure 3.25). Given the probability of structural 
homology between the παMTPs and gpVN combined with conservation of hydrophobic 
side chains of παMTPs residues corresponding to the gpVN core residues, gpVN of E. coli 
phage λ can potentially serve as a model to predict the 3D structure of the παMTP and 
might offer an explanation for the activity of the mutant πα9-6919-4 phage. 
Structural modeling of MTP 
Three-dimensional structures of N-domains of  πα6919-4 MTP and πα9-6919-4 MTP 
were modeled upon phage λ gpVN NMR data using LOMETS (See section 2.2.8.4.3) 
(Wu & Zhang, 2007) . The λ gpVN amino acid sequence derived from its PDB (2K4Q) 
file was used as an internal  control to validate prediction accuracy of LOMETS. High 
score hits for λ gpVN PDB data, as well as for 3D models of παMTP, were suggested on 
the basis of λ gpVN structural data (Figure 3.27). The overall structure of gpVN is 
conserved in πα6919-4 and πα9-6919-4 models except for the β4 and β5 strands that 
appeared to be disordered in both πα MTPs (Figure 3.27a-c). The hydrophobic core 
consisted of β1-β7 and C3 loop (between β2-β3) are known for contributing to the 
formation of hydrophobic interfaces through which the MTP monomers assemble into 
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hexameric ring state. These interfaces facilitate the assembly of tail tube by providing 
protein-protein interactions between lateral interfaces of monomers and on the surfaces at 
the top and bottom of the hexameric rings. The relatively extended C3 loop is preserved 
in the παMTP models and most likely facilitates the interaction between stacking 
hexameric rings at top-bottom interfaces (Pell et al., 2009). The β7 strand and amino 
acids past this region gradually become disordered. It is suggested that these disordered 
string of residues function as a transitional linker to connect the N-domain to the C-
domain. The C-domain is believed to face the external surface of the tail tube where in 
some phages it takes part in recognition and transient binding of phage to its cell surface 
receptors (Bebeacua et al., 2013b; Pell et al., 2009). The β4 strand is immediately 
preceeded by a disordered loop (C5) past a single α-helix. The intervening α1-β4 loop 
showed a drastic difference between three models in terms of their length and amino acid 
compositions. Interestingly, this region contains the three sole sites of sequence variation 
between MTPs of πα69194 and πα9-69194, characterized by three adjacent amino acid 
substitutions (GSD → EPE) (Figure 3.23), indicating a functional role for this loop in 
extending the host range of the mutant phage πα9-6919-4. The C5 loop between α1 helix 
and β4 strand of lambda phage MTP gpVN domain is short and includes only 3 amino 
acids (G106 -T108). Insertion of a stretch of an additional 18 amino acids into the C5 
loop of πα6919-4 and πα9-6919-4 MTPs has progressively resulted in unwinding of α1 
helix increasing the C5 loop length to 21 and 24 amino acids, respectively (Figure 4.1 
and Figure 3.27d-f; Figure 4.1). By the most conservative measures if one considers this 
as the minimal length added to C5 loop and together with their amino acid compositions, 
it has elevated the negatively charged electrostatic state of the protein in this region 
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contributing to its tendency to scape hydrophobic interactions and most probably to face 
the external solvent environment. It is noteworthy that the amino acid changes in πα9-
6919-4 from GSD to EPE is not only a contributing factor to the overall change in 
electrostatic state of πα9-6919-4 C5-loop, also by non-conservaive Ser→Pro mutation an 
additional proline residue is added to the existing proline at position 115. This is 
important given the dynamic structural interconversions that proline resides cause 
especially in a relatively disordered stretches of amino acids in coils and loops providing 
fuctional properties to these structures. In the absence of empirically determined 
structural data for παMTP we speculate that in order for these drastic mutations together 
with C5 loop play a role in contributing to the extended host range of the phage πα9-
69194, the C5 loop must be positioned on the outer surface of the hexameric rings on the 
phage tail tube to be accessible to cell surface receptors. A similar loop to C5 in gpVN 
and an α1 helix-like structures have been identified in Hcp1 protein of SS6 protein 
secretory system in P. aeruginosa (Figure 4.1a) (Leiman et al., 2009; Mougous et al., 
2006; Pell et al., 2009). Mougous et al. (2006) showed stacked hexameric structures 
composed of Hcp1 protein that form a tube with an internal diameter of 40 angstroms that 
function as type VI bacterial protein secretory apparatus (Figure 4.1b). Hcp1 in 
monomeric and hexameric states resemble the gpVN. Most often present in hexameric 
from in solution, the single α1 helix and the proceeding disordered loop assemble in a 
hexagonal symmetry with α1 helix and the loop facing outward when viewed from the 
top of the hexameric assemblies (Figure 4.2b) (Mougous et al., 2006). Interestingly, 
despite the fact that the C5 loop is located between four of the fourteen conserved 
hydrophobic residues in gpVN (Figure 3.26), its structural alignment with Hcp1 was 
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significant and provided support to our hypothesis of a role, previously not described, for 
the C5 loop in host recognition in addition to C-domain (Figure 4.3). Both gpVN and the 
predicted πα6919-4/96919-4 MTP structures given in Figure 3.27 show residues at the C-
terminal end of the πα6919-4 MTP/gpVN alignment that are located at the external 
surface of the hexameric rings, and thus may serve as an anchoring point for a tail tube 
decorating C-domain of gpVN (Pell et al., 2009) and πα6919-4/9-6919-4 MTPs. If the 
πα6919-4 MTP does indeed contain a C-terminus tail decorating domain, it must have 
been comprised of approximately forty-eight residues that do not exhibit any significant 
structural homology with gpVC . The process of mutational bypassing the highly-resistant 
P. acnes strain #9 that affected the C5 loop can only be explained if a role for the N-
domain be considered in host recognition reasonably leading to active infection. Based on 
this study and supporting observations by others, it is reasonable to propose a 
hypothetical binding/infection model that the residues located in the  C5 loop region are 
involved in host specificity by acting as an auxiliary receptor recognition structures in 
cooperation with C-domain and tail fibers. They might achieve this either by assuming a 
properly folded stable structures or might be  induced to assume a conformational change 
in the hexameric ring structure in such a way as to make adsorption to the host receptor 
possible. Overall, this observation provides further evidence in support of the 
significance of the MTP in determining host specificity of P. acnes phages while 
demonstrating the relative ease by which phages may adapt to compensate for resistance 
in nature by virtue of the dynamic phage-host relationship, unlike the static mechanism of 
action by conventional antibiotics. 
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Figure 4.1: A close up view to the α1-β4 loop (C5 loop) in λgpVN, πα6919-4 and πα9-6919-4 
MTP models. 
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Figure 4.2: Prosed models for three dimensional structures of Hcp1 protein in A) 
monomeric state and B) top-bottom view of hexameric Hcp1. Red arrows point to 
the position of a a helix-loop structure in Hcp1 equivalent to λ gpVN  α1 helix and 
α1-β4 loop.  Note the position of helix-loop structures at the outer surface of 
hexamric ring and their exposure to solvent (Mougous et al., 2006). 
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Figure 4.3: Structural homology of gpVN and Hcp1 proteins. A) conservation of α1 
helix and C3 and C5 loops are shown. B) Superimposition of a single monomer of  
gpVN on Hcp1 in monomeric state (upper panel) and Hcp1 in hexameric state (Pell 
et al., 2009).  
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As previously discussed, acne vulgaris is the most common skin condition worldwide, 
thus this study aimed to evaluate the therapeutic potential of a phage collection for a 
broad population of acne sufferers. The P. acnes collections in this study do not represent 
a global population of clinically relevant isolates, therefore this is a limitation of this 
study. Although the isolate collections used in this study originated from Lund and 
various locations within Canada, it would be reasonable to assess the biological activity 
of our phage collection against isolates acquired from other regions of the world in 
support of the therapeutic potential of our phage collection. 
Another limitation of this study is the lack of complete genome sequence information for 
all phages in our collection. Acquiring this information would provide the opportunity to 
assess the congruency between all phage proteins and host range and would allow us to 
further strengthen our statistical analysis of the association between phage MTP and host 
range. There are also limitations involved with structural prediction of phage MTP that 
extend beyond the inherent computational limitations that may only be resolved by 
experimental data. The MTP structure was predicted based on a template, therefore any 
unaligned regions between the template (gpVN) and target (MTP) sequences remain 
unresolved in the predicted protein target structure. Furthermore, identification of 
templates that share a high level of homology with MTP sequences would increase the 
accuracy of the secondary and tertiary structure.         
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 Conclusion  5
As discussed, acne vulgaris is the most prevalent skin condition among adolescents and 
young adults globally (Johnson & Roberts, 1978; Rea et al., 1976; Wolkenstein et al., 
2003). The role of P. acnes in the development and persistence of acne has been 
established (Das & Reynolds, 2014). Treatment is indicated for all levels of severity and 
is often accompanied by a wide range of adverse side effects (Zaenglein et al., 2016). 
Antibiotics are commonly-used for treatment of moderate to severe acne, resulting in the 
rise of widespread, global resistance among P. acnes and other bacteria (Del Rosso & 
Zeichner, 2016). Phage therapy may offer a promising alternative to conventional acne 
treatments.  
In this study, a diverse collection of 224 clinically-relevant P. acnes isolates was 
established from patient samples of healthy and infected superficial and deep tissue sites 
from patients in Canada and Lund, Sweden. All P. acnes phylotype groups were 
represented within the collection, with the largest number of isolates of type IA. The 
frequency of antibiotic resistance among P. acnes isolates was highest for macrolides, 
followed by clindamycin and tetracyclines; as anticipated, a history of antibiotic 
treatment was associated with antibiotic resistant P. acnes phenotypes.  
Seventy P. acnes phages were isolated from raw sewage and six from human subjects, 
then tested against our diverse collection of P. acnes isolates. Just three P. acnes isolates 
in our entire collection were sensitive to less than 50% of our phages thus demonstrating 
the high level of diversity among phages isolated from raw sewage. Unlike the static 
nature of antibiotics, the phage-host relationship is dynamic and can be exploited to 
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overcome any naturally-occuring or evolved resistance, even among multi-drug resistant 
bacteria. Rapid in vitro derivation of a mutant phage that has lytic activity against a 
previously uninfectable P. acnes isolate demonstrates the ease by which P. acnes 
resistance may be overcome. Overall, our phages demonstrated broad host ranges; their 
individual host ranges were highly variable and could be combined to produce a variety 
of minimal phage cocktails having overlapping host ranges to achieve 100% in vitro 
efficacy against all P. acnes isolates in our collection.  
Although we were unable to obtain complete genome sequences for the twelve sequenced 
phages, the information available at the time of this study revealed congruency between 
P. acnes phage MTP sequences and corresponding host ranges. Structural homology 
searches suggest that παMTP N-domain may share a common evolutionary ancestor with 
E. coli λ phage gpVN, while no distant homologs were identified for παMTP N-domain, 
suggesting this domain may be involved in host recognition. Furthermore, modelling of 
the παMTP N-domain revealed a stretch of 18 amino acids which may also be involved in 
host recognition. Relative to the resources required to identify, develop and test 
traditional synthetic antibiotics, the isolation, characterization and assessment of 
therapeutic phage candidates is significantly less expensive and highly accessible in 
nature. In the advent of an increased interest and reliance on personalized medicine, 
phage-based therapeutics offer highly targeted antibacterial alternatives to conventional 
antibiotics, which are widely accessible in nature and easily isolated. 
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Future studies 
Future studies are needed to demonstrate the therapeutic potential of the phage cocktail 
proposed in this study. Efficacy testing of the phage cocktail formulations in animal 
models can support subsequent preclinical trials. To increase the range of phage-based 
acne treatment options, known antibacterial phage products, such as endolysins, may be 
expressed as chimeric proteins to modulate antibacterial specificity. To gain a better 
understanding of the biology of the phages within our collection, orfs of unknown 
function can be functionally characterized, thus revealing new phage products that may 
be considered as candidates for therapeutic applications. 
To further investigate the role of P. acnes phage MTPs in host specificity, structural 
studies of MTPs may be conducted through X-ray crystallography or NMR in 
conjunction with mutagenesis studies. Additionally, host specificity conferred by MTP or 
other tail fibres may be exploited as drug carriers for targetted drug delivery to reduce 
toxicity and dosage, or to delivery higher dosages for short treatment durations. 
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Appendix A  
Microbiological Techniques, Bacterial Culturing and Stock 
Maintenance  
A.1 Reagents, supplements and additives 
 
95 % (v/v) ethanol (EtOH) working solution: 
Added 5mL ddH2O to 95mL anhydrous EtOH, mixed well  
 
128.4 mg/mL calcium chloride (CaCl2) working solution:  
Dissolved 12.84g CaCl2 in 100mL ddH2O 
 
1 M sodium hydroxide (NaOH) working solution:  
Dissolved 40g NaOH (ACS certified) in 1L ddH2O 
 
0.85 % (w/v) sodium chloride (NaCl) solution, sterile  
Dissolved 0.85g NaCl in 100mL ddH2O 
Sterilized by autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes 
 
5 mg/mL hemin working solution  
Mixed 0.5g hemin powder (#H9039, Sigma) into 10mL of 1 M NaOH until hemin 
was completely dissolved 
Added ddH2O to bring the final volume to 100mL 
Sterilized by autoclave, using liquid cycle at 121°C for 15 minutes 
Cooled to room temperature then stored in darkness at 4°C for a maximum of 30 
days  
   
10 mg/mL vitamin K1 stock solution 
Mixed 0.2mL Vitamin K1 (pre-sterilized) solution with 20mL 95% EtOH 
Stored in darkness at 4°C 
 
1 mg/mL vitamin K1 working solution  
Mixed 1mL Vitamin K1 stock solution (10mg/mL) with 9mL sterile ddH2O 
Stored in darkness at 4°C for a maximum of 30 days  
 
Laked sheep blood 
Froze sterile, whole, defibrinated sheep blood at -20°C for a minimum of 8 hours 
Warmed blood to 37°C in a water bath 
Mixed well by inversion prior to use 
 
20% (v/v) glycerol:  
Mixed 0.1L glycerol with 0.4L ddH2O 
Sterilized by autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes. 
A.2 Nutrient media 
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Brain-heart infusion (BHI) broth: 
Approximate formula per litre: 
Casein Peptone  15.0 g 
Meat peptone/brain 
heart infusion   12.0 g 
Dipotassium phosphate 2.5 g  
Dextrose   2.0 g 
Yeast extract   5.0 g 
Sodium chloride   5.5 g 
A total of 42g dehydrated B-HI broth media was dissolved in 1L ddH2O then sterilized 
by autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes.  
 
BHI agar (1.6%): 
1L BHI broth 
16 g bacteriological agar  
Sterilized by autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes.  
 
Brucella broth w/ hemin and vitamin K1 : 
Approximate formula per litre: 
Pancreatic digest of casein 10.0 g 
Peptic digest of  
animal tissue   10.0 g  
Dextrose   1.0 g 
Yeast extract   2.0 g 
Sodium chloride   5.0 g 
Sodium bisulfite  0.1 g 
Hemin    0.005 g 
Vitamin K1   0.001 g 
A total of 28g dehydrated brucella broth media was dissolved in 1L ddH2O. One millilitre 
hemin working solution (5mg/mL) and 1 mL vitamin K1 working solution (1mg/mL) 
were added to the brucella solution then sterilized by autoclave, using liquid cycle at 
121°C and 15 Psi for 30 minutes.  
 
Brucella agar (1.6%) w/ hemin, vitamin K1 and 5% laked sheep blood (BBA): 
1 L brucella broth w/ hemin and vitamin K1  
16 g bacteriological agar  
50 mL laked sheep blood 
Sterilized by autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes. Cooled 
medium to 50°C and added pre-warmed (37°C) laked sheep blood. Mixed media well 
with magnetic stir bar and dispensed 67mL media into 150mm petri dishes for an optimal 
nutrient agar depth of 0.4mm +/- 0.5mm.  
 
BBA w/ 0.1284 mg/L Ca2+ supplement (~ 40 mg/L final [Ca2+]): 
1 L BBA  
1 mL CaCl2 working solution (128.4 mg/mL) 
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Prepared BBA solution without blood and added CaCl2 working solution, mixed well. 
Sterilized media by autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes. 
Cooled medium to 48°C to 50°C and added pre-warmed (37°C) laked sheep blood. 
Mixed media well with magnetic stir bar and dispensed 42mL media into 92mm petri 
dishes for an optimal nutrient agar depth of 0.4mm +/- 0.5mm.  
 
 
Columbia (CB) broth: 
Approximate formula per litre: 
Special peptone mix  23.0 g 
Sodium chloride  5.0 g 
L-cysteine   0.1 g 
Sodium carbonate  0.6 g 
Dextrose   2.5 g 
Magnesium sulfate  0.1 g 
Ferrous sulfate  0.02 g 
Tris    0.83 g 
Tris, hydrochloride  2.86 g 
A total of 35g dehydrated CB broth media was dissolved in 1L deionized water (ddH2O) 
then sterilized by autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes.  
  
CB agar (1.6%): 
1 L CB broth (see above) 
16 g bacteriological agar  
Sterilized by autoclave, using liquid cycle at 121°C for 30 minutes.  
 
CB top agar (0.7%): 
1 L CB broth (see above) 
7 g bacteriological agar  
Sterilized by autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes.  
 
Mueller-Hinton (MH) broth w/ hemin and vitamin K1: 
Approximate formula per litre: 
Dehydrated infusion  
from beef   300.0 g 
Casein hydrolysate  17.5 g 
Starch     1.5 g 
Hemin    0.005 g 
Vitamin K1   0.001 g 
A total of 21g dehydrated MH broth media was dissolved in 1L ddH2O. One millilitre 
hemin working solution (5mg/mL) and 1 mL vitamin K1 working solution (1mg/mL) 
were added to the media solution then sterilized by autoclave, using liquid cycle at 121°C 
and 15 Psi for 30 minutes.  
 
MH agar (1.6%) w/ hemin, vitamin K1 and 5% laked sheep blood (MHB): 
1 L MH broth w/ hemin and vitamin K1 (see above) 
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16 g bacteriological agar  
50 mL laked sheep blood 
Sterilized by autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes. Cooled 
medium to 48°C to 50°C and added pre-warmed (37°C) laked sheep blood. Mixed media 
well with magnetic stir bar and dispensed 42mL media into 92mm petri dishes for an 
optimal nutrient agar depth of 0.4mm +/- 0.5mm. 
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Appendix B  
Molecular Techniques: Buffer and Reagent Preparation 
B.1 Common buffers 
 
1M Tris-HCl, pH 8.0: 
 Dissolved 121.1 g Tris base in 800ml ddH2O  
 Added concentrated HCl until pH 8.0 was achieved 
 Added ddH2O to a final volume of 1000ml, mixed well 
 
 0.5M EDTA, pH 8.0: 
 Mixed 186.12 g EDTA.Na2.2H2O in 800 ml ddH2O 
 While mixing vigorously, NaOH was added into the solution until pH 8.0 was  
achieved 
 Added ddH2O to a final volume of 1000 ml, mixed well 
B.2 Bacterial cell lysis 
 
Cell lysis buffer (CLB), pH 8.0: 
 Added 250 ml 0.1M Tris-HCl pH 8.0 to 735 ml ddH2O 
 Added 5 ml 0.5 mM EDTA pH, 8.0 
 Added 10 ml 100% Triton X-100 
 Mixed solution well 
 
10% Sodium dodecyl sulphate (SDS):  
 Added 100g SDS to 800 ml ddH2O and stirred on a magnetic stirrer until  
dissolved 
 Added ddH2O to a final volume of 1000 ml, mixed well 
 
6 μg/μL pronase: 
 Added 60 mg pronase to 10 mL ddH2O 
 
3 M potassium acetate (KOAc), pH 5.5:  
 Mixed 294.42 g KOAc into 500 mL ddH2O and stirred on a magnetic stirrer until 
 dissolved 
 Adjusted pH to 5.5 with addition of glacial acetic acid (approximately 110 mL)  
 Add ddH2O to a final volume of 1000 mL  
B.3 Phenol-chloroform extraction 
 
25:24:1 phenol chloroform isoamyl alcohol (PCI):  
 Mixed 50 ml phenol (containing 0.2% 8-hydroxyquinoline), 48 ml chloroform 
and 2 ml isoamyl alcohol 
 Added 50 ml 0.1M Tris-HCl pH 8.0, mixed vigorously to saturate with buffer 
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 Solution settled to allow for phase separation 
 A fraction of the upper phase, containing 0.1 M Tris-HCl pH 8.0, was removed  
resulting in a thin layer of Tris-HCl to cover the PCI solution 
B.4 PEG precipitation 
 
30% PEG/3 M NaCl solution:  
 Dissolved 175.5g NaCl in 200 ml ddH2O  
 Added 300g PEG 8000, mixed until fully dissolved 
 Added ddH2O to a final volume of 1000 ml, mixed well 
 
1X Phage extraction buffer, pH 7.5: 
 5.84g NaCl dissolved in 800 ml ddH2O 
 Added 100 ml 1 M Tris-HCl, pH 7.5 
 Added 50 ml 0.5 M EDTA, pH 8.0 
 Added ddH2O to a final volume of 1000 ml, mixed well 
B.5 Ethanol precipitation 
 
3M NaOAc solution: 
 Dissolved 246.01g anhydrous sodium acetate in 800 ml ddH2O 
 Added ddH2O to a final volume of 1000 ml, mixed well 
 
EtOH/0.16M NaOAc solution:  
 Added 852 ml anhydrous ethanol (100%) to 95 ml ddH2O  
 Added 53 ml 3M sodium acetate, mixed well  
B.6 Agarose gel electrophoresis 
 
50X Tris acetate (TAE), pH 8.3:   
 Dissolved 242g Tris base in 500 ml ddH2O 
 Added 57.1 ml 1M Glacial acetic acid and 100 ml 0.5M EDTA pH, 8.0  
 Added ddH2O to a final volume of 1000 ml, mixed well (no pH adjustment  
necessary) 
 
1X TAE running buffer: 
Diluted 80 mL 50X TAE concentrated stock solution in ddH2O to a final volume 
of 4 L 
 
0.7% (w/v) agarose gel: 
 Added 0.7g electrophoresis grade agarose to 100 ml 1X TAE running buffer 
 Mixed well while heating until solution reached boiling point 
 
1.5% (w/v) agarose gel: 
 Added 1.5g electrophoresis grade agarose to 100 ml 1X TAE running buffer 
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 Mixed well while heating until solution reached boiling point 
 
1.8% (w/v) agarose gel: 
 Added 1.8g electrophoresis grade agarose to 100 ml 1X TAE running buffer 
 Mixed well while heating until solution reached boiling point 
 
2.0% (w/v) agarose gel: 
 Added 2.0g electrophoresis grade agarose to 100 ml 1X TAE running buffer 
 Mixed well while heating until solution reached boiling point 
 
6X DNA loading buffer pH 8.0:  
 Combined the following, mixed well:  
 2.0 ml ddH2O 
 6.0 ml glycerol 
 1.0 ml 0.5M EDTA pH 8.0 
 1.0 ml 1% bromophenol blue in ddH2O  
 Distributed 1.0 ml to 2.0 ml screw-capped tubes and stored at -20°C  
 
0.5 μg/mL EtBr solution: 
 Diluted 25 μL 10 mg/mL EtBr stock solution with 500 mL ddH2O 
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Appendix C  
Propionibacterium acnes Collection 
 
Table C.1: Sources of P. acnes isolates used in this study (Sudbury and Ottawa excluded).  
              
  Strain Identifier Specimen Type Source Reference   
  ATCC 6919 Facial acne (severe case) IA 
ATCC 
(Zierdt et al., 1968)   
  ATCC 29399 Forehead (healthy individual) IA (Marples & McGinley, 1974)   
  01-A-087 Blood culture IA 
NML none 
  
  02-A-018 Pleural fluid IB   
  05-A-026 Blood culture IB   
  00-0196 Neck abscess node II   
  03-A-023 Cerebral spinal fluid IA   
  06-0893 Tissue (allograft) IA   
  01-A-009 Blood culture II   
  03-A-024 Fluid- left frontal lesion IB   
  04-A-028 Neck wound IA   
  60743 Abdominal sterile pad II   
  70241 Blood culture IA   
  AD1 Knee prosthesis IA 
CSLU (Holmberg et al., 2009) 
  
  AD2 Sternal Wire IA   
  AD3 Sternal Wire IB   
  AD6 Bone tissue, finger IA   
  AD7 Knee prosthesis II   
  AD8 Hip prosthesis IA   
  AD9 Hip prosthesis IA   
  AD10 Bone tissue, skull II   
  AD11 Hip prosthesis IA   
  AD12 Hip prosthesis IB   
  AD14 Bone tissue, femur II   
  AD15 Prosthetic device, vertebra IA   
  AD16 Bone tissue, skull II   
  AD33 Knee prosthesis IB   
  AD47 Hip prosthesis IA   
  AD48 Prosthetic device, vertebra IA   
  AD49 Bone tissue, skull II   
  AS1 Forehead IB   
  AS2 Forehead IA   
  AS3 Forehead IB   
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  Strain Identifier Specimen Type Source Reference   
  AS4 Forehead IA 
CSLU (Holmberg et al., 2009) 
  
  AS5 Forehead IA   
  AS6 Forehead IA   
  AS7 Forehead IA   
  AS9 Forehead II   
  AS10 Forehead IA   
  AS11 Forehead IB   
  AS13 Forehead IB   
  AS16 Forehead IB   
  AS18 Forehead IB   
  AS20 Forehead II   
  AS21 Forehead II   
  AS22 Forehead II   
  AS24 Forehead IA   
  AS25 Forehead IA   
  AS27 Forehead IA   
  AS28 Forehead II   
  AS30 Forehead IA   
  AS31 Forehead IA   
  AS32 Forehead IA   
  AS33 Forehead IA   
  AS37 Forehead IB   
  AS38 Forehead IB   
  AS39 Forehead II   
  AS50 Forehead IA   
NML, National Microbiology Laboratory (Winnipeg, Canada), courtesy of Ms. Kathryn Bernard; ATCC, 
American Type Culture Collection (Manassas, USA); CSLU, Department of Clinical Sciences of Lund 
University (Lund, Sweden), courtesy of Dr. Anna Holmberg; AD, isolated from sites of deep infection; AS, 
isolated from skin of healthy individuals.  
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Appendix D  
Antibiotic Susceptibility Testing: Interpretive Criteria 
Table D.2: Clinical breakpoints used as interpretive criteria for antibiotic susceptibility of P. acnes clinical isolates. Clinical breakpoint 
does not necessarily distinguish wild-type from non-wild-type organisms, however, it does distinguish treatable organisms from organisms 
that will likely not respond to treatment with the antibiotic in question (Martínez et al., 2015). 
Antibiotic 
MIC (mg/L) 
Reference(s)           S I R 
          Azithromycin 2 ≤ 2  - > 2 (Achermann et al., 2014; EUCAST, 2016; Olsson et al., 2012) 
          Benzylpenicillin  ≤ 0.25 - > 0.5  (EUCAST, 2016) 
          Ceftriaxone  ≤ 16  32 ≥ 64  (Clinical and Laboratory Standards Institute, 2015) 
          Clindamycin  ≤ 4  - > 4  (EUCAST, 2016) 
          Doxycycline 3 ≤ 4  - > 4  - 
          Erythromycin  < 0.5 - ≥ 0.5  (Oprica et al., 2004; Oprica & Nord, 2005) 
          Levofloxacin 1 ≤ 1 - > 2  (Achermann et al., 2014; EUCAST, 2016) 
          Linezolid 1 ≤ 2 - > 4 (Achermann et al., 2014; EUCAST, 2016) 
          Minocycline 3 ≤2 - > 2 - 
          Tetracycline  ≤ 4 8 ≥ 16 (Clinical and Laboratory Standards Institute, 2015) 
          Rifampicin 2 ≤ 0.5 - > 0.5 (Achermann et al., 2014; EUCAST, 2016; Olsson et al., 2012) 
          Vancomycin  ≤2 - > 2 (EUCAST, 2016) 
          
Daptomycin 2 ≤ 1 - > 1 (Achermann et al., 2014; Clinical and Laboratory Standards Institute, 2015; EUCAST, 2016; Olsson et al., 2012; Tyrrell et al., 2006) 
          Trimethoprim/sulfamethoxazole  < 1 - ≥ 1 (Oprica et al., 2004) 
          1Values are non-species specific.  
2Breakpoint values do not exist for anaerobes, therefore breakpoints for other Gram-positive organisms were used.  
3Interpretive MIC values of DC and MC were set as described in Section 2.2.4.3. 
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Appendix E  
Phage Genome Annotation: Reference Sequences 
Table E.3: P. acnes phage sequence database for annotation with the Prokka pipeline v 1.11 
(Seemann, 2014). 
  
Propionibacterium phage: 
Complete Genome ID 
NCBI Reference Sequence 
(RefSeq; Accession.Version) A Genbank (Accession.Version)   
  ATCC29399B_C NC_018851.1 JX262225.1   
  ATCC29399B_T NC_018847.1 JX262224.1   
  Attacne NC_027629.1 KR337651.1   
  Keiki - KR337649.1   
  Kubed NC_027625.1 KR337645.1   
  Lauchelly NC_027628.1 KR337650.1   
  MrAK NC_027620.1 KR337643.1   
  Ouroboros NC_027630.1 KR337654.1   
  P100_1 NC_018840.1 JX262222.1   
  P100_A NC_018838.1 JX262221.1   
  P100D NC_018852.1 JX262220.1   
  P101A NC_018841.1 JX262217.1   
  P104A NC_018845.1 JX262218.1   
  P105 NC_018849.1 JX262219.1   
  P11 NC_018842.1 JX262223.1   
  P144 NC_018839.1 JX262216.1   
  P91 NC_018834.1 JX262215.1   
  PA1-14 NC_028694.1 KT934381.1   
  PA6 NC_009541.1B DQ431235.1   
  PAC1 NC_028967.1 KR902978.1   
  PAC10 - KR902987.1   
  PAC2 - KR902979.1   
  PAC3 - KR902980.1   
  PAC4 - KR902981.1   
  PAC5 - KR902982.1   
  PAC6 - KR902983.1   
  PAC7 - KR902984.1   
  PAC8 - KR902985.1   
  PAC9 - KR902986.1   
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Propionibacterium phage: 
Complete Genome ID 
NCBI Reference Sequence 
(RefSeq; Accession.Version) A Genbank (Accession.Version)   
  Pacnes 2012-15 NC_027371.1 KJ722067.1   
  PAD20  NC_015454.1 FJ706171   
  PAS50  NC_015453.1 FJ706172   
  PHL009M11 NC_027336.1 KJ578758.1   
  PHL010M04 NC_022336.1 JX570704.1   
  PHL025M00 NC_027357.1 KJ578759.1   
  PHL030N00 NC_027373.1 KJ578760.1   
  PHL037M02 - JX570706.1   
  PHL041M10 NC_027391.1 KJ578761.1   
  PHL055N00 NC_027400.1 KJ578762.1   
  PHL060L00 NC_022338.1 JX570705.1   
  PHL064M01 - KJ578763.1   
  PHL064M02 - KJ578764.1   
  PHL066M04 - JX570711.1   
  PHL067M01 - KJ578765.1   
  PHL067M09 - KJ578766.1   
  PHL067M10 NC_022335.1 JX570709.1   
  PHL070N00 NC_027333.1 KJ578767.1   
  PHL071N05 NC_022337.1 JX570710.1   
  PHL073M02 - JX570703.1   
  PHL082M00 NC_027359.1 KJ578768.1   
  PHL082M02 - KJ578769.1   
  PHL082M03 - KJ578770.1   
  PHL082M04 - KJ578771.1   
  PHL085M01 - JX570707.1   
  PHL085N00 NC_027361.1 KJ578772.1   
  PHL092M00 NC_027385.1 KJ578773.1   
  PHL095N00 NC_027401.1 KJ578774.1   
  PHL111M01 NC_022342.1 JX570702.1   
  PHL112N00 NC_022334.1 JX570714.1   
  PHL113M01 NC_022341.1 JX570713.1   
  PHL114L00 NC_022340.1 JX570712.1   
  PHL114N00 - KJ578775.1   
  PHL115M02 - JX570708.1   
 
220 
 
 
 
          
  
Propionibacterium phage: 
Complete Genome ID 
NCBI Reference Sequence 
(RefSeq; Accession.Version) A Genbank (Accession.Version)   
  PHL116M00 NC_027362.1 KJ578776.1   
  PHL116M10 - KJ578777.1   
  PHL117M00 - KJ578778.1   
  PHL117M01 - KJ578779.1   
  PHL132N00 NC_027367.1 KJ578780.1   
  PHL141N00 NC_027389.1 KJ578781.1   
  PHL150M00 NC_027294.1 KJ578782.1   
  PHL151M00 - KJ578783.1   
  PHL151N00 - KJ578784.1   
  PHL152M00 NC_027386.1 KJ578785.1   
  PHL163M00 - KJ578786.1   
  PHL171M01 NC_027346.1 KJ578787.1   
  PHL179M00 NC_027370.1 KJ578788.1   
  PHL194M00 - KJ578789.1   
  PHL199M00 NC_027295.1 KJ578790.1   
  PHL301M00 NC_027354.1 KJ578791.1   
  PHL308M00 - KJ578792.1   
  Pirate NC_027623.1 KR337653.1   
  Procrass1 NC_027626.1 KR337644.1   
  SKKY NC_027624.1 KR337648.1   
  Solid NC_027627.1 KR337647.1   
  Stormborn NC_027622.1 KR337652.1   
  Wizzo NC_027621.1 KR337646.1   
A Reference sequence identical to Genbank sequence except where indicated otherwise    
B Reference sequence derived from Genbank sequence     
 
 
